

**ΝΕΚΤΑΡΙΑ-ΣΤΑΥΡΟΥΛΑ ΖΑΓΟΡΙΑΝΑΚΟΥ,MD, MSc,
PhD**

ΕΠΙΚΟΥΡΟΣ ΚΑΘΗΓΗΤΡΙΑ ΔΗΜΟΣΙΑΣ ΥΓΕΙΑΣ & ΠΡΟΛΗΠΤΙΚΗΣ ΙΑΤΡΙΚΗΣ

ΒΙΟΓΡΑΦΙΚΟ ΣΗΜΕΙΩΜΑ

ΜΟ ΒΙΟΓΡΑΦΙΚΟ ΣΗΜΕΙΩΜΑ



Η Δρ. Νεκταρία-Σταυρούλα Ζαγοριανάκου είναι κάτοχος πτυχίου Ιατρικής, του Πανεπιστημίου της Ρώμης “La Sapienza” (Universita degli studi di Roma “La Sapienza”). Ειδικεύτηκε στην Κυτταρολογία, στο εργαστήριο της Παθολογικής Ανατομικής του Πανεπιστημιακού Νοσοκομείου Ιωαννίνων (ΠΠΓΝ), (δύο χρόνια ειδικότητας στην Παθολογική Ανατομική και τρία χρόνια στην Κυτταρολογία). Εκπόνησε τη διδακτορική της διατριβή, βαθμολογήθηκε με άριστα, στο εργαστήριο της Παθολογικής Ανατομικής, στον Μορφολογικό και Εργαστηριακό Τομέα του Πανεπιστημίου Ιωαννίνων. Το θέμα της ερευνητικής της μελέτης στα πλαίσια των διδακτορικών της σπουδών αφορούσε τη διερεύνηση α) διαταραχών κυτταρικού κύκλου, της απόπτωσης β) του πρότυπου αγγειογένεσης και γ) παρουσίας δομικών και αριθμητικών ανωμαλιών στο φυσιολογικό, υπερπλαστικό και καρκινωματώδες ενδομήτριο. Είναι κάτοχος Μεταπτυχιακού διπλώματος στην «Επαγγελματική και Περιβαλλοντική Υγεία» με ειδίκευση στην «Επαγγελματική Υγεία» (Πανεπιστήμιο Δυτικής Αττικής, Σχολή Δημόσιας Υγείας, Αθήνα, Ελλάδα) διάρκειας τριών εξαμήνων, το οποίο ολοκλήρωσε με την παρουσίαση της διπλωματικής της εργασίας και βαθμολογήθηκε με άριστα. Κατά τη διάρκεια της ειδικότητας της καθώς και με την ολοκλήρωση της ειδίκευσής της, παρακολούθησε και συμμετείχε στη διοργάνωση (organizing committee), των Ευρωπαϊκών Μετεκπαιδευτικών Σεμιναρίων Παθολογικής Ανατομικής και Ογκολογίας, (IUCP courses, Ioannina University Courses in Pathology-Oncology), τα οποία διοργανώνει η Ελληνική Εταιρεία Παθολογικής Ανατομικής. Τα σεμινάρια έχουν μοριοδοτηθεί από την Ευρωπαϊκή Παθολογοανατομική Εταιρεία και τον Πανελλήνιο Ιατρικό Σύλλογο. Πραγματοποιούνται αδιάλειπτα στο Πανεπιστήμιο Ιωαννίνων από το 1996. Από το 2008 έως το 2014 εργάστηκε στο ΤΕΙ Ηπείρου, στο Τμήμα Νοσηλευτικής Ιωαννίνων, ως ωρομίσθια καθηγήτρια με πλήρη προσόντα, έχοντας αυτοδύναμη διδασκαλία στα μαθήματα Ανατομία, Φυσιολογία και Μικροβιολογία. Οι ερευνητικοί της τομείς αφορούν στην έρευνα του γυναικολογικού καρκίνου, του ενδομητρίου, των ωοθηκών, του μαστού, του λάρυγγα και του θυρεοειδούς. Έχει συγγράψει επιστημονικά άρθρα τα οποία έχουν δημοσιευτεί σε διεθνή περιοδικά υψηλής απήχησης (impact factor) με κριτές. Οι μελέτες που έχει δημοσιεύσει αφορούν στη διερεύνηση της νεοαγγειογένεσης, στην παρουσίαση case reports και ανασκοπήσεων (review). Εργάζεται ως ιδιώτης Ιατρός Κυτταρολόγος στα Ιωάννινα μέχρι σήμερα. Εκτός από το ερευνητικό της έργο ως Ιατρός έχει εκδώσει τέσσερα βιβλία, ένα ιστορικό λαογραφικό λεύκωμα, με τίτλο «Γνωριμία με το Ζαγόρι» και τρία ιστορικά μυθιστορήματα, Τα θεριά της μεσογείου, εκδόσεις Ωκεανίδα, «Ο μεγάλος σοφός», εκδόσεις Ωκεανίδα, «Το Μετάξι» εκδόσεις Κέδρος, ενώ, από το 2017, αρθρογραφεί στην εφημερίδα Athens Voice.

ΒΙΟΓΡΑΦΙΚΑ ΣΤΟΙΧΕΙΑ

ΣΠΟΥΔΕΣ-ΕΚΠΑΙΔΕΥΣΗ

- **Σεπτέμβριος 1991:** Εισαγωγή στην Ιατρική Σχολή του Πανεπιστημίου της Ρώμης “La Sapienza”
- **Σεπτέμβριος 1997:** Αποφοίτηση από την Ιατρική Σχολή του Πανεπιστημίου της Ρώμης “La Sapienza” με βαθμό άριστα
- **Μάιος 1998:** Εξετάσεις στο Πανεπιστήμιο της Bologna για τη λήψη της άδειας άσκησης Ιατρικού Επαγγέλματος
- **Οκτώβριος 1998-2000:** Ειδικευόμενη Ιατρός στο Παθολογοανατομικό Εργαστήριο του Πανεπιστημιακού Νοσοκομείου Ιωαννίνων
- **Ιούνιος 2004-2007:** Ειδικευόμενη Ιατρός στο Κυτταρολογικό Εργαστήριο του Πανεπιστημιακού Νοσοκομείου Ιωαννίνων
- **Αύγουστος 2007:** Εξετάσεις Ειδικότητας της Κυτταρολογίας
- **Σεπτέμβριος 2007:** Λήψη της Ιατρικής Ειδικότητας της Κυτταρολογίας
- **Οκτώβριος 2010 – Ιούνιος 2015:** Τετραετής εκπαίδευση στο Ελληνικό Ινστιτούτο Κλασικής Ψυχανάλυσης με συνεχιζόμενη εκπαίδευση σε εποπτείες και κλινικές περιπτώσεις.
- **Απρίλιος - Οκτώβριος 2014:** Εξάμηνη ειδίκευση στην Ψυχολογία Ασθενών, στα πλαίσια του Έργου με τίτλο «ΠΕΓΑ – ΨΥΧΟΛΟΓΙΑ ΑΣΘΕΝΩΝ» του Ε.Π. «Εκπαίδευση και Δια Βίου Μάθηση», του ΤΕΙ Ηπείρου. Συμμετοχή και ολοκλήρωση του προγράμματος ΠΕΓΑ «Πιστοποίηση στην Ψυχολογία Ασθενών». Το Επιχειρησιακό Πρόγραμμα «Εκπαίδευση και δια βίου Μάθηση» (ΕΠΕΔΒΜ) μέσω της εφαρμογής της εθνικής στρατηγικής για την εκπαίδευση και τη δια βίου μάθηση χρηματοδότησε, κατόπιν αξιολόγησης, Προγράμματα Επικαιροποίησης Γνώσεων Αποφοίτων ΑΕΙ (Π.Ε.Γ.Α) με στόχο τη δια βίου εκπαίδευση των αποφοίτων των ΑΕΙ. Συμμετοχή στο Πρόγραμμα ΠΕΓΑ «Ψυχολογία Ασθενών».

ΔΙΔΑΚΤΟΡΙΚΗ ΔΙΑΤΡΙΒΗ

- **Οκτώβριος 2008:** Πανεπιστήμιο Ιωαννίνων-Ιατρική Σχολή. Μορφολογικός-Κλινικοεργαστηριακός Τομέας. Εργαστήριο Παθολογικής Ανατομικής-Διευθυντής-Καθηγητής Νίκη Ι. Αγκάντη.

«Διερεύνηση α) διαταραχών κυτταρικού κύκλου, της απόπτωσης β) του πρότυπου αγγειογένεσης και γ) παρουσίας δομικών και αριθμητικών ανωμαλιών στο φυσιολογικό, υπερπλαστικό και καρκινωματοδές ενδομήτριο»

Επιβλέπουσα: Μαρία Μπάη, Τακτική καθηγήτρια Παθολογικής Ανατομικής Ιατρικής Σχολής Πανεπιστημίου Ιωαννίνων

ΜΕΤΑΠΤΥΧΙΑΚΟ ΔΙΠΛΩΜΑ

- **Μάρτιος 2023:** Πανεπιστήμιο Δυτικής Αττικής-Σχολή Δημόσιας Υγείας-Πρόγραμμα Μεταπτυχιακών Σπουδών «ΕΠΑΓΓΕΛΜΑΤΙΚΗ ΚΑΙ ΠΕΡΙΒΑΛΛΟΝΤΙΚΗ ΥΓΕΙΑ» με ειδίκευση στη «ΕΠΑΓΓΕΛΜΑΤΙΚΗ ΥΓΕΙΑ»

Μεταπτυχιακή Διπλωματική Εργασία: «Η Ιατρική και Νοσηλευτική στην Αρχαία και Μεγάλη Ελλάδα» Βαθμός: Άριστα (Εννέα και Δεκατρία Εκατοστά. 9,13)

Επιβλέπων Καθηγητής: Γεώργιος Ντουινιάς

ΠΑΡΟΥΣΑ ΘΕΣΗ ΕΡΓΑΣΙΑΣ – ΕΠΑΓΓΕΛΜΑΤΙΚΗ ΠΡΟΥΠΗΡΕΣΙΑ

- **2007 – σήμερα:** Ιατρός Κυτταρολόγος στα Ιωάννινα, στο Διαγνωστικό Εργαστήριο Βιολογικών Υλικών.

ΓΛΩΣΣΕΣ

- Ελληνικά: Native (C2 European Framework Level)
- Αγγλικά: English Fluent (C2 European Framework Level)
- Ιταλικά: Very Good (B2 European Framework Level)

ΠΙΣΤΟΠΟΙΗΣΕΙΣ-ΜΕΤΕΚΠΑΙΔΕΥΣΕΙΣ

- **Σεπτέμβριος 1999, (6 έως 20):** Επισκέπτης Παθολογοανατόμος στο Πανεπιστημιακό Νοσοκομείο, Guy's King's and St Thomas' School of Medicine Institute of liver studies, University of London

ΔΙΔΑΚΤΙΚΗ ΚΑΙ ΕΚΠΑΙΔΕΥΤΙΚΗ ΕΜΠΕΙΡΙΑ

- **Σεπτέμβριος 2008 έως Ιούνιος 2014:** Ωρομίσθια καθηγήτρια στο ΤΕΙ Ηπείρου, στο τμήμα της Νοσηλευτικής Σχολής Ιωαννίνων. Κατά τη διάρκεια των ετών αυτών δίδαξε Ανατομία, Φυσιολογία, Μικροβιολογία.

Συντόνισε δυο πτυχιακές εργασίες με τίτλους:

- ο «Αλκοολική ηπατοπάθεια, αιτιολογικοί παράγοντες και νοσηλευτικές παρεμβάσεις» των φοιτητριών Πίργια Εύα-Ρούτσο Σύλβια.
- ο «Σιδηροπενική αναιμία και νοσηλευτικές παρεμβάσεις» της Λίπε Χριστίνα.

- **Συμμετοχή στο Πρόγραμμα Μεταπτυχιακών Σπουδών (ΠΜΣ) «Εφαρμοσμένος Προγεννητικός Έλεγχος»** του Αριστοτελείου Πανεπιστημίου Θεσσαλονίκης (ΑΠΘ), Σχολή Επιστημών Υγείας, Τμήμα Ιατρικής, ως διδάσκουσα στο μάθημα του β εαρινού εξαμήνου «Screening για καρκίνο του τραχήλου στην κύηση» κατά το ακαδημαϊκό έτος 2022-2023.

- **Διοργάνωση και παρακολούθηση εντατικών σεμιναρίων (IUCP Courses in Pathology-Oncology)**

- ο Ενεργός συμμετοχή στη διοργάνωση και παρακολούθηση των IUCP, στα οποία έχουν δοθεί από την Ευρωπαϊκή Εταιρεία Παθολογικής Ανατομικής συγκεκριμένα μόρια παρακολούθησης.
- ο Τα IUCP είναι μεταπτυχιακά εντατικά courses σε επιλεγμένα θέματα της Ανθρώπινης Παθολογικής Ανατομικής και Κυτταρολογίας τα οποία διοργανώνονται κάθε χρόνο, από το 1996. Στόχος των μαθημάτων είναι να φέρει κοντά νέους γιατρούς Παθολογοανατόμους και Καθηγητές Ειδικούς στους διάφορους τομείς της Παθολογικής Ανατομικής, καθώς και να ενθαρρύνει την ενεργό συμμετοχή όλων των συναδέλφων κατά τη διάρκεια των συζητήσεων μετά τις διαλέξεις και των σεμιναρίων, παρέχοντας μια εις βάθος ανασκόπηση κάθε θέματος.

1. Ioannina University Courses in Pathology (IUCP). LIVER Pathology-Oncology, Ioannina 1998.
2. Ioannina University Courses in Pathology (IUCP). LUNG Pathology-Oncology, Ioannina 1998.
3. Ioannina University Courses in Pathology (IUCP). BREAST Pathology-Oncology, Ioannina, 1999.
4. Eurocellpath 1999, June 24-28, 1999.
5. Ioannina University Courses in Pathology (IUCP). PROSTATE Pathology-Oncology, Ioannina, 1999.

6. Ioannina University Courses in Pathology (IUCP). SALIVARY GLANDS Pathology-Oncology, Ioannina 2000.
7. Ioannina University Courses in Pathology (IUCP). THYROID Pathology-Oncology, Ioannina, 2000.
8. Ioannina University Courses in Pathology (IUCP). OESOPHAGUS-STOMACH, Pathology-Oncology, Ioannina, May 15-17, 2001.
9. Ioannina University Courses in Pathology (IUCP). DUODENUM-BILIARY TRACT-PANCREAS Pathology-Oncology, Ioannina, 2001.
10. Ioannina University Courses in Pathology (IUCP). SMALL INTESTINE Pathology-Oncology, Ioannina, May 28-29, 2002.
11. Ioannina University Courses in Pathology (IUCP). LARGE INTESTINE Pathology-Oncology, May 30-1 June, 2002.
12. Ioannina University Courses in Pathology (IUCP). KIDNEY Pathology-Oncology, May 27-28, 2003.
13. Ioannina University Courses in Pathology (IUCP). URINARY BLADDER Pathology-Oncology, May 29-31, 2003.
14. Ioannina University Courses in Pathology (IUCP). VULVA, VAGINA AND CERVIX, Pathology-Oncology, Ioannina, May 25-26, 2004.
15. Ioannina University Courses in Pathology (IUCP). "Endometrium, Ovaries and Accessories". Pathology-Oncology", Ioannina, May 27-28, 2004.
16. Ioannina University Courses in Pathology (IUCP). Neuroendocrine, 'From head to the toe', Pathology-Oncology Part I, May 22-23, 2007.
17. Ioannina University Courses in Pathology (IUCP). BONE, part I, SOFT TISSUE, part II, Pathology-Oncology, May 27-30, 2008.
18. Ioannina University Courses in Pathology (IUCP). KIDNEYS. Pathology-Oncology, September 14-15, 2010.
19. Chairs: Dr. N. Zagorianakou (GR), Prof. J. Georgiou (GR) 18.00-19.00
PLENARY LECTURE
"Ovarian Carcinogenesis, with emphasis on epithelial ovarian tumors"
Ass. Prof. E. Kostopoulou (GR)
20. Ioannina University Courses in Pathology (IUCP). Uterus. Pathology-Oncology, 31 May-1 June , 2011.

21. Ioannina University Courses in Pathology (IUCP). Ovaries, Pathology-Oncology, 2-3 June, 2011.
22. Ioannina University Courses in Pathology (IUCP). LIVER Pathology-Oncology, Part I-II, 24-27 April 2012
23. Ioannina University Courses in Pathology (IUCP). BREAST, Pathology-Oncology, 28- 31 May, 2013.
24. Ioannina University Courses in Pathology (IUCP). Skin 29 Pathology-Oncology, April-31 May, 2014.
25. Ioannina University Courses in Pathology (IUCP). Updeat on Head and Neck, Pathology-Oncology, Part I-II, 12-15 May, 2015.
26. Ioannina University Courses in Pathology (IUCP) Lung, Pathology-Oncology, 19 to 21, May 2017.

ΕΠΙΣΤΗΜΟΝΙΚΟ-ΕΡΕΥΝΗΤΙΚΟ ΕΡΓΟ

- Ερευνητικές μελέτες όπου εμφανίζονται στην τράπεζα δεδομένων Med Line, της Εθνικής Αμερικανικής Βιβλιοθήκης και του Εθνικού Ιδρύματος Υγείας, στο Google Scholar, σε επιστημονικά περιοδικά με κριτές

ΔΗΜΟΣΙΕΥΣΕΙΣ ΣΕ ΔΙΕΘΝΗ ΠΕΡΙΟΔΙΚΑ (με Σύστημα Κριτών Πλήρους Κειμένου)

1. **Zagorianakou N.**, Mantzoukas S., Tatsis F., Tsiloni E., Georgakis S., Nakou A., Gouva M. & Dragioti E. (2023). Associations between physical activity and health outcomes in clinical and non-clinical populations: A systematic meta-umbrella review, F1000Research, (accepted).
2. **Zagorianakou N.**, Tsitsas G., Dragioti E., Konstanti Z., Mantzoukas S. & Gouva M. (2023). Psychometric and factor analysis of the Greek version of the SpREUK Questionnaire. Creative Education, (accepted).
3. **Zagorianakou, N.**, Katrachouras A., Almousa N., Skentou C. & Makrydimas, G. (2023). A Large Exophytic Tumor of the Cervix Causing Vaginal Bleeding in Pregnancy: A Case Report. *Cureus*, 15(3).
4. **Zagorianakou, N.**, Mitrogiannias I., Konis K., Makrydimas, S., Mitrogiannis L. & Makrydimas, G., (2023). The HPV-DNA Test in Pregnancy: A Review of the Literature. *Cureus*, 15(5).

5. **Zagorianakou, N.**, Mitrogiannis I., Konis K. & Makrydimas, G. (2023). Test Papanicolaou during pregnancy: perceptions and reality in clinical practice: a review of the literature. *J Comm Med and Pub Health Rep*, 4(01).
6. Mastora, E., Kitsou, C., Evangelou, T., Zikopoulos, A., **Zagorianakou, N.**, & Georgiou, I. (2021). Presence of HPV 16 and HPV 18 in Spermatozoa and Embryos of Mice. *in vivo*, 35(6), 3203-3209.
7. Tsagkas, N., Troussa, A., Vorgias, G., Tzaida, O., **Zagorianakou, N.**, & Gonidi, M. (2020). Extramedullary Leukemia, Presenting at the Cervix of the Uterus. *Case Reports in Obstetrics and Gynecology*, 2020.
8. Pappa, L., **Zagorianakou, N.**, Kitsiou, E., Sintou-Mantela, E., Bafa, M., & Malamou-Mitsi, V. (2008). Breast Metastasis from Uterine Leiomyosarcoma Diagnosed by Fine Needle Aspiration A Case Report. *Acta cytologica*, 52(4), 485-489.
9. Kaponis, A., Skyrilas, A., **Zagorianakou, N.**, Georgiou, I., Passa, V., Paraskevaidis, E., & Makrydimas, G. (2008). Coelomic cells show apoptosis via Fas/FasL system: a comparative study between healthy human pregnancies and missed miscarriages. *Human reproduction*, 23(5), 1159-1169.
10. Panteli, K., Bai, M., Hatzimichael, E., **Zagorianakou, N.**, Agnantis, N. J., & Bourantas, K. (2007). Serum levels, and bone marrow immunohistochemical expression of, vascular endothelial growth factor in patients with chronic myeloproliferative diseases. *Hematology*, 12(6), 481-486.
11. Batistatou, A., Makrydimas, G., **Zagorianakou, N.**, Zagorianakou, P., Nakanishi, Y., Agnantis, N. J., ... & Charalabopoulos, K. (2007). Expression of dysadherin and E-cadherin in trophoblastic tissue in normal and abnormal pregnancies. *Placenta*. May-Jun; 28(5-6): 590-2.
12. Zagorianakou, P., **Zagorianakou, N.**, Stefanou, D., Makrydimas, G., & Agnantis, N. J. (2006). The enigmatic nature of apocrine breast lesions. *Virchows Archiv*, 448, 525-531.
13. **Zagorianakou, N.**, Stefanou, D., Makrydimas, G., Zagorianakou, P., Briasoulis, E., Karavasilis, V., ... & Agnantis, N. J. (2006). Clinicopathological study of metallothionein immunohistochemical expression, in benign, borderline and malignant ovarian epithelial tumors. *Histology and histopathology*. 21, 341-347.

14. Panteli, K., **Zagorianakou, N.**, Agnantis, N. J., Bourantas, K. L., & Bai, M. (2005). Clinical correlation of bone marrow microvessel density in essential thrombocythemia. *Acta haematologica*, 114(2), 99-103.
15. Mitselou, A., Ioachim, E., Kitsou, E., Vougiouklakis, T., **Zagorianakou, N.**, Makrydimas, G., ... & Agnantis, N. J. (2003). Immunohistochemical study of apoptosis-related Bcl-2 protein and its correlation with proliferation indices (Ki67, PCNA), tumor suppressor genes (p53, pRb), the oncogene c-erbB-2, sex steroid hormone receptors and other clinicopathological features, in normal, hyperplastic and neoplastic endometrium. *In Vivo (Athens, Greece)*, 17(5), 469-477.
16. Zagorianakou P., Malamou-Mitsi V., **Zagorianakou N.**, Stefanou D., Tsatsoulis A., Agnantis N.J. (2005). The Role of Fine-needle Aspiration Biopsy in the Management of Patients with Thyroid Nodules. *In Vivo*, 19(3): 605-9.
17. Zagorianakou, P., Fiaccavento, S., **Zagorianakou, N.**, Makrydimas, G., Stefanou, D., & Agnantis, N. J. (2005). FNAC: its role, limitations and perspective in the preoperative diagnosis of breast cancer. *European journal of gynaecological oncology*, 26(2), 143-149.
18. Mitselou A., Ioachim E., **Zagorianakou N.**, Kitsiou E., Vougiouklakis T., Agnantis N.J. (2004). Expression of the cell-cycle regulatory proteins (cyclins D1 and E) in endometrial carcinomas: correlations with hormone receptor status, proliferating indices, tumor suppressor gene products (p53, pRb), and clinicopathological parameters. *Eur J Gynaecol Oncol*. 25(6): 719-24.
19. **Zagorianakou N.**, Stefanou D., Makrydimas G., Zagorianakou P., Briasoulis E., Karavasilis B., Agnantis N.J. (2004). CD44s expression, in benign, borderline and malignant tumors of ovarian surface epithelium. Correlation with p53, steroid receptor status, proliferative indices (PCNA, MIB1) and survival. *Anticancer Res*. 24 (3a): 1665-70.
20. Panteli K., **Zagorianakou N.**, Bai M., Katsaraki A., Agnantis N.J., Bourantas K. (2004). Angiogenesis in chronic myeloproliferative diseases detected by CD34 expression. *Eur J Haematol*. 72(6): 410-5.
21. **Zagorianakou N.**, Ioachim E., Mitselou A., Kitsou E., Zagorianakou P., Makrydimas G., Salmas M., Agnantis N.J. (2003). Immunohistochemical expression of heat shock protein 27, in normal hyperplastic and neoplastic endometrium: correlation with estrogen and progesterone receptor status, p53, pRb and proliferation associated indices (PCNA, MIB1). *Eur J Gynaecol Oncol*. 24(3-4):299-304.

22. **Zagorianakou N.**, Ioachim E., Mitselou A., Kitsou E., Zagorianakou P., Stefanaki S., Makrydimas G., Agnantis N.J. (2003). Glycoprotein CD44 expression in normal, hyperplastic and neoplastic endometrium. An immunohistochemical study including correlations with p53, steroid receptor status and proliferative indices (PCNA, MIB1). *Eur J Gynaecol Oncol.* 24(6): 500-4.
23. Sebire N.J., Makrydimas G., Agnantis N.J., **Zagorianakou N.**, Rees H., Fisher R.A. (2003). Updated diagnostic criteria for partial and complete hydatidiform moles in early pregnancy. *Anticancer Res.* 23(2C):1723-8.
24. Ioachim E., Kitsiou E., Charalabopoulos K., Mitselou A., **Zagorianakou N.**, Makrydimas G., Tzioras S., Salmas M. (2003). Immunohistochemical evaluation of cathepsin D in normal, hyperplastic and malignant endometrium: correlation with hormone receptor status c-erbB-2, p53, Rb proteins and proliferation associated indices. *Int J Gynecol Cancer.* 13(3):344-351.
25. Makrydimas G., **Zagorianakou N.**, Zagorianakou P., Agnantis N.J. (2003). CD44 family and gynaecological cancer. *In Vivo.* 17(6): 633-40.
26. Makrydimas G., Sebire N.J., Thornton S.E., **Zagorianakou N.**, Lolis D., Fisher R.A. (2002). Complete hydatidiform mole and normal live birth: a novel case of confined placental mosaicism: case report. *Hum Reprod.* 17(9):2459-63.
27. Assimakopoulos, D., Kolettas, E., **Zagorianakou, N.**, Evangelou, A., Skevas, A., & Agnantis, N. J. (2000). Prognostic significance of p53 in the cancer of the larynx. *Anticancer research*, 20(5B), 3555-3564.

ΑΝΑΚΟΙΝΩΣΕΙΣ ΣΕ ΣΥΝΕΔΡΙΑ ΚΑΙ ΔΗΜΟΣΙΕΥΣΕΙΣ ΣΕ ΤΟΜΟΥΣ ΠΕΡΙΛΗΨΕΩΝ (Σε

Συνέδρια με Κριτές]

1. 3^ο Πανελλήνιο Συνέδριο Δεικτών Καρκίνου, Αθήνα, 30 Νοεμβρίου – 2 Δεκεμβρίου, 2000. Ανοσοϊστοχημική ανίχνευση του CD44 σε επιθηλιακές αλλοιώσεις της ωοθήκης. Συσχέτιση αυτού με την έκφραση υποδοχέων οιστρογόνων και προγεστερόνης, δεικτών πολλαπλασιασμού Ki-67 και PCNA, και με την έκφραση της p53 πρωτεΐνης. **Zagorianάκου N.**, Ιωακείμ E., Ζαγοριανάκου Π., Αγκνάντη ΝΙ.
2. 2^ο Πανηπειρωτικό Ιατρικό Συνέδριο, Ιωάννινα, 10-12 Οκτωβρίου, 2002. Ανοσοϊστοχημική ανίχνευση της γλυκοπρωτεΐνης CD44 στο φυσιολογικό, υπερπλαστικό και νεοπλασματικό ενδομήτριο. Συσχέτιση με υποδοχείς οιστρογόνων και προγεστερόνης, δείκτες

- πολλαπλασιασμού (PCNA, MIB1) και με την έκφραση της p53 πρωτεΐνης.Ζαγοριανάκου Ν., Ιωακείμ Ε, Κίτσου Ε., Μητσέλου Α., Ζαγοριανάκου Π., Στεφανάκη Σ., Βουγιουκλάκης Θ., Αγνάντη Ν.Ι.
3. 2^ο Πανεπιστημιακό Ιατρικό Συνέδριο, Ιωάννινα, 10-12 Οκτωβρίου, 2002. Διαγνωστική προσέγγιση οζώδους θυρεοειδικής νόσου με FNA βιοψία. Εμπειρία δέκα χρόνων. Π. Ζαγοριανάκου, Β. Μαλάμου-Μήτση, Ν. Ζαγοριανάκου, Μ. Μπάφα, Α. Παππά, Ε. Σίντου, Α.Τσατσούλης, Ν.Ι.Αγνάντη.
 4. 2^ο Πανεπιστημιακό Ιατρικό Συνέδριο, Ιωάννινα, 10-12 Οκτωβρίου, 2002. Ανοσοιστοχημική έκφραση της p21/WAF-1 πρωτεΐνης στο φυσιολογικό, υπερπλαστικό και νεοπλασματικό ενδομήτριο. Ε. Ιωακείμ, Ν. Ζαγοριανάκου, Α. Μητσέλου, Ε. Κίτσου, Π. Ζαγοριανάκου, Σ. Στεφανάκη, Θ. Βουγιουκλάκης, Ν.Ι.Αγνάντη.
 5. 2^ο Πανεπιστημιακό Ιατρικό Συνέδριο, Ιωάννινα, 10-12 Οκτωβρίου, 2002. Ανοσοιστοχημική ανίχνευση της πρωτεΐνης 27 του θερμιδικού shock (HSP27) στο φυσιολογικό, υπερπλαστικό και νεοπλασματικό ενδομήτριο. Συσχέτιση με υποδοχείς οιστρογόνων και προγεστερόνης, δείκτες πολλαπλασιασμού (PCNA, MIB1) και με την έκφραση της p53 πρωτεΐνης. Α. Μητσέλου, Ε. Ιωακείμ, Ν. Ζαγοριανάκου, Ε. Κίτσου, Π. Ζαγοριανάκου, Σ. Στεφανάκη, Θ. Βουγιουκλάκης, Ν. Ι. Αγνάντη.
 6. Acceptability of human papilloma virus (HPV) vaccine among female students in Greece. Zagorianakou N, Nastou E, Zagorianakou P and Gouva M. European congress of Cytology, Istanbul, September, 2011 Zagorianakou N. Cytopathologist, Nastou E. Student of Nursing Department, Higher Technological Educational Institution of Epirus, Zagorianakou P. Cytopathologist Gouva M. Assistant Professor of Nursing Department, Higher Technological Educational Institution of Epirus, Greece
 7. **Θηλώδες καρκίνωμα Θυρεοειδούς σε νεαρή γυναίκα.** Ζαγοριανάκου Π, Ζαγοριανάκου Ν, Γιωτάκη Ζ, Παππά Α. Πανελλήνιο Συνέδριο Ενδοκρινολογίας.

ΕΠΙΣΤΗΜΟΝΙΚΑ ΒΙΒΛΙΑ

Συγγραφέας (Co-author) του ηλεκτρονικού βιβλίου (e-book) για το μαστό (<http://www.axes.it/mammella>) Άτλας Κυτταροπαθολογίας Μαστού (Atlas of Breast Cytopathology). Author: Sergio Fiaccavento. Responsabile Servizio di Citopatologia Diagnostica Istituto Clinico città di Brescia

Co-author: Nektaria Zagorianakou, Cytologist, MD, PhD, Panagiota Zagorianakou, Cytologist, MD, PhD, Department of Pathology, Ioannina Medical School, University of Ioannina, Niki J.

Agnantis MD, PhD, FRC PathEmeritus Professor of Pathology, Medical School, University of Ioannina, Greece

ΑΛΛΑ ΒΙΒΛΙΑ

- Η Νεκταρία-Σταυρούλα Ζαγοριανάκου έχει εκδώσει τα ακόλουθα ιστορικά μυθιστορήματα:
 1. «Γνωριμία... με το Ζαγόρι» εκδόσεις Εφύρα 2011
 2. «Τα θεριά της Μεσογείου» εκδόσεις Ωκεανίδα, 2014
 3. «Ο μεγάλος σοφός» εκδόσεις Ωκεανίδα, 2015
 4. «Μετάξι» εκδόσεις Κέδρος, 2018

Πηγή: <https://www.biblionet.gr> βιβlionet, The Greek books in print

ΑΡΘΡΟΓΡΑΦΙΑ

- Αρθρογραφεί στη διαδικτυακή εφημερίδα **Athens Voice** από το 2017

[Νεκταρία Ζαγοριανάκου - Athens Voice](#)



[athensvoice.gr](https://www.athensvoice.gr)

<https://www.athensvoice.gr › nektaria-zagorianakoy>

ΠΙΝΑΚΑΣ ΔΙΕΘΝΩΝ ΠΕΡΙΟΔΙΚΩΝ ΓΙΑ ΤΙΣ ΔΗΜΟΣΙΕΥΣΕΙΣ ΠΛΗΡΟΥΣ ΚΕΙΜΕΝΟΥ ΜΕ ΤΟΝ ΑΝΤΙΣΤΟΙΧΟ ΣΥΝΤΕΛΕΣΤΗ ΑΠΗΧΗΣΗΣ (IMPACT FACTOR)

ΣΥΓΚΕΝΤΡΩΤΙΚΟΣ ΠΙΝΑΚΑΣ ΔΗΜΟΣΙΕΥΣΕΩΝ ΑΝΑ ΠΕΡΙΟΔΙΚΟ ΔΕΙΚΤΗΣ ΑΠΗΧΗΣΗΣ ΔΙΕΘΝΩΝ ΠΕΡΙΟΔΙΚΩΝ			
Περιοδικό	Αριθμός Εργασιών	Impact Factor	Total
Acta cytologica	1	1,8	1,8
Acta haematologica	1	3,068	3,068
Anticancer Res.	3	2,435	4,87
Case Reports in Obstetrics and Gynecology	1	0,54	0,54
<i>Creative Education</i>	1	1,02	1,02
Cureus	2	1,2	2,4
Eur J Haematol.	1	3,674	3,674
European journal of gynaecological oncology	2	0,4	0,8
<i>F 1000</i>	1	0,939	0,939
Hematology	1	2,269	2,269
Histology and histopathology	1	2,13	2,13
Human reproduction	2	6,353	12,706
In Vivo	4	2,406	9,624
Int J Gynecol Cancer.	1	4,8	4,8
J Comm Med and Pub Health Rep	1	3,525	3,525
Placenta	1	3,287	3,287
Virchows Archiv,	1	4,548	4,548
Αθροισμα Συντελεστή Απήχησης:			62
Μέσος Συντελεστή Απήχησης:			2,296

ΣΕΙΡΑ ΥΠΟΨΗΦΙΑΣ ΜΕΤΑΞΥ ΣΥΓΓΡΑΦΕΩΝ ΣΤΙΣ ΔΗΜΟΣΙΕΥΣΕΙΣ ΣΕ ΞΕΝΟΓΛΩΣΣΑ ΠΕΡΙΟΔΙΚΑ	
27 ΔΗΜΟΣΙΕΥΣΕΙΣ ΣΕ ΞΕΝΟΓΛΩΣΣΑ ΠΕΡΙΟΔΙΚΑ	
1^η Συγγραφέας:	9
2^η Συγγραφέας:	5
Τελευταία Συγγραφέας:	-
Άλλη Θέση:	13

ΔΕΙΚΤΗΣ HIRSH (H-INDEX Η' H-FACTOR) – ΑΝΑΦΟΡΕΣ

A. Google Scholar

	Όλα	Από το 2018
Παραθέσεις	702	129
h-index	15	6
i10-index	16	5

(πηγή: <https://scholar.google.com/citations?hl=el&user=ZeszQBcAAAAI>)



B. Scopus



Scopus Preview

This author profile is generated by Scopus. [Learn more](#)

Zagorianakou, Nektaria

Cytopathology Laboratory, Ioannina, Greece 6603361074

447

Citations by **426 documents**

24

Documents

12

h-index [View *h*-graph](#)

Γ. ΑΝΑΦΟΡΕΣ ΑΠΟ ΑΛΛΟΥΣ ΣΥΓΓΡΑΦΕΙΣ

- Mastora, E., Kitsou, C., Evangelou, T., Zikopoulos, A., **Zagorianakou, N.**, & Georgiou, I. (2021). Presence of HPV 16 and HPV 18 in Spermatozoa and Embryos of Mice. *in vivo*, 35(6), 3203-3209.
 1. Milano, G., Guarducci, G., Nante, N., Montomoli, E., & Manini, I. (2023). Human Papillomavirus Epidemiology and Prevention: Is There Still a Gender Gap?. *Vaccines*, 11(6), 1060.
 2. Das, S., Doss C, G. P., Fletcher, J., Kannangai, R., Abraham, P., & Ramanathan, G. (2023). The impact of human papilloma virus on human reproductive health and the effect on male infertility: An updated review. *Journal of Medical Virology*, 95(4), e28697.
 3. Tramontano, L., Sciorio, R., Bellaminutti, S., Esteves, S. C., & Petignat, P. (2023). Exploring the potential impact of human papillomavirus on infertility and assisted reproductive technology outcomes. *Reproductive Biology*, 23(2), 100753.
- Tsagkas, N., Troussa, A., Vorgias, G., Tzaida, O., **Zagorianakou, N.**, & Gonidi, M. (2020). Extramedullary Leukemia, Presenting at the Cervix of the Uterus. *Case Reports in Obstetrics and Gynecology*, 2020.
 1. Hamer, J., Alazizi, M., & Tahmasebi, F. (2022). An Unusual Case of Chronic Lymphocytic Leukaemia Involving the Cervix. *Cureus*, 14(2).
 2. Gera, K., Rodriguez, D., Rodriguez, G. A., Elliott, L. A., Seifert, R. P., & Hsu, J. W. (2023). Recurrent Extramedullary Relapse of Immunophenotypically Aberrant B Lymphoblastic Leukemia to Unusual Sites After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report.
- Pappa, L., **Zagorianakou, N.**, Kitsiou, E., Sintou-Mantela, E., Bafa, M., & Malamou-Mitsi, V. (2008). Breast Metastasis from Uterine Leiomyosarcoma Diagnosed by Fine Needle Aspiration A Case Report. *Acta cytologica*, 52(4), 485-489.
 1. Pinto, D., & Schmitt, F. C. (2022). Immunohistochemistry applied to breast cytological material. *Pathobiology*, 89(5), 343-358.

2. DeLair, D. F., Corben, A. D., Catalano, J. P., Vallejo, C. E., Brogi, E., & Tan, L. K. (2013). Non-mammary metastases to the breast and axilla: a study of 85 cases. *Modern Pathology*, 26(3), 343-349.
3. Goyal, A. (2023). Role of Fine Needle Aspiration Cytology in the Diagnosis of Gynecologic Tumors. *Acta Cytologica*, 67(2), 195-212.
4. Koch, A., Richter-Marot, A., Wissler, M. P., Baratte, A., & Mathelin, C. (2013). Métastases mammaires de cancers d'origine extra-mammaire: état des lieux et difficultés diagnostiques. *Gynécologie Obstétrique & Fertilité*, 41(11), 653-659.
5. Ahuja, A., Agarwal, P., Sardana, R., & Bhaskar, S. (2017). Extensively metastasizing leiomyosarcoma: A diagnostic challenge. *Journal of Mid-life Health*, 8(3), 148.
6. Sonoda, K., Nogami, M., Kodama, K., Oda, Y., & Kato, K. (2020). Re-evaluation of preoperative endometrial smears for the cytodiagnosis of uterine leiomyosarcoma. *European Journal of Gynaecological Oncology*, 41(2), 167-170.
7. Мнацканян, И. К., Чекалова, М. А., Лазарева, Н. И., & Феденко, А. А. (2022). Ультразвуковая диагностика метастазов лейомиосаркомы матки. *Саркомы костей, мягких тканей и опухоли кожи*, (3-4), 37-43.
8. Handa, U., Kundu, R., Mehra, R., Trehan, R., & Mohan, H. (2014). Uterine leiomyosarcoma metastasizing to multiple sites: a rare presentation. *International Journal of Reproduction, Contraception, Obstetrics and Gynecology*, 3(2), 454.

- Kaponis, A., Skyrilas, A., Zagorianakou, N., Georgiou, I., Passa, V., Paraskevaidis, E., & Makrydimas, G. (2008). Coelomic cells show apoptosis via Fas/FasL system: a comparative study between healthy human pregnancies and missed miscarriages. *Human reproduction*, 23(5), 1159-1169.

1. Hao, F., Tang, L. C., Sun, J. X., Li, W. X., Zhao, Y., Xu, X. H., & Jin, L. P. (2021). Decreased nitric oxide content mediated by asymmetrical dimethylarginine and protein l-arginine methyltransferase 3 in macrophages induces trophoblast apoptosis: a potential cause of recurrent miscarriage. *Human Reproduction*, 36(12), 3049-3061.
2. Zhang, L., Zhao, M., Jiao, F., Xu, X., Liu, X., Jiang, Y., ... & Hu, X. (2015). Interferon gamma is involved in apoptosis of trophoblast cells at the maternal-fetal interface following Toxoplasma gondii infection. *International Journal of Infectious Diseases*, 30, 10-16.
3. Angeloni, M. B., Silva, N. M., Castro, A. S., Gomes, A. O., Silva, D. A. O., Mineo, J. R., & Ferro, E. A. V. (2009). Apoptosis and S phase of the cell cycle in BeWo trophoblastic and HeLa cells are differentially modulated by Toxoplasma gondii strain types. *Placenta*, 30(9), 785-791.
4. Камилова, М. Я., Рахматуллоева, Д. М., & Арабова, С. У. (2017). Изменения плацентарных гормонов и маркеров апоптоза у женщин с угрозой прерывания беременности и отягощенным невынашиванием беременности. *Sciences of Europe*, (14-1 (14)), 45-48.
5. Karthikeyan, V. J., Lip, G. Y., Baghdadi, S., Lane, D. A., Beevers, D. G., & Blann, A. D. (2012). Soluble Fas and Fas ligand in pregnancy: influence of hypertension. *Angiology*, 63(1), 35-38.
6. 卫红, 于书君, & 曹晓辉. (2012). 27464 例人工流产孕妇高危因素分析. *江苏医药*, 38(22), 2735-2736.
7. Vrachnis, N., Dalainas, I., Papoutsis, D., Samoli, E., Rizos, D., Iliodromiti, Z., ... & Botsis, D. (2013). Soluble Fas and Fas-ligand levels in mid-trimester amniotic fluid and their associations with severe small for gestational age fetuses: a prospective observational study. *Journal of Reproductive Immunology*, 98(1-2), 39-44.
8. Плотко, Е. Э., & Абакумова, Е. И. (2011). Неразвивающаяся беременность. Вопросы диагностики и профилактики осложнений. *Уральский медицинский журнал*. 2011. Т. 90, № 12.
9. 杜晶, 张兆奉, & 徐建华. (2013). 遗传及相关因素与稽留流产关系的研究进展. *生殖与避孕*, 33(8), 552-556.
10. Leon-Martinez, D., Robinson, J. F., Zdravkovic, T., Genbacev, O., Gormley, M., McMaster, M., ... & Bianco, K. (2020). Trisomy 21 is Associated with Caspase-2 Upregulation in Cytotrophoblasts at the Maternal-Fetal Interface. *Reproductive Sciences*, 27, 100-109.
11. Арабова, С. У., Мулкамонова, Л. Н., & Ишан-Ходжаева, Ф. Р. (2016). Роль апоптоза и иммуноэндокринные взаимоотношения при физиологической беременности. *Вестник Авиценны*, (4 (69)), 88-93.
12. Hussein, A. H., Elawamy, W., Abd El-Maboud, A. I., Elghareeb, A. S., & Hamadto, H. A. (2016). The role of toxoplasmosis and coincidental placental inflammation and Fas ligand expression as a cause of spontaneous abortion in pregnant women from Benha city, Egypt. *Egypt J Med Sci*, 37, 185-197.
13. 李泽莲, 程玲慧, 向卉芬, & 曹云霞. (2013). 凋亡基因与早期妊娠结局的关系. *中国实用妇科与产科杂志*, 29(6), 516-518.
14. 马云秀, 杨国嵘, 郭群, 闫秀英, & 赵甲升. (2014). Fas, Survivin, PCNA, Ki-67 在胎盘绒毛滋养细胞生存活性评价中的作用. *中国优生与遗传杂志*, (7), 7-8.
15. Wang, L. Q., Zhao, Y., Yu, X. W., & Zhang, Y. A. (2012). Fas ligand (FasL) and Fas-associated death domain (FADD) were elevated in decidual stromal and glandular epithelial cells in spontaneous early miscarriage women. *African Journal of Microbiology Research*, 6(10), 2252-2257.
16. 马云秀, 杨国嵘, 郭群, 张巍巍, & 赵甲升. (2015). 早期自然流产患者胎盘绒毛滋养细胞中 Fas, Survivin, Ki-67 的表达及意义. *中国优生与遗传杂志*, (7), 20-21.
17. Камилова, М. Я., Давлятова, Г. К., Маликоева, С. А., & Аминзода, Н. З. МАТЬ И ДИТЯ. МАТЬ И ДИТЯ Учредители: *Таджикский научно-исследовательский институт акушерства, гинекологии и перинатологии*, (1), 14-17.
18. 吴玉英, & 陈昌益. (2013). 稽留流产与滋养层细胞凋亡关系的研究进展. *中国临床新医学*, 6(2), 174-178.

19. 朱丽均, 陈亚萍, 陈炳锦, & 梅小会. (2012). 稽留流产绒毛中线粒体膜电位和活性氧的变化. *中国妇幼保健*, 27(33), 5343-5345.
20. 何双, & 顾向应. (2011). Fas/FasL 系统介导的细胞凋亡与卵泡闭锁及稽留流产的关系. *中国计划生育和妇产科*, 3(2), 77-80.
21. 刘云龙, 宋卓, 彭冰洁, 许诗豪, 朱琪, & 王征. (2015). 绿原酸对 Fas/FasL 途径介导的非酒精性脂肪肝细胞凋亡的影响. *中国食物与营养*, 21(7), 67-70.
22. Δαλαϊνας, Η. (2015). *Μοριακοί παράγοντες φλεγμονής στο αμνιακό υγρό του δευτέρου τριμήνου κύησης που οδηγούν σε υπολειπόμενη ανάπτυξη του εμβρύου* (Doctoral dissertation, Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών (ΕΚΠΑ). Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής. Τομέας Υγείας Μητέρας και Παιδιού. Κλινική Β' Μαιευτική και Γυναικολογική ΑΡΕΤΑΙΕΙΟΥ Νοσοκομείου).
23. Karthikeyan, V. J. (2012). *Vascular biology of pregnancy: a study of endothelial markers in hypertension in pregnancy* (Doctoral dissertation, University of Birmingham).
24. Plotko, E. E., & Abakumova, E. I. (2011). Missed abortion. The diagnosis and prevntntion of complications. *Уральский медицинский журнал*, (12), 100-104.
25. Παπαθεοδώρου, Σ. Η. (2011). *Μελέτη βιοχημικών παραγόντων στο εξωεμβρυϊκό υγρό*.
26. 邵芳, & 王冬梅. (2009). 子痫前期胎盘浅植入理论研究进展. *中国优生与遗传杂志*, (6), 5-6.
27. Арабова, С. У. (2018). *КЛИНИЧЕСКОЕ ЗНАЧЕНИЕ УЛЬТРАЗВУКОВОГО И ЛАБОРАТОРНЫХ МЕТОДОВ ИССЛЕДОВАНИЯ В ДИАГНОСТИКЕ ПЛАЦЕНТАРНОЙ НЕДОСТАТОЧНОСТИ У ЖЕНЩИН С УГРОЗОЙ ПЕРЕРЫВАНИЯ БЕРЕМЕННОСТИ* (Doctoral dissertation, ГОСУДАРСТВЕННОЕ УЧРЕЖДЕНИЕ ТАДЖИКСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ АКУШЕРСТВА, ГИНЕКОЛОГИИ И ПЕРИНАТОЛОГИИ).

- Panteli, K., Bai, M., Hatzimichael, E., **Zagorianakou, N.**, Agnantis, N. J., & Bourantas, K. (2007). Serum levels, and bone marrow immunohistochemical expression of, vascular endothelial growth factor in patients with chronic myeloproliferative diseases. *Hematology*, 12(6), 481-486.

1. Bhuria, V., Baldauf, C. K., Schraven, B., & Fischer, T. (2022). Thromboinflammation in myeloproliferative neoplasms (MPN)—a puzzle still to be solved. *International Journal of Molecular Sciences*, 23(6), 3206.
2. Desterke, C., Martinaud, C., Ruzehaji, N., & Bousse-Kerdilès, L. (2015). Inflammation as a keystone of bone marrow stroma alterations in primary myelofibrosis. *Mediators of inflammation*, 2015.
3. Maes, C., Goossens, S., Bartunkova, S., Drogat, B., Coenegrachts, L., Stockmans, I., ... & Haigh, J. J. (2010). Increased skeletal VEGF enhances β -catenin activity and results in excessively ossified bones. *The EMBO journal*, 29(2), 424-441.
4. Greenwald, A. C., Licht, T., Kumar, S., Oladipupo, S. S., Iyer, S., Grunewald, M., & Keshet, E. (2019). VEGF expands erythropoiesis via hypoxia-independent induction of erythropoietin in noncanonical perivascular stromal cells. *Journal of Experimental Medicine*, 216(1), 215-230.
5. Karagianni, A., & Ravid, K. (2022). Myeloproliferative disorders and their effects on bone homeostasis: the role of megakaryocytes. *Blood, The Journal of the American Society of Hematology*, 139(21), 3127-3137.
6. Hoermann, G., Greiner, G., & Valent, P. (2015). Cytokine regulation of microenvironmental cells in myeloproliferative neoplasms. *Mediators of inflammation*, 2015.
7. Yang, J. G., Wang, L. L., & Ma, D. C. (2018). Effects of vascular endothelial growth factors and their receptors on megakaryocytes and platelets and related diseases. *British Journal of Haematology*, 180(3), 321-334.
8. Purton, L. E., & Scadden, D. T. (2008). The hematopoietic stem cell niche. *StemBook [Internet]*.
9. Mesnieres, M., Böhm, A. M., Peredo, N., Trompet, D., Valle-Tenney, R., Bajaj, M., ... & Maes, C. (2021). Fetal hematopoietic stem cell homing is controlled by VEGF regulating the integrity and oxidative status of the stromal-vascular bone marrow niches. *Cell reports*, 36(8).
10. Subotički, T., Mitrović Ajtić, O., Živković, E., Diklić, M., Đikić, D., Tošić, M., ... & Čokić, V. (2021). VEGF regulation of angiogenic factors via inflammatory signaling in myeloproliferative neoplasms. *International Journal of Molecular Sciences*, 22(13), 6671.
11. Wang, Y., & Zuo, X. (2019). Cytokines frequently implicated in myeloproliferative neoplasms. *Cytokine: X*, 1(1), 100005.
12. Alonci, A., Allegra, A., Bellomo, G., Penna, G., D'Angelo, A., Quartarone, E., & Musolino, C. (2008). Evaluation of circulating endothelial cells, VEGF and VEGFR2 serum levels in patients with chronic myeloproliferative diseases. *Hematological oncology*, 26(4), 235-239.
13. Villani, L., Carolei, A., Rosti, V., Massa, M., Campanelli, R., Catarsi, P., ... & Barosi, G. (2021). Clinical relevance of VEGFA (rs3025039)+ 936 C> T polymorphism in primary myelofibrosis: Susceptibility, clinical co-variates, and outcomes. *Genes*, 12(8), 1271.
14. Trelinski, J., Wierzbowska, A., Krawczyńska, A., Sakowicz, A., Pietrucha, T., Smolewski, P., ... & Chojnowski, K. (2010). Circulating endothelial cells in essential thrombocythemia and polycythemia vera: correlation with JAK2-V617F mutational status, angiogenic factors and coagulation activation markers. *International journal of hematology*, 91, 792-798.

15. Lekovic, D., Gotic, M., Skoda, R., Beleslin-Cokic, B., Milic, N., Mitrovic-Ajtic, O., ... & Cokic, V. P. (2017). Bone marrow microvessel density and plasma angiogenic factors in myeloproliferative neoplasms: clinicopathological and molecular correlations. *Annals of hematology*, 96, 393-404.
16. Trelinski, J., Wierzbowska, A., Krawczyńska, A., Sakowicz, A., Pietrucha, T., Smolewski, P., ... & Chojnowski, K. (2010). Plasma levels of angiogenic factors and circulating endothelial cells in essential thrombocythemia: correlation with cytoreductive therapy and JAK2-V617F mutational status. *Leukemia & lymphoma*, 51(9), 1-7.
17. Subotički, T., Mitrović Ajtić, O., Beleslin-Čokić, B. B., Nienhold, R., Diklić, M., Djikić, D., ... & Čokić, V. P. (2017). Angiogenic factors are increased in circulating granulocytes and CD34+ cells of myeloproliferative neoplasms. *Molecular carcinogenesis*, 56(2), 567-579.
18. Gadomska, G., Stankowska, K., Boinska, J., Ślusarz, R., Tylicka, M., Michalska, M., ... & Roś, D. (2017). VEGF-A, sVEGFR-1, and sVEGFR-2 in BCR-ABL negative myeloproliferative neoplasms. *Medicina*, 53(1), 34-39.
19. Allegra, A., Alonci, A., Bellomo, G., D'Angelo, A., Granata, A., Russo, S., ... & Musolino, C. (2009). Evaluation of interleukin-17 serum levels in patients with chronic myeloproliferative diseases. *Tumori*, 95(3), 404.
20. Apostolidou, E., Kantarjian, H., Thomas, D., Burger, I., Borthakur, G., & Verstovsek, S. (2010). Phase II Study of Sunitinib in Patients With Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis. *Clinical Lymphoma Myeloma and Leukemia*, 10(4), 281-284.
21. Корсакова, Н. Е. (2021). Особенности состояния эндотелия при Ph-негативных миелопролиферативных новообразованиях. *Сибирский научный медицинский журнал*, 41(6), 30-44.
22. КОРСАКОВА, Н. Е. (2021). СИБИРСКИЙ НАУЧНЫЙ МЕДИЦИНСКИЙ ЖУРНАЛ. СИБИРСКИЙ НАУЧНЫЙ МЕДИЦИНСКИЙ ЖУРНАЛ Учредители: Федеральный исследовательский центр институт цитологии и генетики СО РАН, Сибирское отделение РАН, 41(6), 30-44.
23. 张晓红, 江和碧, 郭海霞, & 李文益. (2008). 血管内皮生长因子反义核酸对细胞株 HL60 及耐药细胞株 HL60/VCR 的抑制作用. *实用儿科临床杂志*, 23(9), 689-691.
24. 连小赞, 苗玉迪, 魏绪仓, 王一, 张玓, & 王岐山. (2008). As203 影响慢性粒细胞白血病细胞 VEGF, MMP-2mRNA 表达的实验研究. *现代检验医学杂志*, 23(6), 48-50.
25. Poisson, J. (2018). *Physiopathologie des événements cardiovasculaires chez les malades atteints de syndrome myéloprolifératif Bcr/Abl-négatif* (Doctoral dissertation, Sorbonne Paris Cité).
26. Neves, K. B. (2016). *Papel do sistema chemerin/ChemR23 na sinalização vascular da insulina de camundongos C57BL/6j e db/db* (Doctoral dissertation, Universidade de São Paulo).

▪ Batistatou, A., Makrydimas, G., Zagorianakou, N., Zagorianakou, P., Nakanishi, Y., Agnantis, N. J., ... & Charalabopoulos, K. (2007). Expression of dysadherin and E-cadherin in trophoblastic tissue in normal and abnormal pregnancies. *Placenta*. May-Jun; 28(5-6): 590-2.

1. Golias, C. H., Tsoutsis, E., Matziridis, A., Makridis, P., Batistatou, A., & Charalabopoulos, K. (2007). Leukocyte and endothelial cell adhesion molecules in inflammation focusing on inflammatory heart disease. *In vivo*, 21(5), 757-769.
2. Adu-Gyamfi, E. A., Czika, A., Gorleku, P. N., Ullah, A., Panhwar, Z., Ruan, L. L., ... & Wang, Y. X. (2021). The involvement of cell adhesion molecules, tight junctions, and gap junctions in human placentation. *Reproductive Sciences*, 28, 305-320.
3. Peng, P., Song, H., Xie, C., Zheng, W., Ma, H., Xin, D., ... & Qin, J. (2021). miR-146a-5p-mediated suppression on trophoblast cell progression and epithelial-mesenchymal transition in preeclampsia. *Biological Research*, 54(1), 1-12.
4. Harris, L. K., Jones, C. J. P., & Aplin, J. D. (2009). Adhesion molecules in human trophoblast—a review. II. Extravillous trophoblast. *Placenta*, 30(4), 299-304.
5. Kretschmer, T., Turnwald, E. M., Janoschek, R., Zentis, P., Bae-Gartz, I., Beers, T., ... & Appel, S. (2020). Maternal high fat diet-induced obesity affects trophoblast differentiation and placental function in mice. *Biology of reproduction*, 103(6), 1260-1274.
6. McEwan, M., Lins, R. J., Munro, S. K., Vincent, Z. L., Ponnampalam, A. P., & Mitchell, M. D. (2009). Cytokine regulation during the formation of the fetal-maternal interface: focus on cell-cell adhesion and remodelling of the extra-cellular matrix. *Cytokine & growth factor reviews*, 20(3), 241-249.
7. Golias, C., Batistatou, A., Bablekos, G., Charalabopoulos, A., Peschos, D., Mitsopoulos, P., & Charalabopoulos, K. (2011). Physiology and pathophysiology of selectins, integrins, and IgSF cell adhesion molecules focusing on inflammation. A paradigm model on infectious endocarditis. *Cell communication & adhesion*, 18(3), 19-32.
8. Perry, J. K., Lins, R. J., Lobie, P. E., & Mitchell, M. D. (2010). Regulation of invasive growth: similar epigenetic mechanisms underpin tumour progression and implantation in human pregnancy. *Clinical Science*, 118(7), 451-457.
9. Tokhtaeva, E., Sun, H., Deiss-Yehiely, N., Wen, Y., Soni, P. N., Gabrielli, N. M., ... & Dada, L. A. (2016). The O-glycosylated ectodomain of FXD5 impairs adhesion by disrupting cell-cell trans-dimerization of Na, K-ATPase β1 subunits. *Journal of cell science*, 129(12), 2394-2406.
10. Sun, Y. Y., Lu, M., Xi, X. W., Qiao, Q. Q., Chen, L. L., Xu, X. M., & Feng, Y. J. (2011). Regulation of epithelial-mesenchymal transition by homeobox gene DLX4 in JEG-3 trophoblast cells: a role in preeclampsia. *Reproductive sciences*, 18(11), 1138-1145.

11. Stemmler, M. P., & Bedzhov, I. (2010). A Cdh1HA knock-in allele rescues the Cdh1^{-/-} phenotype but shows essential Cdh1 function during placentation. *Developmental Dynamics*, 239(9), 2330-2344.
12. Incebiyik, A., Kocarslan, S., Camuzcuoglu, A., Hilali, N. G., Incebiyik, H., & Camuzcuoglu, H. (2016). Trophoblastic E-cadherin and TGF-beta expression in placenta percreta and normal pregnancies. *The Journal of Maternal-Fetal & Neonatal Medicine*, 29(1), 126-129.
13. Simopoulou, M., Nikolopoulou, E., Dimakakos, A., Charalabopoulos, K., & Koutsilieris, M. (2014). Cell adhesion molecules and in vitro fertilization. *in vivo*, 28(5), 683-690.
14. Moussa, R. A., Eesa, A. N., Abdallah, Z. F., Abdelmeged, A., Mahran, A., & Bahaa, H. (2018). Diagnostic utility of twist1, ki-67, and E-cadherin in diagnosing molar gestations and hydropic abortions. *American Journal of Clinical Pathology*, 149(5), 442-455.
15. Pafilis, J., Batistatou, A., Iliopoulou, A., Tsanou, E., Bakogiannis, A., Dassopoulos, G., & Charalabopoulos, K. (2007). Expression of adhesion molecules during normal pregnancy. *Cell and Tissue Research*, 329, 1-11.
16. Erol, O., Süren, D., Tutuş, B., Toptaş, T., Gökay, A. A., Derbent, A. U., ... & Sezer, C. (2016). Immunohistochemical analysis of E-cadherin, p53 and inhibin-α expression in hydatidiform mole and hydropic abortion. *Pathology & Oncology Research*, 22, 515-521.
17. Şahin, H., Akpak, Y. K., Berber, U., Gün, İ., Demirel, D., & Ergür, A. R. (2014). Expression of P-cadherin (cadherin-3) and E-selectin in the villous trophoblast of first trimester human placenta. *Journal of the Turkish German Gynecological Association*, 15(1), 13.
18. Lan, X., Fu, L. J., Hu, Z. Y., Feng, Q., Liu, X. Q., Zhang, X., ... & Ding, Y. B. (2017). Methylated oligonucleotide (MON)-induced promoter hypermethylation is associated with repression of CDH1 expression and contributes to the migration and invasion of human trophoblast cell lines. *Reproduction, Fertility and Development*, 29(8), 1509-1520.
19. Guo, B., Han, B. C., Tian, Z., Zhang, X. M., Jiang, L. X., Liu, J. X., & Yue, Z. P. (2010). Expression and hormonal regulation of E-cadherin in canine uterus during early pregnancy. *Reproduction in Domestic Animals*, 45(6), e255-e259.
20. Georgolios, A., Eleftheriadou, A., Batistatou, A., & Charalabopoulos, K. (2012). Role of the recently identified dysadherin in E-cadherin adhesion molecule downregulation in head and neck cancer. *Medical Oncology*, 29, 1463-1467.
21. Ruan, H., Dai, Z., Yan, J., Long, X., Chen, Y., Yang, Y., ... & Zhang, X. (2022). ZBTB24 (Zinc Finger and BTB Domain Containing 24) prevents recurrent spontaneous abortion by promoting trophoblast proliferation, differentiation and migration. *Bioengineered*, 13(2), 2777-2790.
23. 张勤建, & 颜建英. (2015). E-钙黏素在胎盘植入发病中的作用. *中华围产医学杂志*, (4), 306-309.
24. Γκόλιας, Χ. Γ. (2010). Ο ρόλος διαλυτών μορίων προσκόλλησης σε φλεγμονώδεις καταστάσεις της καρδιάς.
25. Γκόγκου, Π. (2010). Μελέτη προγνωστικών παραγόντων στα σαρκώματα μαλακών μορίων.
26. Χαραλαμπίδης, Α. (2009). Ο Ρόλος των μορίων προσκόλλησης σε καρκίνους της πεπτικής οδού.
28. Chen, J. (2009). *Twist regulates E-cadherin and N-cadherin expression levels in distinct human trophoblastic cell lines in vitro* (Doctoral dissertation, University of British Columbia).
29. Wilson, M. J. (2008). *High altitude, natural selection, & birth weight: Is small good or bad?*. University of Colorado at Denver.
30. 谢宏民, 张厚德, 杜冀晖, & 李佳璇. (2008). Dysadherin 蛋白的研究进展及其与胰腺癌的关系. *医学综述*, 14(22), 3416-3418.

- Zagorianakou, P., Zagorianakou, N., Stefanou, D., Makrydimas, G., & Agnantis, N. J. (2006). The enigmatic nature of apocrine breast lesions. *Virchows Archiv*, 448, 525-531.

1. Dieci, M. V., Orvieto, E., Dominici, M., Conte, P., & Guarneri, V. (2014). Rare breast cancer subtypes: histological, molecular, and clinical peculiarities. *The oncologist*, 19(8), 805-813.
2. Vranic, S., Schmitt, F., Sapino, A., Costa, J. L., Reddy, S., Castro, M., & Gatalica, Z. (2013). Apocrine carcinoma of the breast: a comprehensive review.
3. Lehmann-Che, J., Hamy, A. S., Porcher, R., Barritault, M., Bouhidel, F., Habuelallah, H., ... & Bertheau, P. (2013). Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15. *Breast Cancer Research*, 15, 1-11.
4. Hanley, K., Wang, J., Bourne, P., Yang, Q., Gao, A. C., Lyman, G., & Tang, P. (2008). Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast. *Human pathology*, 39(3), 386-392.
5. Tanaka, K., Imoto, S., Wada, N., Sakemura, N., & Hasebe, K. (2008). Invasive apocrine carcinoma of the breast: clinicopathologic features of 57 patients. *The breast journal*, 14(2), 164-168.
6. Debily, M. A., Marhomy, S. E., Boulanger, V., Eveno, E., Mariage-Samson, R., Camarca, A., ... & Imbeaud, S. (2009). A functional and regulatory network associated with PIP expression in human breast cancer. *PLoS One*, 4(3), e4696.
7. Dorjgochoo, T., Deming, S. L., Gao, Y. T., Lu, W., Zheng, Y., Ruan, Z., ... & Shu, X. O. (2008). History of benign breast disease and risk of breast cancer among women in China: a case-control study. *Cancer Causes & Control*, 19, 819-828.

8. Ghaderi, F., Ahmadvand, S., Ramezani, A., Montazer, M., & Ghaderi, A. (2018). Production and characterization of monoclonal antibody against a triple negative breast cancer cell line. *Biochemical and biophysical research communications*, 505(1), 181-186.
9. Celis, J. E., Moreira, J. M., Gromova, I., Cabezon, T., Gromov, P., Shen, T., ... & Rank, F. (2007). Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia. *Molecular Oncology*, 1(1), 97-119.
10. Tramm, T., Kim, J. Y., Leibl, S., Moinfar, F., & Tavassoli, F. A. (2016). Expression of C-KIT, CD24, CD44s, and COX2 in benign and non-invasive apocrine lesions of the breast. *Virchows Archiv*, 469, 285-295.
11. Masood, S., & Rosa, M. (2009). The challenge of apocrine proliferations of the breast: a morphologic approach. *Pathology-Research and Practice*, 205(3), 155-164.
12. Gromov, P., Espinoza, J. A., & Gromova, I. (2015). Molecular and diagnostic features of apocrine breast lesions. *Expert Review of Molecular Diagnostics*, 15(8), 1011-1022.
13. Kondo, H., Onuma, M., Shibuya, H., & Sato, T. (2009). Morphological and immunohistochemical studies of spontaneous mammary tumours in Siberian hamsters (*Phodopus sungorus*). *Journal of comparative pathology*, 140(2-3), 127-131.
14. Kaya, H., Bozkurt, S. U., Erbarut, İ., & Djamgoz, M. B. (2008). Apocrine carcinomas of the breast in Turkish women: hormone receptors, c-erbB-2 and p53 immunoexpression. *Pathology-Research and Practice*, 204(6), 367-371.
15. Tan, P. H., Sahin, A. A., Tan, P. H., & Sahin, A. A. (2017). Apocrine lesions. *Atlas of Differential Diagnosis in Breast Pathology*, 191-222.
16. Idowu, M. O., Singh, J. A., & Grimes, M. M. (2018). Overview of Pathology Evaluation of Breast Lesions and Quality Assurance. *Diagnosis and Management of Breast Tumors: A Practical Handbook and Multidisciplinary Approach*, 35-72.
17. Sahin, Y., Erdogdu, I. H., Durak, M. G., Gurel, D., & Sahin, A. A. (2022). Biomarkers in Breast Carcinomas. *Biomarkers in Carcinoma of Unknown Primary*, 309-333.
18. Bezić, J., Forempoher, G., Poljičanin, A., & Gunjača, G. (2007). Apocrine adenoma of the breast coexistent with invasive carcinoma. *Pathology-Research and Practice*, 203(11), 809-812.
19. 张晓东, 张民主, 刘茜, & 朱坤. (2011). 多小切口联合微型钛板治疗颧骨复合体骨折 31 例疗效观察. 蚌埠医学院学报, 36(8), 837-838.
20. 陈金璋, 张继平, 殷宪刚, 李国霞, 徐流河, 杨艳丽, ... & 薛德彬. (2011). 乳腺浸润性大汗腺癌雌激素受体, 孕激素受体和人表皮生长因子受体 2 的表达. 蚌埠医学院学报, 36(8), 839-841.
21. 许艳春, 祝明洁, 管雯斌, 许格淳, & 姚晓虹. (2013). 乳腺病变中异型大汗腺化生的形态学特征及意义. 上海交通大学学报: 医学版, 33(10), 1356-1359.
22. Hong, S. J., Lee, K. H., Kim, M. Y., Suh, C. H., & Kim, Y. J. (2010). Ultrasonographic findings of apocrine lesions arising from the breast. *Journal of the Korean Society of Radiology*, 62(1), 81-85.
23. Ribeiro, R., Vendrame, C. D., de Castilho, T. J. C., Bahr, J. A., Jung, J. E., Zamboni, C. G., & Hatschbach, S. B. B. (2011). Carcinoma apócrino de mama: relato de caso e revisão de literatura. *Revista Brasileira de Mastologia*, 21(2), 81-85.
24. SHARMA, R., CHAUHAN, S., KUMAR, R., PATIL, R. D., & ASRANI, R. APOCRINE ADENOMA IN CANINE-A CASE REPORT.
25. 周珏, 王红卫, 陈洁, & 王华. (2016). 乳腺大汗腺病变 48 例临床病理分析. 浙江实用医学, 21(1), 31-34.
26. Bertheau, P., Espié, M., Janin, A., Cuvier, C., Giacchetti, S., Albitzer, M., ... & Lehmann-Che, J. (2013). Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDPF15.
27. Bakogeorgos, M., Mountzios, G., Dritsakos, K., & Kentepozidis, N. (2012, December). Vulvar apocrine adenocarcinoma: case report and literature review. In *Forum of Clinical Oncology* (p. 22).
28. Shashikala, R. (2013). *Morphologic Spectrum of Co-Existing Lesions in Breast Malignancy-A Study of Mastectomy Specimens* (Doctoral dissertation, Rajiv Gandhi University of Health Sciences (India)).
29. Stolnicu, S., Marian, C., Soanca, D., Preda, O., Boros, M., Podeanu, D. M., & Nogales, F. F. (2011). Low grade intraductal breast carcinoma with apocrine features as a precursor of infiltrating apocrine carcinoma. *Revista Română de Medicină de Laborator Vol*, 19(4/4).
30. Martínez, M. S., & Pomar, J. M. R. N° 1810. Citopatología.
31. García-Tolosa, R., Machado, I., Ruiz, L., & Llombart-Bosch, A. (2009). Carcinoma apocrino mamario: Análisis morfológico e inmunohistoquímico en sus formas infiltrantes puras y mixtas asociadas o no a carcinoma in situ. *Revista Salud Uninorte*, 25(1), 101-117.
32. García-Tolosa, R., Machado, I., Ruiz, L., & Llombart-Bosch, A. (2009). Apocrine breast carcinoma: Morphologic and immunohistochemical analysis of invasive pure and mix forms associated or not with in situ carcinoma. *Revista Salud Uninorte*, 25(1), 101-117.
33. Narita, D., Cireap, N., Ilina, R., Izvernariu, D., Ardelean, A., & Pribac, G. (2009). ER-NEGATIVE BREAST CARCINOMAS--AN IMMUNOPHENOTYPICAL STUDY. *Studia Universitatis Vasile Goldis Seria Stiintele Vietii (Life Sciences Series)*, 19(19).
34. Tolosa, R. G., Machado, I., & Bosch, A. L. (2009). Carcinoma apocrino mamario. Análisis morfológico e inmunohistoquímico en sus formas infiltrantes puras y mixtas asociadas o no a carcinoma in situ/Apocrine breast carcinoma. Morphologic and immunohistochemical analysis of invasive pure and mix forms asoc. *Revista Científica Salud Uninorte*, 25(1).
35. Santos, C. (2007). Biokinetics and dosimetry in patients of 99m Tc-HYNIC-Lys 3-Bombesin: images of GRP receptors.
36. Santos, C. (2007). Biokinetics and dosimetry in patients of {sup 99m} Tc-HYNIC-Lys {sup 3}-Bombesin: images of GRP receptors; Biocinetica y dosimetria en humanos de {sup 99m} Tc-HYNIC-Lys {sup 3}-Bombesina: imagenes de receptores GRP.

37. Lara, B. W., Fernández, A. J., Carballido, S. M., & Pérez, G. P. Carcinoma apocrino puro invasor de mama.

- **Zagorianakou, N., Stefanou, D., Makrydimas, G., Zagorianakou, P., Briasoulis, E., Karavasilis, V., ... & Agnantis, N.J. (2006). Clinicopathological study of metallothionein immunohistochemical expression, in benign, borderline and malignant ovarian epithelial tumors. *Histology and histopathology*. 21, 341-347.**

1. Karihtala, P., & Soini, Y. (2007). Reactive oxygen species and antioxidant mechanisms in human tissues and their relation to malignancies. *Apmis*, 115(2), 81-103.
2. Eckschlagel, T., Adam, V., Hrabeta, J., Figova, K., & Kizek, R. (2009). Metallothioneins and cancer. *Current Protein and Peptide Science*, 10(4), 360-375.
3. Gumulec, J., Raudenska, M., Adam, V., Kizek, R., & Masarik, M. (2014). Metallothionein-immunohistochemical cancer biomarker: a meta-analysis. *PloS one*, 9(1), e85346.
4. Kanda, M., Nomoto, S., Okamura, Y., Nishikawa, Y., Sugimoto, H., Kanazumi, N., ... & Nakao, A. (2009). Detection of metallothionein 1G as a methylated tumor suppressor gene in human hepatocellular carcinoma using a novel method of double combination array analysis. *International journal of oncology*, 35(3), 477-483.
5. Dziegiel, P., Pula, B., Kobierzycki, C., Stasiolek, M., & Podhorska-Okolow, M. (2016). *Metallothioneins in normal and cancer cells* (Vol. 218, pp. 1-117). Springer.
6. Tarapore, P., Shu, Y., Guo, P., & Ho, S. M. (2011). Application of phi29 motor pRNA for targeted therapeutic delivery of siRNA silencing metallothionein-IIA and survivin in ovarian cancers. *Molecular Therapy*, 19(2), 386-394.
7. Ozer, H., Yenicesu, G., Arici, S., Cetin, M., Tuncer, E., & Cetin, A. (2012). Immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumors. *Diagnostic Pathology*, 7(1), 1-10.
8. Kobierzycki, C., Pula, B., Skiba, M., Jablonska, K., Latkowski, K., Zabel, M., ... & Dziegiel, P. (2013). Comparison of minichromosome maintenance proteins (MCM-3, MCM-7) and metallothioneins (MT-I/II, MT-III) expression in relation to clinicopathological data in ovarian cancer. *Anticancer Research*, 33(12), 5375-5383.
9. Nagamine, T., & Nakajima, K. (2013). Significance of metallothionein expression in liver disease. *Current Pharmaceutical Biotechnology*, 14(4), 420-426.
10. Шафран, Л. М., Пыхтеева, Е. Г., & Большой, Д. В. (2011). Металлотионеины.
11. Ogrodniczak, A., Menkiszak, J., Gronwald, J., Tomiczek-Szwiec, J., Szwiec, M., Cybulski, C., ... & Jakubowska, A. (2022). Association of recurrent mutations in BRCA1, BRCA2, RAD51C, PALB2, and CHEK2 with the risk of borderline ovarian tumor. *Hereditary Cancer in Clinical Practice*, 20(1), 1-8.
12. Dziegiel, P., Pula, B., Kobierzycki, C., Stasiolek, M., Podhorska-Okolow, M., Dziegiel, P., ... & Podhorska-Okolow, M. (2016). The role of metallothioneins in carcinogenesis. *Metallothioneins in Normal and Cancer Cells*, 29-63.
13. Johann, A. C. B. R., Caldeira, P. C., Caliar, M. V., de Abreu, M. H. N. G., Aguiar, M. C. F., & Mesquita, R. A. (2011). Metallothionein in the radicular, dentigerous, orthokeratinized odontogenic cysts and in keratocystic odontogenic tumor. *Journal of oral pathology & medicine*, 40(3), 270-276.
14. Johann, A. C. B. R., Caldeira, P. C., Souto, G. R., de Abreu, M. H. N. G., Aguiar, M. C. F., & Mesquita, R. A. (2014). Metallothionein immunoexpression in selected benign epithelial odontogenic tumors. *Journal of oral pathology & medicine*, 43(3), 177-182.
15. König, R., Cai, P., Guo, X., & Ansari, G. A. S. (2008). Transcriptomic analysis reveals early signs of liver toxicity in female MRL+/+ mice exposed to the acylating chemicals dichloroacetyl chloride and dichloroacetic anhydride. *Chemical research in toxicology*, 21(3), 572-582.
16. Zhang, J., Ruijie, S. U. N., Yue, L. I. U., Guinian, W. A. N. G., & Qinglu, W. A. N. G. (2014). Metallothionein lower under-expression in benign tumors than that in malignant tumors: Systematic review article and meta-analysis. *Iranian Journal of Public Health*, 43(6), 696.
17. 牛焕国, 白岚, & 李树祝. (2012). 金属硫蛋白在生殖系统肿瘤中的研究进展. 临床军医杂志, 40(6), 1560-1562.

- **Panteli, K., Zagorianakou, N., Agnantis, N. J., Bourantas, K. L., & Bai, M. (2005). Clinical correlation of bone marrow microvessel density in essential thrombocythemia. *Acta haematologica*, 114(2), 99-103.**

1. Cartiser, N., Bévalot, F., Fanton, L., Gaillard, Y., & Guitton, J. (2011). State-of-the-art of bone marrow analysis in forensic toxicology: a review. *International journal of legal medicine*, 125, 181-198.
2. Boveri, E., Passamonti, F., Rumi, E., Pietra, D., Elena, C., Arcaini, L., ... & Lazzarino, M. (2008). Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations. *British journal of haematology*, 140(2), 162-168.
3. Vikman, S., Larsson, A., Thulin, M., & Karlsson, T. (2023). Increased levels of a subset of angiogenesis-related plasma proteins in essential thrombocythemia. *Uppsala Journal of Medical Sciences*, 128.
4. Steiniger, B. S., Stachniss, V., Wilhelmi, V., Seiler, A., Lampp, K., Neff, A., ... & Lobachev, O. (2016). Three-dimensional arrangement of human bone marrow microvessels revealed by immunohistology in undecalcified sections. *PLoS One*, 11(12), e0168173.

5. Lobachev, O. (2018). On three-dimensional reconstruction.
6. Соколова, М. А., Хорошко, Н. Д., Цветаева, Н. В., Семенова, Е. А., Капланская, И. Б., Франк, Г. А., & Мисюрин, А. В. (2010). Исследование плотности микрососудов костного мозга-один из диагностических подходов у больных Ph-негативными хроническими миелопролиферативными заболеваниями. *Терапевтический архив*, 82(12), 47-51.
7. Sokolova, M. A., Khoroshko, N. D., Tsvetaeva, N. V., Semenova, E. A., Kaplanskaya, I. B., Frank, G. A., ... & Misyurin, A. V. (2010). Study of bone marrow microvessel density is one of the diagnostic approaches in patients with Ph-negative chronic myeloproliferative diseases. *Terapevticheskii arkhiv*, 82(12), 47-51.
8. Redwitz, M. (2011). Entwicklung der Vaskularisierung und des Fasergehaltes im Knochenmark von CML-Patienten während der Behandlung mit Imatinib.
9. Horn, L. C., & Wickenhauser, C. Entwicklung der Vaskularisierung und des Fasergehaltes im Knochenmark von CML-Patienten während der Behandlung mit Imatinib.

- Mitselou, A., Ioachim, E., Kitsou, E., Vougiouklakis, T., **Zagorianakou, N.**, Makrydimas, G., ... & Agnantis, N. J. (2003). Immunohistochemical study of apoptosis-related Bcl-2 protein and its correlation with proliferation indices (Ki67, PCNA), tumor suppressor genes (p53, pRb), the oncogene c-erbB-2, sex steroid hormone receptors and other clinicopathological features, in normal, hyperplastic and neoplastic endometrium. *In Vivo (Athens, Greece)*, 17(5), 469-477.

1. Sanderson, P. A., Critchley, H. O., Williams, A. R., Arends, M. J., & Saunders, P. T. (2017). New concepts for an old problem: the diagnosis of endometrial hyperplasia. *Human reproduction update*, 23(2), 232-254.
2. Кузнецова, И. В. (2007). Гиперпластические процессы эндометрия. *Вопросы гинекологии, акушерства и перинатологии*, 6(5), 68-77.
3. Mirakhor Samani, S., Ezazi Bojnordi, T., Zarghampour, M., Merat, S., & Fouladi, D. F. (2018). Expression of p53, Bcl-2 and Bax in endometrial carcinoma, endometrial hyperplasia and normal endometrium: a histopathological study. *Journal of Obstetrics and Gynaecology*, 38(7), 999-1004.
4. Fathizadeh, H., Saffari, M., Esmaeili, D., Moniri, R., & Mahabadi, J. A. (2021). Anticancer effect of enterocin A-colicin E1 fusion peptide on the gastric cancer cell. *Probiotics and Antimicrobial Proteins*, 13(5), 1443-1451.
5. Porichi, O., Nikolaidou, M. E., Apostolaki, A., Tserkezoglou, A., Arnogiannaki, N., Kassanos, D., ... & Panotopoulou, E. (2009). BCL-2, BAX and P53 expression profiles in endometrial carcinoma as studied by real-time PCR and immunohistochemistry. *Anticancer research*, 29(10), 3977-3982.
6. Amalinei, C., Cianga, C., Balan, R., Cianga, P., Giusca, S., & Caruntu, I. D. (2011). Immunohistochemical analysis of steroid receptors, proliferation markers, apoptosis related molecules, and gelatinases in non-neoplastic and neoplastic endometrium. *Annals of Anatomy-Anatomischer Anzeiger*, 193(1), 43-55.
7. Balta, A. Z., Filiz, A. I., Kurt, Y., Sucullu, I., Yucel, E., & Akin, M. L. (2012). Prognostic value of oncoprotein expressions in thyroid papillary carcinoma. *Medical Oncology*, 29, 734-741.
8. Махина, Е. В., Пичигина, А. К., Колдышева, Е. В., Молодых, О. П., & Лушникова, Е. Л. (2014). Диагностическая и прогностическая значимость оценки пролиферативной активности клеточных популяций эндометрия при гиперпластических и неопластических процессах. *Фундаментальные исследования*, (10-2), 420-427.
9. Антонеева, И. И., & Петров, С. Б. (2008). Маркеры апоптоза и пролиферации опухолевых клеток в динамике прогрессирования рака яичника.
10. Germeyer, A., von Wolff, M., Jauckus, J., Strowitzki, T., Sharma, T., & Grazul-Bilska, A. T. (2010). Changes in cell proliferation, but not in vascularisation are characteristic for human endometrium in different reproductive failures-a pilot study. *Reproductive biology and endocrinology*, 8, 1-7.
11. ЧЕРНУХА, Г. Е., ДУМАНОВСКАЯ, М. Р., БУРМЕНСКАЯ, О. В., ШУБИНА, Е. С., КОГАН, Е. А., & ТРОФИМОВ, Д. Ю. (2013). Экспрессия генов, регулирующих апоптоз, при разных типах гиперплазии эндометрия и эндометриальной карциноме. *Акушерство и гинекология*, (1), 63-69.
12. Оразов, М. Р., Михалева, Л. М., & Муллина, И. А. (2022). Гиперплазия эндометрия: современный взгляд на проблему. *Акушерство и гинекология: Новости. Мнения. Обучения*, 10(3 (37)), 62-67.
13. Савельева, Г. М., Бреусенко, В. Г., Голова, Ю. А., Мишиева, О. И., & Ивановская, Т. Н. (2012). Гиперпластические процессы эндометрия в пре- и постменопаузе. Методы терапии. *Онкогинекология*, (1), 43-46.
14. Laas, E., Ballester, M., Cortez, A., Gonin, J., Daraï, E., & Graesslin, O. (2014). Supervised clustering of immunohistochemical markers to distinguish atypical endometrial hyperplasia from grade 1 endometrial cancer. *Gynecologic Oncology*, 133(2), 205-210.
15. Driak, D., Dvorska, M., Svandova, I., Sehnal, B., Benkova, K., Spurkova, Z., & Halaska, M. (2011). Changes in expression of some apoptotic markers in different types of human endometrium. *Folia Biol (Praha)*, 57(3), 104-111.
16. Озолиня, Л. А., Патрушев, Л. И., & Болдина, Е. Б. (2013). Современные представления о патогенезе гиперпластических процессов эндометрия и возможности их лечения. *Лечение и профилактика*, (2), 106-112.
17. Zhang, L. P., Shi, X. Y., Zhao, C. Y., Liu, Y. Z., & Cheng, P. (2011). RNA interference of pax2 inhibits growth of transplanted human endometrial cancer cells in nude mice. *Chinese journal of cancer*, 30(6), 400.
18. Mitselou, A., Karapiperides, D., Nesseris, I., Vougiouklakis, T., & Agnantis, N. J. (2010). Altered expression of cell cycle and apoptotic proteins in human liver pathologies. *Anticancer research*, 30(11), 4493-4501.

19. Кузнецова, И. В., & Томилова, М. В. (2006). Патогенез гиперпластических процессов эндометрия в репродуктивном периоде. *Вопросы гинекологии, акушерства и перинатологии*, 5(4), 58-63.
20. Bozkurt, K. K., Yalçın, Y., Erdemoğlu, E., Tatar, B., Erdemoğlu, E., Çerçi, S. S., ... & Kapucuoglu, N. (2016). The role of immunohistochemical adrenomedullin and Bcl-2 expression in development of type-1 endometrial adenocarcinoma: adrenomedullin expression in endometrium. *Pathology-Research and Practice*, 212(5), 450-455.
21. Ribeiro-Silva, A. (2007). Immunohistochemical features of a papillary squamous cell carcinoma of the endometrium with transitional cell differentiation. *Diagnostic Pathology*, 2, 1-4.
22. Оразов, М. Р., Михалёва, Л. М., & Муллина, И. А. (2021). Прогнозирование рецидивирующей гиперплазии эндометрия. *Трудный пациент*, 19(7), 6-8.
23. Samuel, J., Kanwar, R. K., Kanwar, J. R., Khetan, V., & Krishnakumar, S. (2016). A study of gene expression of survivin, its antiapoptotic variants, and targeting survivin in vitro for therapy in retinoblastoma. *Journal of Pediatric Hematology/Oncology*, 38(7), e230-e242.
24. Ahmed, A. R. H., Bakheet, R. A., Abdelmohsen, W., Mohammed, M., & Adly, M. A. (2020). Balance of glandular and stromal Bcl2/Bax expression in pre-neoplastic and neoplastic endometrial tissues. *European Journal of Gynaecological Oncology*, 41(2), 265-272.
25. Zhi, X., Honda, K. I., Sumi, T., Yasui, T., Nobeyama, H., Yoshida, H., & Ishiko, O. (2007). Estradiol-17 β regulates vascular endothelial growth factor and Bcl-2 expression in HHUA cells. *International Journal of oncology*, 31(6), 1333-1338.
26. Chernukha, G. E., Dumanovskaya, M. R., Burmenskaya, O. V., Shubina, E. S., Kogan, E. A., & TROFIMOV, D. (2013). Expression of apoptosis-regulatory genes in different endometrial hyperplasia types and endometrioid carcinoma. *Obstetrics and gynecology*, (1), 63-69.
27. Носенко, М. А. (2016). ПАТОГЕНЕТИЧЕСКИЕ НЮАНСЫ ХРОНИЧЕСКОГО ЭНДОМЕТРИТА (ОБЗОР ЛИТЕРАТУРЫ). *Международный журнал экспериментального образования*, (5-1), 63-66.
28. Литвинова, Н. А., Задонская, Ю. Н., Демура, Т. А., Ежова, Л. С., & Доброхотова, Ю. Э. (2009). Проллиферативная активность эндометрия у пациенток с миомой матки, перенесших эмболизацию маточных артерий. *Акушерство и гинекология*, (4), 41-43.
29. Мартирисян, К. А., Караченцова, И. В., Политова, А. П., & Голова, Ю. А. (2011). Комплексное лечение гиперпластических процессов эндометрия у больных периода пре-и постменопаузы. *Вестник РГМУ*, 2, 106-109.
30. Костин, А. А., Андриухин, М. И., Бабиченко, И. И., Пульбере, С. А., Мотин, П. И., & Тальбергер, П. И. (2015). Продукция факторов роста при доброкачественных и злокачественных болезнях предстательной железы. *Вестник Российского университета дружбы народов. Серия: Медицина*, (3), 75-83.
31. Laas, E., Ballester, M., Cortez, A., Graesslin, O., & Darai, E. (2019). Unsupervised Clustering of Immunohistochemical Markers to Define High-Risk Endometrial Cancer. *Pathology & Oncology Research*, 25, 461-469.
32. Karakas, L. A., Tohma, Y. A., Kuscü, E., Ozen, O., & Ayhan, A. (2019). Analysis of Bcl-2, PTEN, p53, and Ki-67 expressions in endometrial cancer arising from endometrial polyp. *European Journal of Gynaecological Oncology*, 40(5), 796-802.
33. 况南珍, 傅颖媛, 黄红卫, 王福财, & 曾小平. (2012). VEGF, PCNA 及 Survivin 与膀胱癌病理分级, 临床分期的关系. *重庆医学*, 41(7), 651-653.
34. 徐霞, 刘美莲, 卢瑾, 谢平, & 宋惠萍. (2005). 长期雌激素替代治疗对大鼠子宫内膜 bcl-2 和 H-ras 基因与蛋白表达的影响. *中南大学学报: 医学版*, 30(1), 41-45.
35. Перевозчиков, П. А., Борзенко, С. А., Карбань, О. В., & Васильев, Ю. Г. (2018). Модуляция репаративных процессов с помощью имплантации нанодисперсной плаценты.
36. DƯ'ONG, N. K. nghiên cứu m «b'Ōnh h'ac v'at s'ù b'éc lé mét s'è d'êu Ên h'ã m «m'iŌn d'p'ch ung th-b'i'ôu m «tuy'Ōn c'ĩa néi m¹c t'õ cung v'at bu'àng tr'ong.
37. 杨丽娜, & 周莉莉. (2011). 不同类型子宫内膜组织中 Bcl-2, Bax 基因的表达. *中国妇幼保健*, 26(10), 1526-1528.
38. Torres-Bernal, L. F., Díaz-Rubio, J. L., Sánchez, P., Rodríguez-Reyes, A., y Valles-Valles, D. R., & Benítez-Bribiesca, L. (2006). Análisis de expresión de PCNA, p53 y bcl-2 en la secuencia melanosis adquirida primaria-melanoma conjuntival. *Revista Mexicana de Oftalmología*, 80(5), 234-240.
39. 石绍兰, & 高宝莲. (2010). 子宫内膜癌中 Bcl-2, PTEN 表达的研究. *中国妇幼保健*, 25(12), 1632-1634.
40. 冯旺琴, & 崔竹梅. (2009). 细胞分化与子宫内膜癌. *肿瘤学杂志*, 15(5), 455-459.
41. Shalini, P., Suresh, N., & Ganapathy, H. (2019). Expression of Ki-67 AND Bcl-2 in Endometrial Hyperplasia. *Indian Journal of Public Health Research & Development*, 10(11).
42. 吴韩梅, & 张森. (2007). Bcl-2 在子宫内膜增生及子宫内膜癌的表达及意义. *广东医学院学报*, 25(5), 533-535.
43. 王婷, 马丽丽, & 李素娟. (2007). 子宫内膜癌基因的研究现状. *河北医药*, 29(9), 994-995.
44. Дуб, А. А., & Четер, И. Р. (2018). Характеристика маркеров клеточного обновления при АМАСР-позитивном фенотипе атипической мелкоацинарной пролиферации и аденокарциномах предстательной железы различной степени градации. *Уральский медицинский журнал*, (2), 36-38.
45. Дуб, А. А., & Четер, И. Р. (2018). Характеристика маркеров клеточного обновления при АМАСР-позитивном фенотипе атипической мелкоацинарной пролиферации и аденокарциномах предстательной железы различной степени градации. *Уральский медицинский журнал. 2018. Т. 157. № 2*.
46. 勝部憲一. (2016). Notch シグナルとがんの増殖・浸潤. *東都医療大学紀要*, 6(1), 1-10.
47. Kostin, A. A., Andriukhin, M. I., Babichenko, I. I., Pul'bere, S. A., Motin, P. I., & Tal'berg, P. I. (2015). Production of growth factors in benign and malignant prostatic diseases. *RUDN Journal of Medicine*, (3), 75-83.
48. Григорян, И. Ю., Полякова, В. О., Линькова, Н. С., Куканова, Е. О., & Пальцева, Е. М. (2015). Возрастные особенности профиля сигнальных молекул эндометрия: перспективы оптимизации диагностики гинекологической патологии. *Молекулярная медицина*, (3), 48-52.

49. Κοσμάς, Κ. (2015). *Πλοειδία του DNA και ανοσοκυτταροχημεία στη μελέτη του καρκίνου του ενδομητρίου: συσχέτιση με κλασσικούς προγνωστικούς παράγοντες* (Doctoral dissertation, Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών (ΕΚΠΑ). Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής. Τομέας Κλινικοεργαστηριακός. Εργαστήριο Α' Παθολογικής Ανατομικής).
50. Агеева, Т. А., & Зенкова, М. А. (2014). *МОЛЕКУЛЯРНО-КЛЕТОЧНЫЕ И ПАТОМОРФОЛОГИЧЕСКИЕ ОСОБЕННОСТИ ПРОЯВЛЕНИЙ ОПУХОЛЕВОЙ ПРОГРЕССИИ В ЗЛОКАЧЕСТВЕННЫХ ЛИМФОМАХ В УСЛОВИЯХ ПОЛИХИМИОТЕРАПИИ* (Doctoral dissertation, НОВОСИБИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ).
51. 汪燕舞, 陈智龙, 江惠, 顾磊, 文斐, 金欢, ... & 肖和平. (2013). 子宫内膜上皮内瘤变标准评估绝经前诊刮标本及分子标记的意义. *中国肿瘤临床与康复*, (12), 1333-1335.
52. Rouette, A. (2011). *Un inhibiteur intracellulaire de l'apoptose: son implication dans la chimiorésistance* (Doctoral dissertation, Université du Québec à Trois-Rivières).
53. Atasoy, L. (2011). Endometriyal polip zemininde gelişen endometriyum kanserlerinde BCL-2, PTEN, p53 ve Ki-67 ekspresyonlarının değerlendirilmesi.
54. 董秀哲, 朴敏虎, 刘东明, & 朴勇瑞. (2009). 膀胱移行细胞癌组织中 PCNA 的表达变化及意义. *山东医药*, 49(22), 34-35.
55. Καλογιαννίδης, Ι. Α. (2008). *Η προγνωστική αξία έκφρασης των πρωτεϊνικών δεικτών p53 και Bcl-2 στον καρκίνο του ενδομητρίου* (Doctoral dissertation, Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης).
56. Петров, Ю. А. (2018). Хронический эндометрит.
57. Гришкіна, А. А. (2021). *МОРФОФУНКЦИОНАЛЬНЫЕ КРИТЕРИИ ЭНДОМЕТРИАЛЬНОЙ ДИСФУНКЦИИ У ЖЕНЩИН С ПЕРВИЧНЫМ БЕСПЛОДИЕМ ПРИ ПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЯХ МАТКИ* (Doctoral dissertation, Военно-медицинская академия имени СМ Кирова).
58. Сергейко, И. В. (2014). *Научное обоснование снижения материнской смертности и репродуктивных потерь* (Doctoral dissertation, Всероссийский научно-исследовательский институт железнодорожной гигиены Роспотребнадзора).
59. Воронина, Е. И. (2014). *Молекулярно-клеточные и патоморфологические особенности в злокачественных лимфомах при проявлении опухолевой прогрессии в условиях полихимиотерапии (экспериментально-клиническое исследование)* (Doctoral dissertation, Науч. центр клин. и эксперим. медицины СО РАН).
60. Зенкина, В. Г. (2019). *Фолликулогенез и апоптоз в яичниках*. Медицина ДВ.
61. 齐欣, 孟令新, & 章明放. (2005). Bcl-2 基因及其在子宫内膜增生, 癌变中的表达及意义. *实用肿瘤学杂志*, 19(1), 66-69.
62. 宗瑞平. (2006). Bcl-2 基因及其与子宫内膜癌的关系. *医学理论与实践*, 19(4), 403-405.

- Zagorianakou P., Malamou-Mitsi V., **Zagorianakou N.**, Stefanou D., Tsatsoulis A., Agnantis NJ. (2005). The Role of Fine-needle Aspiration Biopsy in the Management of Patients with Thyroid Nodules. *In Vivo*, 19(3): 605-9.

1. Baloch, Z. W., LiVolsi, V. A., Asa, S. L., Rosai, J., Merino, M. J., Randolph, G., ... & Frible, W. J. (2008). Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. *Diagnostic cytopathology*, 36(6), 425-437.
2. Tee, Y. Y., Lowe, A. J., Brand, C. A., & Judson, R. T. (2007). Fine-needle aspiration may miss a third of all malignancy in palpable thyroid nodules: a comprehensive literature review. *Annals of surgery*, 246(5), 714-720.
3. Theoharis, C. G., Schofield, K. M., Hammers, L., Udelsman, R., & Chhieng, D. C. (2009). The Bethesda thyroid fine-needle aspiration classification system: year 1 at an academic institution. *Thyroid*, 19(11), 1215-1223.
4. Kim, M. J., Kim, E. K., Park, S. I., Kim, B. M., Kwak, J. Y., Kim, S. J., ... & Park, S. H. (2008). US-guided fine-needle aspiration of thyroid nodules: indications, techniques, results. *Radiographics*, 28(7), 1869-1886.
5. Румянцев, П. О., Ильин, А. А., Румянцева, У. В., & Саенко, В. А. (2009). Рак щитовидной железы.
6. Polyzos, S. A., Kita, M., & Avramidis, A. (2007). Thyroid nodules-stepwise diagnosis and management. *HORMONES-ATHENS*, 6(2), 101.
7. Seningen, J. L., Nassar, A., & Henry, M. R. (2012). Correlation of thyroid nodule fine-needle aspiration cytology with corresponding histology at Mayo Clinic, 2001-2007: An institutional experience of 1,945 cases. *Diagnostic cytopathology*, 40(S1), E27-E32.
8. Lobo, C., McQueen, A., Beale, T., & Kocjan, G. (2011). The UK Royal College of Pathologists thyroid fine-needle aspiration diagnostic classification is a robust tool for the clinical management of abnormal thyroid nodules. *Acta cytologica*, 55(6), 499-506.
9. Lee, M. J., Hong, S. W., Chung, W. Y., Kwak, J. Y., Kim, M. J., & Kim, E. K. (2011). Cytological results of ultrasound-guided fine-needle aspiration cytology for thyroid nodules: emphasis on correlation with sonographic findings. *Yonsei medical journal*, 52(5), 838-844.
10. Calvete, A. C., Mestre, J. D. B., Gonzalez, J. M. R., Martinez, E. S., Sala, B. T., & Zambudio, A. R. (2014). Acoustic radiation force impulse imaging for evaluation of the thyroid gland. *Journal of Ultrasound in Medicine*, 33(6), 1031-1040.
11. Daskalakis, A., Kostopoulos, S., Spyridonos, P., Glotsos, D., Ravazoula, P., Kardari, M., ... & Nikiforidis, G. (2008). Design of a multi-classifier system for discriminating benign from malignant thyroid nodules using routinely H&E-stained cytological images. *Computers in biology and medicine*, 38(2), 196-203.

12. Jing, X., Knoepp, S. M., Roh, M. H., Hookim, K., Placido, J., Davenport, R., ... & Michael, C. W. (2012). Group consensus review minimizes the diagnosis of "follicular lesion of undetermined significance" and improves cytohistologic concordance. *Diagnostic cytopathology*, 40(12), 1037-1042.
13. Calvete, A. C., Rodríguez, J. M., de Dios Berná-Mestre, J., Ríos, A., Abellán-Rivero, D., & Reus, M. (2013). Interobserver agreement for thyroid elastography: value of the quality factor. *Journal of Ultrasound in Medicine*, 32(3), 495-504.
14. Sakorafas, G. H., Peros, G., & Farley, D. R. (2006). Thyroid nodules: Does the suspicion for malignancy really justify the increased thyroidectomy rates? *Surgical oncology*, 15(1), 43-55.
15. Vriens, M. R., Schreinemakers, J. M., Suh, I., Guerrero, M. A., & Clark, O. H. (2009). Diagnostic markers and prognostic factors in thyroid cancer. *Future Oncology*, 5(8), 1283-1293.
16. Jing, X., Michael, C. W., & Pu, R. T. (2008). The clinical and diagnostic impact of using standard criteria of adequacy assessment and diagnostic terminology on thyroid nodule fine needle aspiration. *Diagnostic cytopathology*, 36(3), 161-166.
17. Szporn, A. H., Yuan, S., Wu, M., & Burstein, D. E. (2006). Cellular swirls in fine needle aspirates of papillary thyroid carcinoma: a new diagnostic criterion. *Modern pathology*, 19(11), 1470-1473.
18. Rizzo, M., Sindoni, A., Rossi, R. T., Bonaffini, O., Panetta, S., Scisca, C., ... & Benvenga, S. (2013). Annual increase in the frequency of papillary thyroid carcinoma as diagnosed by fine-needle aspiration at a cytology unit in Sicily. *Hormones*, 12, 46-57.
19. Theoharis, C., Adeniran, A. J., Roman, S., Ann Sosa, J., & Chhieng, D. (2013). The impact of implementing The Bethesda System for reporting of thyroid FNA at an academic center. *Diagnostic Cytopathology*, 41(10), 858-863.
20. Shah, S. S., Faquin, W. C., Izquierdo, R., & Khurana, K. K. (2009). FNA of misclassified primary malignant neoplasms of the thyroid: Impact on clinical management. *Cytojournal*, 6.
21. Jing, X., Roh, M. H., Knoepp, S. M., Zhao, L., & Michael, C. W. (2011). Minimizing the diagnosis of "follicular lesion of undetermined significance" and identifying predictive features for neoplasia. *Diagnostic Cytopathology*, 39(10), 737-742.
22. Polyzos, S. A., Kita, M., Goulis, D. G., Benos, A., Flaris, N., Leontsini, M., & Avramidis, A. (2008). Epidemiologic analysis of thyroid fine needle aspiration biopsies over a period of 18 years (1987-2004). *Experimental and clinical endocrinology & diabetes*, 496-500.
23. An, H. J., Kim, M. H., Na, J. M., Yang, J. W., Baek, H. J., Ryu, K. H., & Song, D. H. (2021). Diagnostic Utility of p62 Expression in Intracellular Inclusions in Thyroid Core Needle Biopsy Specimens. *in vivo*, 35(3), 1769-1775.
24. 吴峰, 王国坤, 安丽娜, 倪飞华, 董斐斐, 吕慧, ... & 秦永文. (2012). 丹参多酚酸盐对斑马鱼胚胎血管新生的影响及分子机制初步研究. *现代生物医学进展*, 12(36), 7005-7007.
25. 彭丽, & 顾明君. (2007). Meta 分析比较常规和超声引导下甲状腺细针穿刺细胞学检查对甲状腺结节的诊断价值. *第二军医大学学报*, 28(9), 968-972.
26. Mittal, N., Selhi, P., Kaur, H., Mittal, A., Nagiraj, A., Singh, A., & Sood, N. (2018). Cytomorphological analysis of categories in the Bethesda system and its accuracy in predicting thyroid neoplasms. *Thyroid Research and Practice*, 15(2), 84-88.
27. 李芳, 汪多平, 徐茂林, 段绪伟, 韦正波, & 许坚. (2015). 血清胸苷激酶检测在甲状腺良恶性疾病鉴别诊断中的应用价值. *广西医科大学学报*, 32(5), 728-730.
28. Rashed, B. (2015). *Retrospektive Analyse der qualitätsbestimmenden Faktoren der Feinnadelaspiration der Schilddrüse* (Doctoral dissertation, Staats- und Universitätsbibliothek Hamburg Carl von Ossietzky).
29. 王芳, 赵伟明, & 周丽艳. (2010). 联合应用细胞学检查与 P53 蛋白检测提高甲状腺癌术前诊断率. *哈尔滨医科大学学报*, 44(5), 497-499.
30. Torregrosa Pérez, N. M. (2016). Estudio de la selección de pacientes subsidiarios de supresión de la PAAF en el algoritmo diagnóstico del nódulo tiroideo. *Proyecto de investigación*.
31. Bhattacharjee, A., & Dutta, U. C. Fine Needle Aspiration of Thyroid Nodules-A Cyto-Morphologic Approach to Diagnosis.
32. Tatlipinar, A., & Kartal, İ. (2015). The evaluation of thyroid nodules. *Thyroid Disorders Ther*, 4(2).
33. 何春年, 张静, & 邢颖. (2006). 甲状腺乳头状癌的诊治进展. *现代诊断与治疗*, 17(5), 290-292.
34. 周国志, 曹秀峰, 朱斌, 吕进, & 陈仿军. (2012). 血清 TK1 的检测在甲状腺癌诊治中的临床意义. *现代生物医学进展*, 12(36), 7083-7085.
35. Jing, X. (2018). Thyroid Fine Needle Aspiration Cytology. *Atlas of Non-Gynecologic Cytology*, 19-42.
36. Spieler, P., Rössle, M., Spieler, P., & Rössle, M. (2012). Thyroid and Parathyroid Glands. *Nongynecologic Cytopathology: A Practical Guide*, 323-397.
37. Theoharis, C., & Hui, P. (2012). Molecular Diagnostics in the Evaluation of Thyroid Samples. In *Surgery of the Thyroid and Parathyroid Glands* (pp. 107-119). Berlin, Heidelberg: Springer Berlin Heidelberg.
38. Kelling, K. Subtotale versus totale Thyreoidektomie in der Therapie des papillären Mikrokarcinomes.
39. Le, T. S. H. Le nodule thyroïdien solitaire.
40. میرصدرايي, سعادت, موسوی, فرزادنيا, باوفای حقیقی, آصفه, & کاخی. (2007). ارزش تشخیصی اسپیراسیون سوزنی در ندولهای تیروئید. *مجله دانشکده پزشکی دانشگاه علوم پزشکی مشهد*, 15(1), 23-30.
41. 이미경. (2007). *Ultrasound-guided fine needle aspiration biopsy (FNAB) on thyroid nodules: correlation with sonographic findings* (Doctoral dissertation, Graduate School, Yonsei University).
42. Jing, X., & Michael, C. W. (2015). The Bethesda system for reporting thyroid cytopathology: current status and future directions. *J Basic Clin Med*, 4, 52-64.

- Zagorianakou, P., Fiaccavento, S., **Zagorianakou, N.**, Makrydimas, G., Stefanou, D., & Agnantis, N. J. (2005). FNAC: its role, limitations and perspective in the preoperative diagnosis of breast cancer. *European journal of gynaecological oncology*, 26(2), 143-149.
1. Wallis, M., Tarvidon, A., Helbich, T., & Schreer, I. (2007). Guidelines from the European Society of Breast Imaging for diagnostic interventional breast procedures. *European radiology*, 17, 581-588.
2. Masih, M., Agarwal, S., Kaur, R., & Gautam, P. K. (2022). Role of chemokines in breast cancer. *Cytokine*, 155, 155909.
3. Wei, Q., Zeng, S. E., Wang, L. P., Yan, Y. J., Wang, T., Xu, J. W., ... & Cui, X. W. (2022). The added value of a computer-aided diagnosis system in differential diagnosis of breast lesions by radiologists with different experience. *Journal of Ultrasound in Medicine*, 41(6), 1355-1363.
4. Chandanwale, S. S., Gupta, K., Dharwadkar, A. A., Pal, S., Buch, A. C., & Mishra, N. (2014). Pattern of palpable breast lesions on fine needle aspiration: A retrospective analysis of 902 cases. *Journal of mid-life health*, 5(4), 186.
5. Bukhari, M. H., & Akhtar, Z. M. (2009). Comparison of accuracy of diagnostic modalities for evaluation of breast cancer with review of literature. *Diagnostic cytopathology*, 37(6), 416-424.
6. Chaiwun, B., & Thorner, P. (2007). Fine needle aspiration for evaluation of breast masses. *Current Opinion in Obstetrics and Gynecology*, 19(1), 48-55.
7. Yamaguchi, R., Tsuchiya, S. I., Koshikawa, T., Ishihara, A., Masuda, S., Maeda, I., ... & Tokoro, Y. (2012). Diagnostic accuracy of fine-needle aspiration cytology of the breast in Japan: report from the Working Group on the Accuracy of Breast Fine-Needle Aspiration Cytology of the Japanese Society of Clinical Cytology. *Oncology reports*, 28(5), 1606-1612.
8. Bajwa, R., & Zulfiqar, T. (2010). Association of fine needle aspiration cytology with tumor size in palpable breast lesions. *Biomedica*, 26(Jul.-Dec.), 124-129.
9. Nandini, N. M., Rekha, T. S., & Manjunath, G. V. (2011). Evaluation of scoring system in cytological diagnosis and management of breast lesion with review of literature. *Indian journal of cancer*, 48(2), 240-245.
10. Cherath, S. K., & Chithrabhanu, S. M. (2017). Evaluation of masood's and modified Masood's scoring systems in the cytological diagnosis of palpable breast lump aspirates. *Journal of clinical and diagnostic research: JCDR*, 11(4), EC06.
11. Dawande, P., Bhatt, N., Noman, O., Bahadure, S., & Bhake, A. (2020). Corelation between Cytological and Histological Grading of Breast Cancer and Its Utility in Patient's Management. *Int J Cur Res Rev| Vol*, 12(14).
12. Gong, Y. (2013). Breast cancer: Pathology, cytology, and core needle biopsy methods for diagnosis. In *Breast and Gynecological Cancers: An Integrated Approach for Screening and Early Diagnosis in Developing Countries* (pp. 19-37). New York, NY: Springer New York.
13. Rekha, T. S., Nandini, N. M., & Dhar, M. (2011). Validity of different cytological grading systems of breast carcinoma-a hospital-based study in South India. *Asian Pac J Cancer Prev*, 12, 3013-6.
14. Harigopal, M., & C Chhieng, D. (2010). Breast cytology: Current issues and future directions. *The open breast cancer journal*, 2(1).
15. Rekha, T. S., Nandini, N. M., & Dhar, M. (2013). Expansion of Masood's cytologic index for breast carcinoma and its validity. *Journal of Indian Academy of Cytologists*, 30(4), 233.
16. Walk, E. L., McLaughlin, S., Coad, J., & Weed, S. A. (2014). Use of high frequency ultrasound to monitor cervical lymph node alterations in mice. *PloS one*, 9(6), e100185.
17. 李玉阳, 洪凡真, 王永胜, 仲伟霞, & 左文述. (2007). Mammotome 在早期乳腺癌原发肿瘤诊断中的应用. *中华肿瘤防治杂志*, 14(9), 706-708.
18. Rama, K., Bitla, A. R., Hulikal, N., Yootla, M., Yadagiri, L. A., Asha, T., ... & Rao, P. S. (2023). Assessment of serum microRNA-21 and miRNA-205 as diagnostic markers for stage I and II breast cancer in Indian population. *Indian Journal of Cancer*, 10-4103.
19. Liao, L. J., Kang, C. C., Jan, I. S., Chen, H. C., Wang, C. L., Lou, P. J., & Chang, T. C. (2009). Improved diagnostic accuracy of malignant neck lumps by a simple BMVC staining assay. *Analyst*, 134(4), 708-711.
20. Yamaguchi, R., Tsuchiya, S. I., Koshikawa, T., Yokoyama, T., Mibuchi, K., Nonaka, Y., ... & Yano, H. (2012). Evaluation of inadequate, indeterminate, false-negative and false-positive cases in cytological examination for breast cancer according to histological type. *Diagnostic Pathology*, 7(1), 1-8.
21. Chandanwale, S., Mishra, N., Kaur, S., Paranjape, S., Pandey, A., & Jha, M. (2016). Comparative analysis of six cytological grading systems in breast carcinoma. *Clin Cancer Invest J*, 5, 409-15.
22. Mishra, A., & Sharma, V. (2022). Surgical Oncology: An Overview. *Cancer Diagnostics and Therapeutics: Current Trends, Challenges, and Future Perspectives*, 261-270.
23. Masroor, I., Afzal, S., & Sufian, S. N. (2016). Imaging guided breast interventions. *Journal of the College of Physicians and Surgeons Pakistan*, 26(6), 521.
24. Duflloth, R. M., Alves, J. M., Martins, D., Vieira, D. S. C., Chikota, H., Zeferino, L. C., & Schmitt, F. (2009). Cytological criteria to predict basal phenotype of breast carcinomas. *Diagnostic Cytopathology*, 37(11), 809-814.
25. Yamaguchi, R., Tsuchiya, S. I., Koshikawa, T., Yokoyama, T., Mibuchi, K., Nonaka, Y., ... & Yano, H. (2012). Comparison of the accuracy of breast cytological diagnosis at seven institutions in southern Fukuoka Prefecture, Japan. *Japanese Journal of Clinical Oncology*, 42(1), 21-28.
26. 张亚男, 李俊生, 尤承忠, 刘万花, 郝悦悦, & 汤文浩. (2007). 全视野数字化乳腺摄像与细针穿刺细胞学检查对乳腺肿块的诊断意义. *实用癌症杂志*, 22(5), 457-459.

27. Kumar, N., Sharma, P., Gupta, M., Sharma, S., Bansal, R., & Sharma, V. K. (2020). Role of Fine Needle Aspiration Cytology in Classifying Breast Lesions with Special Reference to Borderline Cases. *Indian Journal of Public Health Research & Development*, 11(7), 515-521.
28. Sangri, A. M., Shaikh, A. G., & Unar, F. (2017). Benign breast diseases in pregnancy. *Journal of Surgery Pakistan (International)*, 22, 4.
29. Patumanond, J., Kayee, T., & Sukkasem, U. (2009). Empirical accuracy of fine needle aspiration cytology (FNAC) for preoperative diagnoses of malignant breast lumps in hospitals with restricted health resources. *Eur. J. Gynaec. Oncol.-ISSN*, 30(3), 2009.
30. Ghanghoria, S., Soni, S., Patidar, H., & Likhar, K. (2016). Pattern of palpable breast lesions on fine needle aspiration cytology: a retrospective and prospective analysis of 1,000 cases. *International Journal of Medical Science and Public Health*, 5(1), 97-101.
31. Rekha, T. S., & Nandini, N. M. (2015). Evaluation of breast neoplastic lesions by different cytology grading methods. *Sci J Clin Med*, 4, 26-30.
32. Vyas, A., & Rai, N. N. (2018). A Study of Role of FNAC in Palpable Breast Lump. *Journal of Mahatma Gandhi University of Medical Sciences and Technology*, 3(1), 2.
33. Saunakiya, P., Rai, S., Jain, A., & Gaur, R. Comparative Study of Cytomorphological Robinson's grading for Breast Carcinoma with Modified Bloom-Richardson Histopathological Grading.
34. 黄丛改, 李孟泽, 汪少华, 万宇, 王洁琼, 汪澍, & 韦思平. (2015). 细针穿刺对男性乳腺癌的诊断价值及临床分析. *中国基层医药*, (14), 2115-2117.
35. Sidhwani, S. K., Mahesh, P., Chand, H., Mandviwala, H. A., Rajbhoy, Z. S., & Qureshi, J. A. (2020). FNAC of Different Breast Lesions in Subset of Rural Areas of Sindh. *Journal of Advances in Medicine and Medical Research*, 32(4), 10-15.
36. Haq, S. M., Niazi, S., Shah, A., & ul Haq, M. I. (2012). Breast Lumps Presenting During Pregnancy. *Journal of Rawalpindi Medical College*, 16(1).
37. 付春林, 凌象红, & 李军川. (2011). 乳腺癌细针穿刺的细胞形态学观察. *国际肿瘤学杂志*, 38(4), 310.
38. Zhang, Y., Li, J., Ji, Z., & Tang, W. (2008). Combined use of fine needle aspiration cytology and full field digital mammography in preoperative assessment of breast masses. *The Chinese-German Journal of Clinical Oncology*, 7, 473-476.
39. Mariotti, C., Raffaeli, E., Lenti, E., Gentili, M., Baldassarre, S., & Giuseppetti, G. M. (2018). Interventional Diagnostic in DCIS. *Ductal Carcinoma in Situ of the Breast*, 57-73.
40. Fatima, M., Khan, M. A., Jamal, S., Ansari, J. K., & Ullah, M. U. (2016). Endobronchial Ultrasound Guided Transbronchial Needle Aspiration (EBUS-TBNA) for diagnosis of mediastinal and hilar masses. *Journal of the College of Physicians and Surgeons Pakistan*, 26(9), 766-769.
41. Rajachidambaram, K., & Sowmya, T. K. (2016). Modified triple assessment in breast lumps. *Journal of Evolution of Medical and Dental Sciences*, 5(36), 2123-2131.
42. Giuseppetti, G. M., Ottaviani, L., Lenti, E., Simonetti, B. F., & Baldassarre, S. (2014). Instrumental and Interventional Diagnostics. *Oncologic Breast Surgery*, 3-22.
43. Salman, D. Y., ElGaili, E. M., Khalid, K. E., & Taha, S. M. (2018). The Accuracy of FNAC for Diagnosis of Breast Carcinoma in Gezira State, Central Sudan. *Gezira Journal of Health Sciences*, 9(2).
44. SATOH, H., NARITA, M., ITOH10, H. I. T. O. S. H. I., & KITAMURA11, T. A. K. A. S. H. I. Diagnostic accuracy of fine-needle aspiration cytology of the breast in Japan: Report from the Working Group on the Accuracy of Breast Fine-Needle Aspiration Cytology of the Japanese Society of Clinical Cytology.
45. Martins, D. R. F. (2013). *Transition from In situ to invasive Breast Carcinomas* (Doctoral dissertation, Universidade do Porto (Portugal)).
46. Weed, S. A. (2014). Elyse L. Walk1, 3, 5, Sarah McLaughlin4, 5, James Coad2 and Scott A. Weed*, 1Department of Neurobiology and Anatomy, 2Department of Pathology, 3Program in Cancer Cell Biology, 4Animal Models and Imaging Facility, 5Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, West Virginia, 26506-9300, United States of America. *Head and Neck Cancer Invasion: Contributions of Actin Regulatory Proteins and the Microenvironment*, 1001, 104.
47. Alves, J. M. (2008). Critérios citológicos para prever o fenótipo basal do carcinoma de mama.
48. Vázquez, S., Fabra, G., Travé, J., Domínguez, M. A., Fernández-Cid, C., Masana, M., ... & Ramos, C. (1995). Resultados de la punción aspiración con aguja fina y la biopsia por punción con estudio anatomopatológico definitivo en lesiones mamarias. *REVISTA DE SENOLOGÍA*, 2011(99), 0214-1582.
49. 马宏岩. (2010). 乳腺癌微创治疗的研究进展. *中国普外基础与临床杂志*, (3), 214-218.
50. Singh, R., & Sapru, N. (2016). Pattern of breast lesions on fine-needle aspiration cytology in consecutive 70 cases: a retrospective and prospective analysis of one year. *Int J Res Med Sci*, 4(5), 1711-5.
51. Mughal, Z., Altaf, A., & Altaf, M. O. (2018). To determine the Efficacy of Fine Needle Aspiration Cytology of Axillary Lymph Nodes in patients with Primary Breast Cancer using Sentinel Lymph Nodal Biopsy as Standard Reference. *Asian Journal of Multidisciplinary Studies*, 6, 12.
52. PADMINI, N. *FINE NEEDLE ASPIRATION CYTOLOGY OF PALPABLE BREAST LESIONS WITH HISTOPATHOLOGIC CORRELATION* (Doctoral dissertation, Rajiv Gandhi University of Health Sciences).
53. 焦喜林, & 赵增顺. (2009). Mammotome 系统在乳腺微创外科中的应用. *华北国防医药*, 21(4), 78-80.

- Mitselou A., Ioachim E., Zagorianakou N., Kitsiou E., Vougiouklakis T., Agnantis N.J. (2004). Expression of the cell-cycle regulatory proteins (cyclins D1 and E) in endometrial

carcinomas: correlations with hormone receptor status, proliferating indices, tumor suppressor gene products (p53, pRb), and clinicopathological parameters. *Eur J Gynaecol Oncol.* 25(6): 719-24.

1. Eritja, N., Yeramian, A., Chen, B. J., Llobet-Navas, D., Ortega, E., Colas, E., ... & Matias-Guiu, X. (2017). Endometrial carcinoma: specific targeted pathways. *Molecular Genetics of Endometrial Carcinoma*, 149-207.
2. Wang, Y., Qiu, H., Hu, W., Li, S., & Yu, J. (2014). RPRD1B promotes tumor growth by accelerating the cell cycle in endometrial cancer. *Oncology reports*, 31(3), 1389-1395.
3. Khabaz, M. N., Abdelrahman, A. S., Butt, N. S., Al-Maghrabi, B., & Al-Maghrabi, J. (2017). Cyclin D1 is significantly associated with stage of tumor and predicts poor survival in endometrial carcinoma patients. *Annals of diagnostic pathology*, 30, 47-51.
4. Horrée, N., van Diest, P. J., van der Groep, P., Sie-Go, D. M., & Heintz, A. P. M. (2008). Progressive derailment of cell cycle regulators in endometrial carcinogenesis. *Journal of clinical pathology*, 61(1), 36-42.
5. Tang, L., Wang, T. T., Wu, Y. T., Zhou, C. Y., & Huang, H. F. (2009). High expression levels of cyclin B1 and Polo-like kinase 1 in ectopic endometrial cells associated with abnormal cell cycle regulation of endometriosis. *Fertility and sterility*, 91(4), 979-987.
6. Santala, S., Talvensaaari-Mattila, A., Soini, Y., & Santala, M. (2015). Cyclin E expression correlates with cancer-specific survival in endometrial endometrioid adenocarcinoma. *Anticancer Research*, 35(6), 3393-3397.
7. LIU, H. L., Chen, Y., CUI, G. H., WU, Q. L., & He, J. (2005). Regulating expressions of cyclin D1, pRb, and anti-cancer effects of deguelin on human Burkitt's lymphoma Daudi cells in vitro 1. *Acta Pharmacologica Sinica*, 26(7), 873-880.
8. 周开梅, & 郭瑞珍. (2010). 细胞周期蛋白在恶性肿瘤中的表达. 医学综述, (4), 533-536.
9. 刘红利, 陈燕, 吴秋玲, 陈卫华, & 何静. (2007). 鱼藤素对淋巴瘤 Daudi 细胞株细胞增殖细胞凋亡的影响及其机制. 中华肿瘤杂志, 29(3), 176-180.
10. 熊艳, & 熊永炎. (2010). p16, Cyclin D1 和 COX-2 蛋白在子宫内膜不同增生性病变中的表达及意义. 肿瘤防治研究, 37(5), 551-554.
11. Santala, S. (2020). Prognostic role of cyclins A, B, and E and p27 in endometrial endometrioid adenocarcinoma.
12. Faruqi, S. A., Saquib, M., Harsch, C., & Noumoff, J. S. (2012). Fluorescence in situ hybridization of three oncogenes on a leiomyoma. *Microscopy Research and Technique*, 75(8), 1147-1149.
13. 顾松, 徐敏, 洪莉, 张忠德, 殷敏智, 陈其民, & 吴晔明. (2009). Bax 与 p53, Bcl-2, PCNA 在不同类型神经母细胞瘤中的表达及意义. 临床小儿外科杂志, 8(3), 36-39.
14. 李建华, 刘玉峰, 张景航, 王家勤, & 郭学鹏. (2016). DDX1 基因在神经母细胞瘤中的表达. 中华实用儿科临床杂志, 31(6), 445-447.
15. 冯旺琴, & 崔竹梅. (2009). 细胞分化与子宫内膜癌. 肿瘤学杂志, 15(5), 455-459.
16. 陈军, 张桃华, 陈玲玲, & 胡永均. (2008). 细胞周期素 E 和 p53 在乳腺癌中表达及意义. 临床与实验病理学杂志, 24(4), 436-438.
17. 李旭东. (2005). 细胞周期蛋白 E 和 p53 在肾癌中的表达及其意义. 沈阳医学院学报, 7(3), 162-163.
18. Pérez González, Y. C. (2017). Análisis descriptivo de la frecuencia de inestabilidad de microsátélites en el cáncer de endometrio de tipo I de mujeres menores de 60.
19. 吉本賢史, 江口礼好, & 柳沼裕二. (2015). 子宫体癌の分子生物学的発生機序. 熊本大学医学部保健学科紀要, 11, 1-12.
20. 涂剑宏, 瞿伟, & 於德军. (2011). 基底细胞样型乳腺癌的临床病理分析. 中国医药导报, 8(1), 86-86.
21. ÇINAR, E., Güngör, T., Müftüoğlu, K., Mustafa, Ö. Z. A. T., ALTINKAYA, Ö., Doğanay, M., ... & Mollamahmutoğlu, L. (2009). NORMAL, HİPERPLASTİK VE NEOPLASTİK ENDOMETRİYUM DOKUSUNDA CYCLIN-E VE CASPASE-3 EKSPRESYONUNUN İMMÜNOHİSTOKİMYASAL ANALİZİ. *Türk Jinekolojik Onkoloji Dergisi*, 12(3), 60-65.
22. 백윤지, 정혜인, 장호진, 서동수, 윤만수, & 최경운. (2008). 임상연구: 자궁내막암종에서 cyclin E, CDK2, p27 발현에 관한 임상병리학적 연관성. *Obstetrics & Gynecology Science*, 51(10), 1112-1120.
23. Horrée, N. (2007). *Hypoxia and cell cycle deregulation in endometrial carcinogenesis*. Utrecht University.

▪ **Zagorianakou N., Stefanou D., Makrydimas G., Zagorianakou P., Briasoulis E., Karavasilis B., Agnantis NJ. (2004). CD44s expression, in benign, borderline and malignant tumors of ovarian surface epithelium. Correlation with p53, steroid receptor status, proliferative indices (PCNA, MIB1) and survival. *Anticancer Res.* 24 (3a): 1665-70.**

1. Ween, M. P., Oehler, M. K., & Ricciardelli, C. (2011). Role of versican, hyaluronan and CD44 in ovarian cancer metastasis. *International journal of molecular sciences*, 12(2), 1009-1029.
2. Sacks, J. D., & Barbolina, M. V. (2015). Expression and function of CD44 in epithelial ovarian carcinoma. *Biomolecules*, 5(4), 3051-3066.
3. Gao, Y., Foster, R., Yang, X., Feng, Y., Shen, J. K., Mankin, H. J., ... & Duan, Z. (2015). Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer. *Oncotarget*, 6(11), 9313.
4. Cho, E. J., Sun, B., Doh, K. O., Wilson, E. M., Torregrosa-Allen, S., Elzey, B. D., & Yeo, Y. (2015). Intraperitoneal delivery of platinum with in-situ crosslinkable hyaluronic acid gel for local therapy of ovarian cancer. *Biomaterials*, 37, 312-319.

5. Banzato, A., Bobisse, S., Rondina, M., Renier, D., Bettella, F., Esposito, G., ... & Rosato, A. (2008). A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity. *Clinical cancer research*, 14(11), 3598-3606.
6. Ordóñez, N. G. (2005). Value of estrogen and progesterone receptor immunostaining in distinguishing between peritoneal mesotheliomas and serous carcinomas. *Human pathology*, 36(11), 1163-1167.
7. Zhang, J., Chang, B., & Liu, J. (2013). CD44 standard form expression is correlated with high-grade and advanced-stage ovarian carcinoma but not prognosis. *Human pathology*, 44(9), 1882-1889.
8. Tse, G. M. K., Tan, P. H., Ma, T. K. F., Gilks, C. B., Poon, C. S. P., & Law, B. K. B. (2005). CD44s is useful in the differentiation of benign and malignant papillary lesions of the breast. *Journal of clinical pathology*, 58(11), 1185-1188.
9. Elzarkaa, A. A., Sabaa, B. E., Abdelkhalik, D., Mansour, H., Melis, M., Shaalan, W., ... & Soliman, A. A. (2016). Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: A prospective study. *Journal of cancer research and clinical oncology*, 142, 949-958.
10. Ryabtseva, O. D., Lukianova, N. Y., Shmurakov, Y. A., Polishchuk, L. Z., & Antipova, S. V. (2013). Significance of adhesion molecules expression for estimation of serous ovarian cancer prognosis. *Experimental oncology*, (35, № 3), 211-218.
11. Zhao, L., Gu, C., Huang, K., Zhang, Z., Ye, M., Fan, W., ... & Meng, Y. (2016). The prognostic value and clinicopathological significance of CD44 expression in ovarian cancer: a meta-analysis. *Archives of gynecology and obstetrics*, 294, 1019-1029.
12. Kar, K., Ghosh, S., & Roy, A. K. (2021). A study of CD44 positive cancer cells in epithelial ovarian cancer and their correlation with P53 and Ki67. *Journal of Laboratory Physicians*, 13(01), 050-057.
13. Banzato, A., Rondina, M., Meléndez-Alafort, L., Zangoni, E., Nadali, A., Renier, D., ... & Rosato, A. (2009). Biodistribution imaging of a paclitaxel-hyaluronan bioconjugate. *Nuclear medicine and biology*, 36(5), 525-533.
14. Campisi, M., & Renier, D. (2011). ONCOFID™-P a hyaluronic acid paclitaxel conjugate for the treatment of refractory bladder cancer and peritoneal carcinosis. *Current Bioactive Compounds*, 7(1), 27-32.
15. Ciepliński, K., Jóźwik, M., Semczuk Sikora, A., Gogacz, M., Lewkowicz, D., Ignatov, A., & Semczuk, A. (2018). Expression of p53 and selected proliferative markers (Ki-67, MCM3, PCNA, and topoisomerase IIα) in borderline ovarian tumors: correlation with clinicopathological features.
16. Roy, P., Mignet, N., Pocard, M., & Boudy, V. (2021). Drug delivery systems to prevent peritoneal metastasis after surgery of digestive or ovarian carcinoma: A review. *International Journal of Pharmaceutics*, 592, 120041.
17. Sanei, M. H., Mirmosayyeb, O., Chehrei, A., Ansari, J., & Saberi, E. (2019). 5-year survival in gastric adenocarcinoma with epithelial and stromal versican expression. *Iranian Journal of Pathology*, 14(1), 26.
18. Qasim, Y. A., Saeed, S. Z., & Rashid, I. M. (2017). Immunohistochemical study of P53 and Ki 67 expression in surface epithelial tumor of the ovary. *Saudi J. Pathol. Microbiol*, 2(3), 52-9.
19. 田丽媛, 赵亚力, & 韩为东. (2007). 雌激素受体在卵巢癌发生发展中作用的研究进展. 国外医学: 妇产科学分册, 34(4), 254-257.
20. Ghany, M. M. A., Khattab, Y. I., & Al-Kurtas, M. A. (2016). Immunohistochemical Expression of CD44v6 and P53 Status in Borderline and Malignant Ovarian Surface Epithelial Tumors. A Clinico-Pathologic Study. *Iraqi Journal of Medical Sciences*, 14(1).
21. Suhonen, K. (2007). *Prognostic Role of Cell Adhesion Factors and Angiogenesis in Epithelial Ovarian Cancer (Syöpösolujen kiinnittymiseen liittyvien tekijöiden ja kasvaimen verisuonituksen ennusteellinen merkitys epiteliaalisessa munasarjasyövässä)*. Kuopion yliopisto.
22. 荆雪宁, 张玲, 王芸, 毛海婷, 温培娥, 李登华, ... & 顾洪涛. (2004). 瞬时转染 CD44 反义寡核苷酸抑制人胃癌 MGC80-3 细胞增生并诱导凋亡. 世界华人消化杂志, 12(11), 2551-2554.
23. Ghany, M. M. A., AlKurtas, M. A., & Hassan, I. T. (2016). Correlation of CD44v6 and type IV collagen immunohistochemical expression in borderline and malignant surface epithelial tumors. *Al-Kindy College Medical Journal*, 12(2), 34-42.
24. Ween, M. P. (2010). *The biological role of extracellular matrix in ovarian cancer metastasis* (Doctoral dissertation).
25. Yurdakan, G., Kandemir, N. O., Çolak, S., Gül, A. E., Karadayı, N., & Özdamar, Ş. O. (2007). Immunohistochemical Study of the CD44 Expression in Benign, Borderline and Malignant Surface Epithelial Ovarian Tumors and Metastatic Ovarian Tumors. *Gynecology Obstetrics & Reproductive Medicine*, 13(3), 160-163.
26. 王绍光, & 姜学强. (2008). 华蟾素对卵巢癌 3AO 细胞 CD44s 表达的影响. 国际中医中药杂志, 30(6), 405-406.
27. Elnashar, A. T., & Hafez, A. S. (2012). Immunohistochemical expression of CD44V6, P53 and BCL-2 in Epithelial Ovarian Tumors. *J Am Sci*, 8(8), 258-264.

▪ Panteli K., Zagorianakou N., Bai M., Katsaraki A., Agnantis N.J, Bourantas K. (2004). Angiogenesis in chronic myeloproliferative diseases detected by CD34 expression. *Eur J Haematol*. 72(6): 410-5.

1. Chen, W., Lu, Y., Wu, J., Gao, M., Wang, A., & Xu, B. (2011). Beta-elemene inhibits melanoma growth and metastasis via suppressing vascular endothelial growth factor-mediated angiogenesis. *Cancer chemotherapy and pharmacology*, 67, 799-808.
2. Thiele, J., & Kvasnicka, H. M. (2005). Diagnostic impact of bone marrow histopathology in polycythemia vera (PV). *Histology and histopathology*.

3. Panteli, K. E., Hatzimichael, E. C., Bouranta, P. K., Katsaraki, A., Seferiadis, K., Stebbing, J., & Bourantas, K. L. (2005). Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. *British journal of haematology*, 130(5), 709-715.
4. Chen, W., Lu, Y., Gao, M., Wu, J., Wang, A., & Shi, R. (2011). Anti-angiogenesis effect of essential oil from *Curcuma zedoaria* in vitro and in vivo. *Journal of Ethnopharmacology*, 133(1), 220-226.
5. Medinger, M., Skoda, R., Gratwohl, A., Theocharides, A., Buser, A., Heim, D., ... & Tzankov, A. (2009). Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status. *British journal of haematology*, 146(2), 150-157.
6. Hasselbalch, H. C., & Riley, C. H. (2006). Statins in the treatment of polycythaemia vera and allied disorders: an antithrombotic and cytoreductive potential?. *Leukemia research*, 30(10), 1217-1225.
7. Boveri, E., Passamonti, F., Rumi, E., Pietra, D., Elena, C., Arcaini, L., ... & Lazzarino, M. (2008). Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations. *British journal of haematology*, 140(2), 162-168.
8. Florena, A. M., Tripodo, C., Iannitto, E., Porcasi, R., Ingrao, S., & Franco, V. (2004). Value of bone marrow biopsy in the diagnosis of essential thrombocythemia. *Haematologica*, 89(8), 911-919.
9. Gianelli, U., Vener, C., Raviele, P. R., Savi, F., Somalvico, F., Calori, R., ... & Deliliersx, G. L. (2007). VEGF expression correlates with microvessel density in Philadelphia chromosome-negative chronic myeloproliferative disorders. *American journal of clinical pathology*, 128(6), 966-973.
10. Sarkaria, S. M., Zhou, J., Bao, S., Zhao, W., Fang, Y., Que, J., ... & Ding, L. (2023). Systematic dissection of coordinated stromal remodeling identifies Sox10+ glial cells as a therapeutic target in myelofibrosis. *Cell Stem Cell*, 30(6), 832-850.
11. Yao, H., Cui, P., Xu, D., Liu, Y., Tian, Q., & Zhang, F. (2018). A water-soluble polysaccharide from the roots of *Polygala tenuifolia* suppresses ovarian tumor growth and angiogenesis in vivo. *International journal of biological macromolecules*, 107, 713-718.
12. Boiocchi, L., Vener, C., Savi, F., Bonoldi, E., Moro, A., Fracchiolla, N. S., ... & Gianelli, U. (2011). Increased expression of vascular endothelial growth factor receptor 1 correlates with VEGF and microvessel density in Philadelphia chromosome-negative myeloproliferative neoplasms. *Journal of clinical pathology*, 64(3), 226-231.
13. Lekovic, D., Gotic, M., Skoda, R., Beleslin-Cokic, B., Milic, N., Mitrovic-Ajtic, O., ... & Cokic, V. P. (2017). Bone marrow microvessel density and plasma angiogenic factors in myeloproliferative neoplasms: clinicopathological and molecular correlations. *Annals of hematology*, 96, 393-404.
14. Koopmans, S. M., Bot, F. J., Schouten, H. C., Janssen, J., & van Marion, A. M. (2012). The involvement of Galectins in the modulation of the JAK/STAT pathway in myeloproliferative neoplasia. *American journal of blood research*, 2(2), 119.
15. Steurer, M., Zoller, H., Augustin, F., Fong, D., Heiss, S., Strasser-Weippl, K., ... & Tzankov, A. (2007). Increased angiogenesis in chronic idiopathic myelofibrosis: vascular endothelial growth factor as a prominent angiogenic factor. *Human pathology*, 38(7), 1057-1064.
16. Perego, R. A., Corizzato, M., Brambilla, P., Ferrero, S., Bianchi, C., Fasoli, E., ... & Mocarelli, P. (2008). Concentration and microsatellite status of plasma DNA for monitoring patients with renal carcinoma. *European Journal of Cancer*, 44(7), 1039-1047.
17. Ponce, C. C., Chauffaille, M. D. L. L. F., Ihara, S. S. M., & Silva, M. R. R. (2014). Increased angiogenesis in primary myelofibrosis: latent transforming growth factor- β as a possible angiogenic factor. *Revista brasileira de hematologia e hemoterapia*, 36, 322-328.
18. Panteli, K., Bai, M., Hatzimichael, E., Zagorianakou, N., Agnantis, N. J., & Bourantas, K. (2007). Serum levels, and bone marrow immunohistochemical expression of, vascular endothelial growth factor in patients with chronic myeloproliferative diseases. *Hematology*, 12(6), 481-486.
19. Abruzzese, E., Gozzetti, A., Galimberti, S., Trawinska, M. M., Caravita, T., Siniscalchi, A., ... & De Fabritiis, P. (2007). Characterization of Ph-negative abnormal clones emerging during imatinib therapy. *Cancer*, 109(12), 2466-2472.
20. Smolej, L., & Kašparová, P. (2008). Choice of endothelial marker is crucial for assessment of bone marrow microvessel density in chronic lymphocytic leukemia. *Apmis*, 116(12), 1058-1062.
21. Davis, D. W., Herbst, R. S., & Abbruzzese, J. L. (Eds.). (2007). *Antiangiogenic cancer therapy*. CRC Press.
22. Koopmans, S. M., Schouten, H. C., & Van Marion, A. M. (2014). Anti-apoptotic pathways in bone marrow and megakaryocytes in myeloproliferative neoplasia. *Pathobiology*, 81(2), 60-68.
23. Alexandrakis, M. G., Passam, F. H., Kyriakou, D. S., Dambaki, C., Katrinakis, G., Tsirakis, G., ... & Stathopoulos, E. N. (2004). Expression of the proliferation-associated nuclear protein MIB-1 and its relationship with microvascular density in bone marrow biopsies of patients with myelodysplastic syndromes. *Journal of molecular histology*, 35, 857-863.
24. Shahrabi, S., Ehsanpour, A., Heidary, S., Shahjahani, M., & Behzad, M. M. (2018). Expression of CD markers in JAK2V617F positive myeloproliferative neoplasms: Prognostic significance. *Oncology reviews*, 12(2).
25. Mambet, C., Necula, L., Mihai, S., Matei, L., Bleotu, C., Chivu-Economescu, M., ... & Diaconu, C. C. (2018). Increased Dkk-1 plasma levels may discriminate disease subtypes in myeloproliferative neoplasms. *Journal of Cellular and Molecular Medicine*, 22(8), 4005-4011.
26. Yigit, N., Covey, S., Barouk-Fox, S., Turker, T., Geyer, J. T., & Orazi, A. (2015). Nuclear factor-erythroid 2, nerve growth factor receptor, and CD34-microvessel density are differentially expressed in primary myelofibrosis, polycythemia vera, and essential thrombocythemia. *Human Pathology*, 46(8), 1217-1225.
27. Arora, B., Mesa, R., & Tefferi, A. (2004). Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasia. *Leukemia & lymphoma*, 45(12), 2373-2386.

28. Panteli, K., Zagorianakou, N., Agnantis, N. J., Bourantas, K. L., & Bai, M. (2005). Clinical correlation of bone marrow microvessel density in essential thrombocythemia. *Acta haematologica*, 114(2), 99-103.
29. Jesus, C. R. D., Neiva, T. D. J. C., & Vituri, C. D. L. (2011). Assessment of fibrosis and vascularization of bone marrow stroma of chronic myeloid leukemia patients treated with imatinib mesylate and their relationship with the cytogenetic response. *Brazilian Journal of Pharmaceutical Sciences*, 47, 313-322.
30. Qian, X. U., & Feng-yun, W. A. N. G. (2016). The Effect of Ruxolitinib on the Expression of VEGF and HIF-1 α in Leukemia HEL Cells. *Journal of Sichuan University (Medical Science Edition)*, 47(5).
31. 徐倩, 赵亚玲, 付建珠, 谷蕾, 刘贵敏, 梁文同, & 成志勇. (2015). AG490 对 HEL 细胞 VEGF 和 HIF-1 α 表达的影响. *中国病理生理杂志*, 31(12), 2158-2163.
32. Carl Hasselbalch, H., & Riley, C. H. (2007). The mevalonate pathway as a therapeutic target in the Ph-negative chronic myeloproliferative disorders. *Current Drug Targets*, 8(2), 247-256.
33. 徐倩, 刘贵敏, 王凤云, 张丽军, 梁文同, & 成志勇. (2016). Ruxolitinib 对人红白血病 HEL 细胞 VEGF, HIF-1 α 表达的影响. *四川大学学报: 医学版*, 47(5), 669-673.
34. Helm, P. *Quantitative und qualitative Veränderungen der Angiogenese im Knochenmark bei primärer Myelofibrose (PMF) nach Imatinib-Therapie* (Doctoral dissertation, Köln, Univ., Diss., 2010).
35. Vilches, S. F., Sánchez, J. M. R., Vega, L. M., Santos, T. M., García, M. T. H., Argüelles, H. Á., ... & de Canarias, H. C. H. U. POLICITEMIA VERA: ANÁLISIS INTEGRADO CLÍNICO, MOLECULAR E HISTOPATOLÓGICO EN 22 PACIENTES DE UN SOLO CENTRO. *Una aproximación al espíritu de las Academias Feijoo y Sarmiento en la Medicina del Siglo XVIII Física Médica y Premios Nobel de Medicina: Von Békésy Pulmones Blancos. Evolución histórica de la*, 12.
36. 钟亚平, 黄晶, 张艳丽, & 刘农军. (2008). 小剂量沙利度胺治疗原发性骨髓纤维化的疗效观察. *现代保健: 医学创新研究*, 5(15), 13-14.
37. Αγγελίδου, Α. (2008). *Μοριακή μελέτη του υπεύθυνου για την αγγειογένεση αυξητικού παράγοντα του αγγειακού ενδοθήλιου (VEGF) σε ασθενείς με οξεία μυελογενή λευχαιμία* (Doctoral dissertation, Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης (ΑΠΘ). Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής. Τομέας Παθολογίας. Κλινική Β' Παθολογική Γενικού Περιφερειακού Νοσοκομείου Θεσσαλονίκης ΙΠΠΟΚΡΑΤΕΙΟ).
38. Θεοδωρίδου, Σ. (2007). *Μελέτη της αγγειογένεσης στην αληθή πολυκυτταραιμία* (Doctoral dissertation, Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης (ΑΠΘ). Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής. Τομέας Παθολογίας. Κλινική Β' Προπαιδευτική Παθολογική Περιφερειακού Γενικού Νοσοκομείου ΙΠΠΟΚΡΑΤΕΙΟ Θεσσαλονίκης).
39. Hasselbalch, H. C., & Lengfelder, E. (2004). THALIDOMID IN IDIOPATHIC MYELOFIBROSIS.
40. Benetatos, L., Chaidos, A., Alymara, V., Vassou, A., & Bourantas, K. L. (2005). Combined treatment with thalidomide, corticosteroids, and erythropoietin in patients with idiopathic myelofibrosis.
41. Afroz, S., Kabir, A. N., Dey, B. P., Rahman, M. M., Rahman, P., Karim, R., ... & Jahan, S. (2023). Degree of fibrosis and its association with angiogenesis in the myelofibrotic bone marrow: Degree of myelofibrosis and angiogenesis. *Bangabandhu Sheikh Mujib Medical University Journal*, 16(1), 26-34.
42. Afroz, S., Kabir, A. N., Dey, B. P., Rahman, M. M., Rahman, P., Karim, R., ... & Umama-Tun-Nesa Emta, S. J. Degree of fibrosis and its association with angiogenesis in the myelofibrotic bone marrow.
43. Tefferi, A. (2006). *Myeloproliferative Disorders*. Elsevier.
44. Kulandaivel, A. L., & Gunasekaran, K. P. A Correlative Study on Bone Marrow Angiogenesis with Bone Marrow Fibrosis and Splenomegaly.
45. 张金巧, 宋晓宁, & 王金铠. (2006). 反应停联合糖皮质激素治疗原发性骨髓纤维化临床分析. *临床内科杂志*, 23(11), 764-765.

- **Zagorianakou N., Ioachim E., Mitselou A., Kitsou E., Zagorianakou P., Makrydimas G., Salmas M., Agnantis N.J. (2003). Immunohistochemical expression of heat shock protein 27, in normal hyperplastic and neoplastic endometrium: correlation with estrogen and progesterone receptor status, p53, pRb and proliferation associated indices (PCNA, MIB1). *Eur J Gynaecol Oncol*. 24(3-4):299-304.**

1. Ferns, G., Shams, S., & Shafi, S. (2006). Heat shock protein 27: its potential role in vascular disease. *International journal of experimental pathology*, 87(4), 253-274.
2. Cappello, F., Ribbene, A., Campanella, C., Czarnecka, A. M., Anzalone, R., & Bucchieri, F. (2006). The value of immunohistochemical research on PCNA, p53 and heat shock proteins in prostate cancer management: a review. *European Journal of Histochemistry*, 50(1), 25-34.
3. Hrudka, J., Jelínková, K., Fišerová, H., Matěj, R., Mandys, V., & Waldauf, P. (2021). Heat shock proteins 27, 70, and 110: Expression and prognostic significance in colorectal cancer. *Cancers*, 13(17), 4407.
4. Ceylan, Y., Akpınar, G., Doger, E., Kasap, M., Guzel, N., Karaosmanoglu, K., ... & Yucesoy, I. (2020). Proteomic analysis in endometrial cancer and endometrial hyperplasia tissues by 2D-DIGE technique. *Journal of Gynecology Obstetrics and Human Reproduction*, 49(2), 101652.
5. Romani, A. A., Crafa, P., Desenzani, S., Graiani, G., Lagrasta, C., Sianesi, M., ... & Borghetti, A. F. (2007). The expression of HSP27 is associated with poor clinical outcome in intrahepatic cholangiocarcinoma. *BMC cancer*, 7(1), 1-10.
6. Cappello, F., David, S., Ardizzone, N., Rappa, F., Marasà, L., Bucchieri, F., & Zummo, G. (2006). Expression of heat shock proteins HSP10, HSP27, HSP60, HSP70, and HSP90 in urothelial carcinoma of urinary bladder. *J Cancer Mol*, 2(2), 73-77.

7. El-Ghobashy, A. A., Shaaban, A. M., Innes, J., Prime, W., & Herrington, C. S. (2005). Upregulation of heat shock protein 27 in metaplastic and neoplastic lesions of the endocervix. *International Journal of Gynecological Cancer*, 15(3).
8. Gutierrez-Castañeda, L. D., Polo, J. F., Carmona, C., Sanabria, D., Caballero, D. M., Jutínico, A., & Parra-Medina, R. (2020). Expression of heat shock protein Hsp 27 in ovarian carcinoma. *European Journal of Gynaecological Oncology*, 41(2), 221-226.
9. Ceylan, Y. (2016). Endometrium kanseri ve endometrial hiperplazi dokularında 2D-DIGE yöntemiyle proteomik analizi.
10. Buchner, D. (2014). *Einfluss der qualitativen und quantitativen HSP27 Expression auf die in vitro Chemo-und Radiosensitivität von Pankreaskarzinomzellen* (Doctoral dissertation, lmu).

- **Zagorianakou N., Ioachim E., Mitselou A., Kitsou E., Zagorianakou P., Stefanaki S., Makrydimas G., Agnantis N.J. (2003).** Glycoprotein CD44 expression in normal, hyperplastic and neoplastic endometrium. An immunohistochemical study including correlations with p53, steroid receptor status and proliferative indices (PCNA, MIB1). *Eur J Gynaecol Oncol*. 24(6): 500-4.

1. Elbasateeny, S. S., Salem, A. A., Abdelsalam, W. A., & Salem, R. A. (2016). Immunohistochemical expression of cancer stem cell related markers CD44 and CD133 in endometrial cancer. *Pathology-Research and Practice*, 212(1), 10-16.
2. Merisio, C., Berretta, R., De Ioris, A., Pultrone, D. C., Rolla, M., Giordano, G., ... & Melpignano, M. (2005). Endometrial cancer in patients with preoperative diagnosis of atypical endometrial hyperplasia. *European Journal of Obstetrics & Gynecology and Reproductive Biology*, 122(1), 107-111.
3. Park, J. Y., Hong, D., & Park, J. Y. (2019). Association between morphological patterns of myometrial invasion and cancer stem cell markers in endometrial endometrioid carcinoma. *Pathology & Oncology Research*, 25, 123-130.
4. Zhou, L., Meng, Z., Wu, Y., Zhu, H., & Wang, X. (2014). Prediction of endometrial carcinogenesis probability while diagnosed as atypical endometrial hyperplasia: a new risk model based on age, CA199 and CA125 assay. *European Journal of Obstetrics & Gynecology and Reproductive Biology*, 183, 5-9.
5. Wojciechowski, M., Krawczyk, T., Śmigielski, J., & Malinowski, A. (2015). CD44 expression in curettage and postoperative specimens of endometrial cancer. *Archives of Gynecology and Obstetrics*, 291, 383-390.
6. Zagorianakou, N., Stefanou, D., Makrydimas, G., Zagorianakou, P., Briasoulis, E., Karavasilis, B., & Agnantis, N. J. (2004). CD44s expression, in benign, borderline and malignant tumors of ovarian surface epithelium. Correlation with p53, steroid receptor status, proliferative indices (PCNA, MIB1) and survival. *Anticancer research*, 24(3A), 1665-1670.
7. 胡芬, 张炜, 康晓楠, & 刘银坤. (2008). 应用 SELDI-TOF-MS 技术初步建立子宫内膜异位症诊断模型. *生殖与避孕*, 28(3), 168-173.
8. Wojciechowski, M., Krawczyk, T., Śmigielski, J., & Malinowski, A. (2010). The role of adhesive molecules in endometrial cancer: part II. *Menopause Review/Przegląd Menopauzalny*, 9(6), 357-361.

- **Sebire N.J., Makrydimas G., Agnantis N.J., Zagorianakou N., Rees H., Fisher R.A. (2003).** Updated diagnostic criteria for partial and complete hydatidiform moles in early pregnancy. *Anticancer Res*. 23(2C):1723-8.

1. Seckl, M. J., Sebire, N. J., & Berkowitz, R. S. (2010). Gestational trophoblastic disease. *The Lancet*, 376(9742), 717-729.
2. Lurain, J. R. (2010). Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. *American journal of obstetrics and gynecology*, 203(6), 531-539.
3. Hui, P., Buza, N., Murphy, K. M., & Ronnett, B. M. (2017). Hydatidiform moles: genetic basis and precision diagnosis. *Annual Review of Pathology: Mechanisms of Disease*, 12, 449-485.
4. Stevens, F. T., Katzorke, N., Tempfer, C., Kreimer, U., Bizjak, G. I., Fleisch, M. C., & Fehm, T. N. (2015). Gestational trophoblastic disorders: an update in 2015. *Geburtshilfe und Frauenheilkunde*, 75(10), 1043-1050.
5. Fowler, D. J., Lindsay, I., Seckl, M. J., & Sebire, N. J. (2006). Routine pre-evacuation ultrasound diagnosis of hydatidiform mole: experience of more than 1000 cases from a regional referral center. *Ultrasound in obstetrics & gynecology*, 27(1), 56-60.
6. Allen, S. D., Lim, A. K., Seckl, M. J., Blunt, D. M., & Mitchell, A. W. (2006). Radiology of gestational trophoblastic neoplasia. *Clinical radiology*, 61(4), 301-313.
7. McConnell, T. G., Murphy, K. M., Hafez, M., Vang, R., & Ronnett, B. M. (2009). Diagnosis and subclassification of hydatidiform moles using p57 immunohistochemistry and molecular genotyping: validation and prospective analysis in routine and consultation practice settings with development of an algorithmic approach. *The American journal of surgical pathology*, 33(6), 805-817.
8. Xing, D., Adams, E., Huang, J., & Ronnett, B. M. (2021). Refined diagnosis of hydatidiform moles with p57 immunohistochemistry and molecular genotyping: updated analysis of a prospective series of 2217 cases. *Modern Pathology*, 34(5), 961-982.

9. Hoffner, L., & Surti, U. (2012). The genetics of gestational trophoblastic disease: a rare complication of pregnancy. *Cancer genetics*, 205(3), 63-77.
10. Bolze, P. A., Attia, J., Massardier, J., Seckl, M. J., Massuger, L., van Trommel, N., ... & Golfier, F. (2015). Formalised consensus of the European Organisation for Treatment of Trophoblastic Diseases on management of gestational trophoblastic diseases. *European journal of cancer*, 51(13), 1725-1731.
11. Wells, M. (2007). The pathology of gestational trophoblastic disease: recent advances. *Pathology*, 39(1), 88-96.
12. Ronnett, B. M., DeScipio, C., & Murphy, K. M. (2011). Hydatidiform moles: ancillary techniques to refine diagnosis. *International journal of gynecological pathology*, 00, 101-116.
13. Lima, L. D. L. A., Parente, R. C. M., Maestá, I., Amim Junior, J., Rezende Filho, J. F. D., Montenegro, C. A. B., & Braga, A. (2016). Clinical and radiological correlations in patients with gestational trophoblastic disease. *Radiologia brasileira*, 49, 241-250.
14. Ronnett, B. M. (2018). Hydatidiform moles: ancillary techniques to refine diagnosis. *Archives of Pathology & Laboratory Medicine*, 142(12), 1485-1502.
15. Hui, P., Martel, M., & Parkash, V. (2005). Gestational trophoblastic diseases: recent advances in histopathologic diagnosis and related genetic aspects. *Advances in anatomic pathology*, 12(3), 116-125.
16. Sebire, N. J., Lindsay, I., Fisher, R. A., Savage, P., & Seckl, M. J. (2005). Overdiagnosis of complete and partial hydatidiform mole in tubal ectopic pregnancies. *International journal of gynecological pathology*, 24(3), 260-264.
17. Sebire, N. J. (2010). Histopathological diagnosis of hydatidiform mole: contemporary features and clinical implications. *Fetal and pediatric pathology*, 29(1), 1-16.
18. Braga, A., Moraes, V., Maestá, I., Júnior, J. A., de Rezende-Filho, J., Elias, K., & Berkowitz, R. (2016). Changing trends in the clinical presentation and management of complete hydatidiform mole among Brazilian women. *International Journal of Gynecologic Cancer*, 26(5).
19. Gupta, M., Vang, R., Yemelyanova, A. V., Kurman, R. J., Li, F. R., Maambo, E. C., ... & Ronnett, B. M. (2012). Diagnostic reproducibility of hydatidiform moles: ancillary techniques (p57 immunohistochemistry and molecular genotyping) improve morphologic diagnosis for both recently trained and experienced gynecologic pathologists. *The American journal of surgical pathology*, 36(12), 1747.
20. Golfier, F., Clerc, J., Hajri, T., Massardier, J., Frappart, L., Duvillard, P., ... & Raudrant, D. (2011). Contribution of referent pathologists to the quality of trophoblastic diseases diagnosis. *Human reproduction*, 26(10), 2651-2657.
21. Padrón, L., Rezende Filho, J., Junior, J. A., Sun, S. Y., Charry, R. C., Maestá, I., ... & Berkowitz, R. S. (2018). Manual compared with electric vacuum aspiration for treatment of molar pregnancy. *Obstetrics & Gynecology*, 131(4), 652-659.
22. Campos, V., Paiva, G., Padron, L., Freitas, F., Pedrotti, L. G., Sun, S. Y., ... & Berkowitz, R. S. (2023). Influence of COVID-19 pandemic on molar pregnancy and postmolar gestational trophoblastic neoplasia: An observational study. *BJOG: An International Journal of Obstetrics & Gynaecology*, 130(3), 292-302.
23. Madi, J. M., Braga, A., Paganella, M. P., Litvin, I. E., & Wendland, E. M. (2018). Accuracy of p57 KIP 2 compared with genotyping to diagnose complete hydatidiform mole: a systematic review and meta-analysis. *BJOG: An International Journal of Obstetrics & Gynaecology*, 125(10), 1226-1233.
24. Nadhan, R., Vaman, J. V., Nirmala, C., Sengodan, S. K., Hemalatha, S. K., Rajan, A., ... & Srinivas, P. (2017). Insights into dovetailing GTD and Cancers. *Critical reviews in oncology/hematology*, 114, 77-90.
25. Niemann, I., Hansen, E. S., & Sunde, L. (2007). The risk of persistent trophoblastic disease after hydatidiform mole classified by morphology and ploidy. *Gynecologic oncology*, 104(2), 411-415.
26. Fisher, R. A., Tommasi, A., Short, D., Kaur, B., Seckl, M. J., & Sebire, N. J. (2014). Clinical utility of selective molecular genotyping for diagnosis of partial hydatidiform mole; a retrospective study from a regional trophoblastic disease unit. *Journal of clinical pathology*, 67(11), 980-984.
27. Sebire, N. J., Savage, P. M., Seckl, M. J., & Fisher, R. A. (2013). Histopathological features of biparental complete hydatidiform moles in women with NLRP7 mutations. *Placenta*, 34(1), 50-56.
28. Fowler, D. J., Lindsay, I., Seckl, M. J., & Sebire, N. J. (2007). Histomorphometric features of hydatidiform moles in early pregnancy: relationship to detectability by ultrasound examination. *Ultrasound in obstetrics & gynecology: the official journal of the International Society of Ultrasound in Obstetrics and Gynecology*, 29(1), 76-80.
29. López, C. L., Lopes, V. G. S., Resende, F. R., Steim, J. L., Padrón, L., Sun, S. Y., ... & Braga, A. (2018). Gestational trophoblastic neoplasia after ectopic molar pregnancy: clinical, diagnostic, and therapeutic aspects. *Revista Brasileira de Ginecologia e Obstetrícia*, 40, 294-299.
30. Joneborg, U., Folkvaljon, Y., Papadogiannakis, N., Lambe, M., & Marions, L. (2018). Temporal trends in incidence and outcome of hydatidiform mole: a retrospective cohort study. *Acta Oncologica*, 57(8), 1094-1099.
31. Braga, A., Biscaro, A., do Amaral Giordani, J. M., Viggiano, M., Elias, K. M., Berkowitz, R. S., & Seckl, M. J. (2018). Does a human chorionic gonadotropin level of over 20,000 IU/L four weeks after uterine evacuation for complete hydatidiform mole constitute an indication for chemotherapy for gestational trophoblastic neoplasia?. *European Journal of Obstetrics & Gynecology and Reproductive Biology*, 223, 50-55.
32. Braga, A., Canelas, A. C., Torres, B., Maesta, I., Giongo Pedrotti, L., Bessel, M., ... & Berkowitz, R. S. (2022). Neutrophil/lymphocyte ratio and other blood cell component counts are not associated with the development of postmolar gestational trophoblastic neoplasia. *Plos one*, 17(12), e0277892.
33. Sebire, N. J., May, P. C., Kaur, B., Seckl, M. J., & Fisher, R. A. (2016). Abnormal villous morphology mimicking a hydatidiform mole associated with paternal trisomy of chromosomes 3, 7, 8 and unipaternal disomy of chromosome 11. *Diagnostic Pathology*, 11, 1-8.

34. Joneborg, U., Eloranta, S., Johansson, A. L., Marions, L., Weibull, C. E., & Lambe, M. (2014). Hydatidiform mole and subsequent pregnancy outcome: a population-based cohort study. *American Journal of Obstetrics and Gynecology*, 211(6), 681-e1.
35. Athanasiou, A., Féki, A., Fruscalzo, A., Guani, B., & Ben Ali, N. (2022). Ruptured ectopic pregnancy as complete hydatidiform mole: Case report and review of the literature. *Frontiers in Surgery*, 9, 1036435.
36. Buza, N., & Hui, P. (2010). Gestational trophoblastic disease: histopathological diagnosis in the molecular era. *Diagnostic histopathology*, 16(11), 526-537.
37. Kerkmeijer, L. G., Massuger, L. F., ten Kate-Booij, M. J., Sweep, F. C., & Thomas, C. M. (2009). Earlier diagnosis and serum human chorionic gonadotropin regression in complete hydatidiform moles. *Obstetrics & Gynecology*, 113(2 Part 1), 326-331.
38. Uberti, E. M. H., do Carmo Fajardo, M., da Cunha, A. G. V., Rosa, M. W., Ayub, A. C. K., da Silveira Graudenz, M., & Schmid, H. (2009). Prevention of postmolar gestational trophoblastic neoplasia using prophylactic single bolus dose of actinomycin D in high-risk hydatidiform mole: a simple, effective, secure and low-cost approach without adverse effects on compliance to general follow-up or subsequent treatment. *Gynecologic oncology*, 114(2), 299-305.
39. Beena, D., Teerthanath, S., Jose, V., & Shetty, J. (2016). Molar pregnancy presents as tubal ectopic pregnancy: a rare case report. *Journal of Clinical and Diagnostic Research: JCDR*, 10(1), ED10.
40. Niemann, I., Petersen, L. K., Hansen, E. S., & Sunde, L. (2007). Differences in current clinical features of diploid and triploid hydatidiform mole. *BJOG: An International Journal of Obstetrics & Gynaecology*, 114(10), 1273-1277.
41. Kim, K. R., Park, B. H., Hong, Y. O., Kwon, H. C., & Robboy, S. J. (2009). The villous stromal constituents of complete hydatidiform mole differ histologically in very early pregnancy from the normally developing placenta. *The American journal of surgical pathology*, 33(2), 176-185.
42. Ronnett, B. M. (2019). Hydatidiform moles: differential diagnosis, diagnostic reproducibility, genetics and ancillary techniques to refine diagnosis. *Diagnostic Histopathology*, 25(2), 35-52.
43. Lescoat, D., Jouan, H., Loeuillet-Olivo, L., & Le Calve, M. (2005). Fluorescent in situ hybridization (FISH) on paraffin-embedded placental tissues as an adjunct for understanding the etiology of early spontaneous abortion. *Prenatal Diagnosis: Published in Affiliation With the International Society for Prenatal Diagnosis*, 25(4), 314-317.
44. Braga, A., Andrade, T., de Souza, M. D. C. B., Campos, V., Freitas, F., Maestá, I., ... & Berkowitz, R. S. (2023). Presentation, medical complications and development of gestational trophoblastic neoplasia of hydatidiform mole after intracytoplasmic sperm injection as compared to hydatidiform mole after spontaneous conception-a retrospective cohort study and literature review. *Gynecologic Oncology*, 170, 179-185.
45. Mayun, A. A., Rafindadi, A. H., & Shehu, M. S. (2010). Pathomorphology of molar gestation in Zaria. *Nigerian Medical Journal*, 51(1), 1.
46. Thomas, C. M., Kerkmeijer, L. G., Ariaens, H. J., van der Steen, R. C., Massuger, L. F., & Sweep, F. C. (2010). Pre-evacuation hCG glycoforms in uneventful complete hydatidiform mole and persistent trophoblastic disease. *Gynecologic oncology*, 117(1), 47-52.
47. Hasan, A., Elhawary, A., Abdelaleem, M. F., Hegazy, T., Nafie, K. M., & Abdelaleem, M. F. A. (2021). Partial Hydatidiform Mole in an Ectopic Tubal Pregnancy. *Cureus*, 13(6).
48. Paul, M., Goodman, S., Felix, J., Lewis, R., Hawkins, M., & Drey, E. (2010). Early molar pregnancy: experience in a large abortion service. *Contraception*, 81(2), 150-156.
49. Tanha, F. D., ShirAli, E., Rahmanpour, H., & Haghollahi, F. (2011). Molar pregnancy presents as tubal ectopic pregnancy. *International journal of fertility & sterility*, 4(4), 184.
50. Sebire, N. J., Fokkett, M., Fisher, R. A., Lindsay, I., & Seckl, M. J. (2005). Persistent gestational trophoblastic disease is rarely, if ever, derived from non-molar first-trimester miscarriage. *Medical hypotheses*, 64(4), 689-693.
51. Grinschgl, I., Mannweiler, S., Holzapfel-Bauer, M., Pferschy, U., Hoefler, G., & Guertl, B. (2013). The role of morphology in combination with ploidy analysis in characterizing early gestational abortion. *Virchows Archiv*, 462, 175-182.
52. Lelic, M., Fatusic, Z., Iljazovic, E., Ramic, S., Markovic, S., & Alicelebic, S. (2017). Challenges in the routine praxis diagnosis of hydatidiform mole: A Tertiary health center experience. *Medical Archives*, 71(4), 256.
53. Heller, D. S. (2022). Molar pregnancies. *Benirschke's Pathology of the Human Placenta*, 771-790.
54. Hodgson, A., Dube, V., Strickland, S., Kolomietz, E., Noor, A., Akbari, A., ... & Turashvili, G. (2021). Androgenetic/Biparental Mosaic/Chimeric Conceptions with a Molar Component: A Diagnostic and Clinical Challenge. *International Journal of Gynecological Pathology*, 40(5), 510-517.
55. Lima, L. D. L. A., Parente, R. C. M., Maestá, I., Amim Junior, J., Rezende Filho, J. F. D., Montenegro, C. A. B., & Braga, A. (2016). Correlações clinicoradiológicas em pacientes com doença trofoblástica gestacional. *Radiologia Brasileira*, 49, 241-250.
56. Lund, H., Nielsen, S., Grove, A., Vyberg, M., & Sunde, L. (2020). p57 in hydatidiform moles: evaluation of antibodies and expression in various cell types. *Applied Immunohistochemistry & Molecular Morphology*, 28(9), 694.
57. Lund, H., Vyberg, M., Eriksen, H. H., Grove, A., Jensen, A. Ø., & Sunde, L. (2018). hydatidiform mole: validity of the registration in the Danish national Patient registry, the Danish Cancer registry, and the Danish Pathology registry 1999-2009. *Clinical Epidemiology*, 1223-1231.
58. Ramos, M. M., Maesta, I., de Araújo Costa, R. A., Mazeto, G. M., Horowitz, N. S., Elias, K. M., ... & Berkowitz, R. S. (2022). Clinical characteristics and thyroid function in complete hydatidiform mole complicated by hyperthyroidism. *Gynecologic Oncology*, 165(1), 137-142.
59. Dresang, L. T. (2005). A molar pregnancy detected by following β -human chorionic gonadotropin levels after a first trimester loss. *The Journal of the American Board of Family Practice*, 18(6), 570-573.

60. Murphy, K. M., & Ronnett, B. M. (2010). Molecular analysis of hydatidiform moles: utilizing p57 immunohistochemistry and molecular genotyping to refine morphologic diagnosis. *AJSP: Reviews & Reports*, 15(4), 126-134.
61. Ribbeck, G., Muñoz, C., & Gutiérrez, S. (2006). Mola incompleta, eclampsia y síndrome de HELLP: un caso clínico. *Rev Chil Ultrasonog*, 9(2), 62-6.
62. Triratanachat, S., Nakaporntham, P., Tantbirojn, P., Shuangshoti, S., & Lertkhachonsuk, R. (2016). Role of P57KIP2 immunohistochemical expression in histological diagnosis of hydatidiform moles. *Asian Pacific Journal of Cancer Prevention*, 17(4), 2061-2066.
63. Sebire, N. J., Lindsay, I., & Fisher, R. A. (2007). Recent advances in gestational trophoblastic neoplasia. *Current Diagnostic Pathology*, 13(3), 210-221.
64. Sebire, N. J., & Seckl, M. J. (2009). Gestational trophoblastic disease. *Management of unintended and abnormal pregnancy: Comprehensive abortion care*, 293-301.
65. Al Wahaibi, F., Al Ghaithi, H., AlShamsi, R., Gowri, V., & Al Rawahi, T. (2019). Gestational Trophoblastic Disease: Prevalence, Management and Follow-Up at a Tertiary Center in Oman—An 11-Year Study. *Indian Journal of Gynecologic Oncology*, 17, 1-4.
66. Malpica, A., Euscher, E. D., Ramalingam, P., Aguilera-Barrantes, I., & Alvarado-Cabrero, I. (2020). Gynecological Pathology. *Oncological Surgical Pathology*, 1049-1521.
67. López, C. L., Lopes, V. G. S., Resende, F. R., Steim, J. L., Padrón, L., Sun, S. Y., ... & Braga, A. (2018). Neoplasia trofoblástica gestacional após gestação molar ectópica: aspectos clínicos, diagnósticos e terapêuticos. *Rev. Bras. Ginecol. Obstet*, 40(5).
68. Pant, A., & Lurain, J. R. (2018). Gestational trophoblastic disease. *The American Cancer Society's Oncology in Practice: Clinical Management*, 318-328.
69. Ghazi, G. F., & Donovan, P. O. (2006). Partial mole in ectopic pregnancy. *Gynecological Surgery*, 3, 141-143.
70. Joneborg, U. (2016). *Hydatidiform Mole: Prevalence and Outcome*. Karolinska Institutet (Sweden).
71. Silveira, L. P. (2019). Aspiração manual intrauterina versus aspiração elétrica no tratamento da gestação molar.
72. Eroğlu, H. A., & Adalı, Y. (2019). Predictivity of inflammatory cell counts in early diagnosis of hydatidiform mole.
73. Ranaei, M., Kaviyani, A., Hosseini, A., Galeshi, M., & Yazdani, S. (2020). Survey on risk Factors and clinical symptoms of hydatiform-mole in pregnant women referred to Ayatollah Rouhani hospital in Babol: 2011-2017. *The Iranian Journal of Obstetrics, Gynecology and Infertility*, 23(4), 31-38.
74. Christien, R. J. J. PRISE EN CHARGE DES MOLES HYDATIFORMES A L'HOPITAL UNIVERSITAIRE DE GYNECOLOGIE ET OBSTETRIQUE DE BEFELATANANA.
75. Dakouo, A. P. (2014). Aspects épidémiologiques et histopathologiques des maladies trophoblastiques au service d'anatomie et cytologie pathologiques du CHU POINT-G de 2009 à 2013.
76. Filipescu, G. A., Boiangiu, A. G., Clim, N., & Andrei, F. (2014). Fertility preserving treatment in a nulliparous with a molar pregnancy: a case report. *Rom J Morphol Embryol*, 55(2), 449-452.
77. Patrier, S., & Bolze, P. (2014). Diagnostic anatomopathologique des maladies trophoblastiques. *Oncologie (Tech Science Press)*, 16(6).
78. رعنائی، کاویانی، حسینی، دکتر اکرم السادات، گلشی، یزدانی، & دکتر شهلا. (2020). بررسی عوامل خطر و علائم بالینی مول هیداتیفورم در زنان باردار مراجعه کننده به مرکز آموزشی درمانی آیتالله روحانی بابل: 1390-1396. *مجله زنان، مامایی و نازایی ایران*, 23(4), 38-31.
79. Patrier, S., & Bolze, P. A. (2014). Pathological diagnosis of trophoblastic disease. *Oncologie*, 16, 279-284.
80. Kumari, S., Bansal, A., Poonia, M., & Simlot, A. (2012). A Cross-Sectional Study of Clinical Analysis and Management of Molar Pregnancy. *Journal of Medical Science and Research*, 3(1), 13.
81. 潘地铃, 王行富, 马宏, & 吴荔香. (2011). 早期完全性水泡状胎块临床病理分析. *湖北民族学院学报: 医学版*, 28(3), 14-17.
82. Bolze, P. A., Massardier, J., & Golfier, F. Research Perspectives and Current Management of Gestational Trophoblastic Diseases in Europe.
83. President, M. D. R. M., Filali, M. A. A., Dami, M. A., & Nazih, M. M. Interet Du Dosage De L'hormone Chorionique Gonadotrope Dans Les Maladies Trophoblastiques Gestationnelles (Etude prospective à propos de 35 patients).
84. Kakumanu, M. R., Reddy, G. R. K., Sagar, M. J. P., Reddy, K. V., & Naik, V. R. (2015). Partial hydatidiform mole with a live fetus: a rare entity. *Journal of Evolution of Medical and Dental Sciences*, 4(60), 10590-10597.
85. Fahd, M. I. Les Maladies Trophoblastiques Gestationnelles. Gestationnelles, M. T., & Charge, D. E. P. E. (2010). *Recommandations De Bonne Pratique*.
86. Kerkmeijer, L. G. W. (2010). *Human chorionic gonadotrophin in the prediction of persistent trophoblastic disease*. [Sl: sn].
87. McHugo, J. M. (2006). Pathology of the uterus, cervix and vagina. *Practical Gynaecological Ultrasound*, 54.
88. Sebire, N. J. (2005). The diagnosis of gestational trophoblastic disease in early pregnancy: implications for screening, counseling and management. *Ultrasound in Obstetrics and Gynecology: The Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology*, 25(5), 421-424.
89. Patrier, S. (2010). Pathologie du placenta. Cas n° 1. Môle hydatiforme complète vue précocement: Histoséminaire SFP. *Annales de pathologie (Print)*, 30(4), 275-279.
90. Patrier, S. (2010). Pathologie du placenta. Cas n° 5. Môle hydatiforme partielle: Histoséminaire SFP. *Annales de pathologie (Print)*, 30(4), 296-300.
91. Guides, P. E., & Code, J. View a Demo!
92. Murphy, K. M. Molecular Diagnostics of Hydatidiform Moles.
93. Mott, D. D. Hydatidiform Mole.

- Ioachim E., Kitsiou E., Charalabopoulos K., Mitselou A., **Zagorianakou N.**, Makrydimas G., Tzioras S., Salmas M. (2003). Immunohistochemical evaluation of cathepsin D in normal, hyperplastic and malignant endometrium: correlation with hormone receptor status c-erbB-2, p53, Rb proteins and proliferation associated indices. *Int J Gynecol Cancer*. 13(3):344-351.
1. Mylonas, I., Makovitzky, J., Richter, D. U., Jeschke, U., Briese, V., & Friese, K. (2004). Expression of the inhibin-alpha subunit in normal, hyperplastic and malignant endometrial tissue: an immunohistochemical analysis. *Gynecologic oncology*, 93(1), 92-97.
2. Tokyol, C., Köken, T., Demirbas, M., Dilek, F. H., Yörükoglu, K., Mungan, U., & Kirkali, Z. (2006). Expression of cathepsin D in bladder carcinoma: correlation with pathological features and serum cystatin C levels. *Tumori Journal*, 92(3), 230-235.
3. 张丽志, & 薛凤霞. (2009). pS2, Cath-D, PR 和 ER-α 的表达与子宫内膜癌淋巴结转移关系的研究. *天津医药*, (4), 277-279.
4. Mylonas, I., Makovitzky, J., Shabani, N., Richter, D. U., Jeschke, U., Briese, V., & Friese, K. (2005). Parathyroid hormone-related peptide (PTH-rp) in normal, hyperplastic and malignant endometrial tissue: an immunohistochemical analysis. *Anticancer research*, 25(3A), 1633-1638.
5. Atasoy, P. Y. N. A. R., & Bozdoğan, Ö. N. D. E. R. (2006). Molecular markers in endometrial hyperplasia.
6. 陈明芳, 汪泉, 曹清, 徐晓, & 周燕. (2009). HER-2 在上皮性卵巢癌组织的表达及其临床意义. *中国民族民间医药*, 18(16), 32-33.
7. Kim, J. S., Lee, S., Kim, J. M., & Cho, M. J. (2008). The Clinical Significance of Cathepsin D and p53 Expression in Locally Advanced Rectal Cancer. *The Journal of the Korean Society for Therapeutic Radiology and Oncology*, 26(1), 56-64.
8. Bou Serra, J. (2008). Estudio de los factores biológicos del adenocarcinoma de endometrio y su relación con la supervivencia.
- Makrydimas G., **Zagorianakou N.**, Zagorianakou P., Agnantis N.J. (2003). CD44 family and gynaecological cancer. *In Vivo*. 17(6): 633-40.
1. Rathnavelu, V., Alitheen, N. B., Sohila, S., Kanagesan, S., & Ramesh, R. (2016). Potential role of bromelain in clinical and therapeutic applications. *Biomedical reports*, 5(3), 283-288.
2. Chobotova, K., Vernallis, A. B., & Majid, F. A. A. (2010). Bromelain's activity and potential as an anti-cancer agent: current evidence and perspectives. *Cancer letters*, 290(2), 148-156.
3. Mythreye, K., & Blobe, G. C. (2009). Proteoglycan signaling co-receptors: roles in cell adhesion, migration and invasion. *Cellular signalling*, 21(11), 1548-1558.
4. Banzato, A., Bobisse, S., Rondina, M., Renier, D., Bettella, F., Esposito, G., ... & Rosato, A. (2008). A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity. *Clinical cancer research*, 14(11), 3598-3606.
5. Kannagi, R., Sakuma, K., Miyazaki, K., Lim, K. T., Yusa, A., Yin, J., & Izawa, M. (2010). Altered expression of glycan genes in cancers induced by epigenetic silencing and tumor hypoxia: clues in the ongoing search for new tumor markers. *Cancer science*, 101(3), 586-593.
6. Pillai, K., Akhter, J., Chua, T. C., & Morris, D. L. (2013). Anticancer property of bromelain with therapeutic potential in malignant peritoneal mesothelioma. *Cancer investigation*, 31(4), 241-250.
7. Lindström, A. K., Ekman, K., Stendahl, U., Tot, T., Henriksson, R., Hedman, H., & Hellberg, D. (2008). LRIG1 and squamous epithelial uterine cervical cancer: correlation to prognosis, other tumor markers, sex steroid hormones, and smoking. *International Journal of Gynecologic Cancer*, 18(2).
8. Swant, J. D., Rendon, B. E., Symons, M., & Mitchell, R. A. (2005). Rho GTPase-dependent signaling is required for macrophage migration inhibitory factor-mediated expression of cyclin D1. *Journal of Biological Chemistry*, 280(24), 23066-23072.
9. Vos, M. C., Hollemans, E., Ezendam, N., Feijen, H., Boll, D., Pijlman, B., ... & Massuger, L. F. (2016). MMP-14 and CD44 in Epithelial-to-Mesenchymal Transition (EMT) in ovarian cancer. *Journal of ovarian research*, 9(1), 1-9.
10. De Stefano, I., Battaglia, A., Zannoni, G. F., Prisco, M. G., Fattorossi, A., Travaglia, D., ... & Gallo, D. (2011). Hyaluronic acid-paclitaxel: Effects of intraperitoneal administration against CD44 (+) human ovarian cancer xenografts. *Cancer chemotherapy and pharmacology*, 68, 107-116.
11. Pu, C., Biyuan, Xu, K., & Zhao, Y. (2022). Glycosylation and its research progress in endometrial cancer. *Clinical and Translational Oncology*, 24(10), 1865-1880.
12. Allison, K. H., Fligner, C. L., & Tony Parks, W. (2004). Radiographically occult, diffuse intrasinusoidal hepatic metastases from primary breast carcinomas: a clinicopathologic study of 3 autopsy cases. *Archives of pathology & laboratory medicine*, 128(12), 1418-1423.
13. Gao, L., Yan, L., Lin, B., Gao, J., Liang, X., Wang, Y., ... & Masao, I. (2011). Enhance effects of Lewis y antigen on CD44-mediated adhesion and spreading of human ovarian cancer cell line RMG-I. *Journal of Experimental & Clinical Cancer Research*, 30(1), 1-8.

14. Gibbs, P., Clingan, P. R., Ganju, V., Strickland, A. H., Wong, S. S., Tebbutt, N. C., ... & Brown, T. J. (2011). Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial. *Cancer chemotherapy and pharmacology*, 67, 153-163.
15. Hu, Z., Gao, J., Zhang, D., Liu, Q., Yan, L., Gao, L., ... & Lin, B. (2013). High expression of Lewis y antigen and CD44 is correlated with resistance to chemotherapy in epithelial ovarian cancers. *PloS one*, 8(2), e57250.
16. Gibbs, P., Brown, T. J., Ng, R., Jennens, R., Cinc, E., Pho, M., ... & Fox, R. M. (2008). A pilot human evaluation of a formulation of irinotecan and hyaluronic acid in 5-fluorouracil-refractory metastatic colorectal cancer patients. *Chemotherapy*, 55(1), 49-59.
17. Hellberg, D., Tot, T., & Stendahl, U. (2009). Pitfalls in immunohistochemical validation of tumor marker expression—exemplified in invasive cancer of the uterine cervix. *Gynecologic Oncology*, 112(1), 235-240.
18. Lindström, A. K., Stendahl, U., Tot, T., Lidström, B. M., & Hellberg, D. (2007). Predicting the outcome of squamous cell carcinoma of the uterine cervix using combinations of individual tumor marker expressions. *Anticancer research*, 27(3B), 1609-1615.
19. Banzato, A., Rondina, M., Meléndez-Alafort, L., Zangoni, E., Nadali, A., Renier, D., ... & Rosato, A. (2009). Biodistribution imaging of a paclitaxel-hyaluronan bioconjugate. *Nuclear medicine and biology*, 36(5), 525-533.
20. Toro de Méndez, M., & Bosch, A. L. (2011). Abnormal immunoexpression of cell adhesion molecules (CAMs) in cervical cancer. *International Journal of Surgical Pathology*, 19(6), 733-742.
21. Xiao, S., Zhou, Y., Jiang, J., Yuan, L., & Xue, M. (2014). CD44 affects the expression level of FOS-like antigen 1 in cervical cancer tissues. *Molecular medicine reports*, 9(5), 1667-1674.
22. Tan, A., Argenta, P., Ramirez, R., Bliss, R., & Geller, M. (2009). The use of Sodium Hyaluronate–Carboxymethylcellulose (HA-CMC) barrier in gynecologic malignancies: A retrospective review of outcomes. *Annals of surgical oncology*, 16, 499-505.
23. Campisi, M., & Renier, D. (2011). ONCOFID™-P a hyaluronic acid paclitaxel conjugate for the treatment of refractory bladder cancer and peritoneal carcinosis. *Current Bioactive Compounds*, 7(1), 27-32.
24. Kim, S. K., Shim, H. S., Lee, K. G., An, H. J., Lee, K. R., & Cho, N. H. (2009). Glassy cell carcinoma predominantly commits to a squamous lineage and is strongly associated with high-risk type human papillomavirus infection. *International journal of gynecological pathology*, 28(4), 389-395.
25. Hahne, J. C., Meyer, S. R., Kranke, P., Dietl, J., Guckenberger, M., Polat, B., & Hönig, A. (2013). Studies on the role of osteopontin-1 in endometrial cancer cell lines. *Strahlentherapie Und Onkologie*, 189(12), 1040.
26. Safavinia, A., Dehestani, S., Salmasi, Z., Kalalinia, F., Etemad, L., & Hashemi, M. (2023). Recent advances in nanocarriers containing Bromelain: In vitro and in vivo studies. *Nanomedicine Journal*, 10(3), 163-170.
27. Lindström, A. K., Stendahl, U., Tot, T., & Hellberg, D. (2007). Associations between ten biological tumor markers in squamous cell cervical cancer and serum estradiol, serum progesterone and smoking. *Anticancer research*, 27(3B), 1401-1406.
28. Maheshwari, D. G., Shah, J. S., Shah, D. B., Patel, P. K., & Singh, Y. R. (2022). Emerging trends in extraction and analytical techniques for bromelain. *Journal of Liquid Chromatography & Related Technologies*, 45(9-12), 107-119.
29. Данилова, Н. В., Андреева, Ю. Ю., Завалишина, Л. Э., & Мальков, П. Г. (2012). Маркеры стромальной инвазии при фоновых и предраковых изменениях железистого эпителия и аденокарциноме шейки матки. *Архив патологии*, 74(4), 28-33.
30. Vos, M. C., Hollemans, E., van der Steen, S. C., van Kuppevelt, T. H., van der Wurff, A. A., & Massuger, L. F. (2020). Primary Ovarian Tumors With Lymphogenic and Hematogenic Metastasis Express High MMP-14, Which Colocalizes With Highly Sulfated Chondroitin Sulfate in the Stroma. *International Journal of Gynecological Pathology*, 39(2), 184-192.
31. Gu, C., Du, Y., Gao, Y., Yao, Z., Gu, X., Zhang, Q., ... & Deng, W. (2012). Anti-CD44 mAb remodels biological behaviors of spheroid cells with stemness from human ovarian cancer cell line SKOV-3. *Chinese Science Bulletin*, 57, 1288-1297.
32. 吴静, 周芸, 路红, 王玉玲, 王爱勤, & 薛群基. (2005). D-氨基葡萄糖衍生物对人胃癌细胞系 SGC-7901 增生的影响. *世界华人消化杂志*, 13(6), 720-723.
33. 郑核, 钟德珩, & 苗雄鹰. (2006). CD44v5, CD44v6 在胆囊癌组织中的表达研究. *中国现代手术学杂志*, 10(3), 189-192.
34. Καπρίνης, Κ. Ι. (2016). Απεικονιστική και βιοχημική διερεύνηση των oligosaccharitών και polysaccharitών του valouronικού οξέος κατά την παραγωγική διαβητική αμφιβληστροειδοπάθεια και τη ρηγματογενή αποκόλληση του αμφιβληστροειδούς (Doctoral dissertation, Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης).
35. Vos, M. C. (2019). *Matrix metalloproteinases in ovarian cancer; studies on MMP-14 and MMP-2* (Doctoral dissertation, [SI]:[Sn]).
36. ДАНИЛОВА, Н., ЮЛИНДРНВА, Ю., МАЛЬКОВ, П., ЗАВАЛИШИНА, Л., & ФРАНК, Г. ПРИМЕНЕНИЕ CD44 И ТЕНАСЦИНА ДЛЯ ДИАГНОСТИКИ РАННЕЙ СТРОМАЛЬНОЙ ИНВАЗИИ В АДЕНОКАРЦИНОМЕ ШЕЙКИ МАТКИ.
37. Данилова, Н. В., Попов, П. В., Олейникова, Н. А., Мальков, П. Г., Харлова, О. А., Юсупова, Х. И., & Агапов, М. А. (2017). Аденокарцинома в гигантском гиперпластическом полипе желудка. *Архив патологии*, 6(2017).
38. Witte, N. Aus der Klinik für Allgemein-, Visceral-, Gefäß-und Thoraxchirurgie der Medizinischen Fakultät Charité–Universitätsmedizin Berlin.
39. Khan, S. A. (2004). *Regulation of CD44 and apoptosis-related gene Bcl-XL expression by osteopontin*. Rutgers The State University of New Jersey, School of Graduate Studies.
40. 马笮, 胡姗姗, 周洋, 孙昊量, 李慧, & 栗巧玲. (2015). CD44v3 和 CD44v5 在口腔黏液表皮样癌中的表达及临床意义. *中国美容医学*, 24(4), 32-35.

41. Hahne, J. C., Meyer, S. R., Kranke, P., Dietl, J., Guckenberger, M., Polat, B., & Hönig, A. (2013). Untersuchungen zur Rolle von Osteopontin-1 in Endometriumkarzinomzelllinien.
42. Adibah Bazilah binti Abdul Rani, A. B. (2011). Modeling of hyaluronan-cisplatin targeted delivery in human colorectal cancer cells.
43. Witte, N. (2010). *Der Einfluss der intraoperativen Applikation von Taurolin/Heparin, Intergel und Interceed auf das lokale und peritoneale Tumorwachstum sowie die Expression der Adhäsionsmoleküle CD44, Beta-1-Integrin und E-Cadherin bei offen-chirurgischer Intervention in einem Kolonkarzinommodell bei Ratten* (Doctoral dissertation).
44. de Méndez Morelva, T. (2010). Abnormal Immunoexpression of Cell Adhesion Molecules (CAMs) in Cervical Cancer.
45. 郑智国. (2006). 卵巢癌转移相关基因及其信号传导途径. 科学技术与工程, 6(1), 45-48.
46. Shiftan, L. (2005). *Development of magnetic resonance imaging contrast material for detection and measurement of hyaluronidase activity*. The Weizmann Institute of Science (Israel).

▪ Makrydimas G., Sebire N.J., Thornton S.E., **Zagorianakou N.**, Lolis D., Fisher R.A. (2002). Complete hydatidiform mole and normal live birth: a novel case of confined placental mosaicism: case report. *Hum Reprod.* 17(9):2459-63.

1. Seckl, M. J., Sebire, N. J., & Berkowitz, R. S. (2010). Gestational trophoblastic disease. *The Lancet*, 376(9742), 717-729.
2. Fisher, R. A., & Maher, G. J. (2021). Genetics of gestational trophoblastic disease. *Best Practice & Research Clinical Obstetrics & Gynaecology*, 74, 29-41.
3. Fitzgerald, R. C., Hardwick, R., Huntsman, D., Carneiro, F., Guilford, P., Blair, V., ... & Caldas, C. (2010). Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. *Journal of medical genetics*, 47(7), 436-444.
4. Stevens, F. T., Katzorke, N., Tempfer, C., Kreimer, U., Bizjak, G. I., Fleisch, M. C., & Fehm, T. N. (2015). Gestational trophoblastic disorders: an update in 2015. *Geburtshilfe und Frauenheilkunde*, 75(10), 1043-1050.
5. Lucifero, D., Chaillet, J. R., & Trasler, J. M. (2004). Potential significance of genomic imprinting defects for reproduction and assisted reproductive technology. *Human reproduction update*, 10(1), 3-18.
6. Savage, J., Adams, E., Veras, E., Murphy, K. M., & Ronnett, B. M. (2017). Choriocarcinoma in women. *The American journal of surgical pathology*, 41(12), 1593-1606.
7. Kaiser-Rogers, K. A., Mcfadden, D. E., Livasy, C. A., Dansereau, J., Jiang, R., Knops, J. F., ... & Robinson, W. P. (2006). Androgenetic/biparental mosaicism causes placental mesenchymal dysplasia. *Journal of medical genetics*, 43(2), 187-192.
8. Middelkamp, S., van Tol, H. T., Spierings, D. C., Boymans, S., Guryev, V., Roelen, B. A., ... & Kuijk, E. W. (2020). Sperm DNA damage causes genomic instability in early embryonic development. *Science Advances*, 6(16), eaaz7602.
9. Wilson, J. R., Bateman, A. C., Hanson, H., An, Q., Evans, G., Rahman, N., ... & Eccles, D. M. (2010). A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations. *Journal of medical genetics*, 47(11), 771-774.
10. Massardier, J., Golfier, F., Journet, D., Frappart, L., Zalaquett, M., Schott, A. M., ... & Raudrant, D. (2009). Twin pregnancy with complete hydatidiform mole and coexistent fetus: obstetrical and oncological outcomes in a series of 14 cases. *European Journal of Obstetrics & Gynecology and Reproductive Biology*, 143(2), 84-87.
11. Golubovsky, M. D. (2003). Postzygotic diploidization of triploids as a source of unusual cases of mosaicism, chimerism and twinning. *Human Reproduction*, 18(2), 236-242.
12. Deveault, C., Qian, J. H., Chebaro, W., Ao, A., Gilbert, L., Mehio, A., ... & Slim, R. (2009). NLRP7 mutations in women with diploid androgenetic and triploid moles: a proposed mechanism for mole formation. *Human molecular genetics*, 18(5), 888-897.
13. Hoffner, L., & Surti, U. (2012). The genetics of gestational trophoblastic disease: a rare complication of pregnancy. *Cancer genetics*, 205(3), 63-77.
14. Wee, L., & Jauniaux, E. (2005). Prenatal diagnosis and management of twin pregnancies complicated by a co-existing molar pregnancy. *Prenatal Diagnosis: Published in Affiliation With the International Society for Prenatal Diagnosis*, 25(9), 772-776.
15. Kotzot, D. (2008). Complex and segmental uniparental disomy updated. *Journal of medical genetics*, 45(9), 545-556.
16. Malan, V., Vekemans, M., & Turleau, C. (2006). Chimera and other fertilization errors. *Clinical genetics*, 70(5), 363-373.
17. Hoffner, L., Dunn, J., Esposito, N., Macpherson, T., & Surti, U. (2008). P57KIP2 immunostaining and molecular cytogenetics: combined approach aids in diagnosis of morphologically challenging cases with molar phenotype and in detecting androgenetic cell lines in mosaic/chimeric conceptions. *Human pathology*, 39(1), 63-72.
18. Destouni, A., Esteki, M. Z., Catteeuw, M., Tšuiiko, O., Dimitriadou, E., Smits, K., ... & Vermeesch, J. R. (2016). Zygotes segregate entire parental genomes in distinct blastomere lineages causing cleavage-stage chimerism and mixoploidy. *Genome research*, 26(5), 567-578.
19. Usui, H. (2022). Auxiliary and experimental diagnostic techniques for hydatidiform moles. *Journal of Obstetrics and Gynaecology Research*, 48(12), 3077-3086.
20. Hui, P., Martel, M., & Parkash, V. (2005). Gestational trophoblastic diseases: recent advances in histopathologic diagnosis and related genetic aspects. *Advances in anatomic pathology*, 12(3), 116-125.

21. Xing, D., Adams, E., Zou, Y. S., Morsberger, L., Scanga, L. R., Gao, F. F., ... & Ronnett, B. M. (2022). Twin/Multiple Gestations With a Hydatidiform Mole: Clinicopathologic Analysis of 21 Cases With Emphasis on Molecular Genotyping and Parental Contribution. *The American Journal of Surgical Pathology*, 46(9), 1180-1195.
22. Wilson, M., Peters, G., Bennetts, B., McGillivray, G., Wu, Z. H., Poon, C., & Algar, E. (2008). The clinical phenotype of mosaicism for genome-wide paternal uniparental disomy: Two new reports. *American Journal of Medical Genetics Part A*, 146(2), 137-148.
23. Robinson, W. P., Lauzon, J. L., Innes, A. M., Lim, K., Arsovska, S., & McFadden, D. E. (2007). Origin and outcome of pregnancies affected by androgenetic/biparental chimerism. *Human Reproduction*, 22(4), 1114-1122.
24. Piura, B., Rabinovich, A., HersHKovitz, R., Maor, E., & Mazor, M. (2008). Twin pregnancy with a complete hydatidiform mole and surviving co-existent fetus. *Archives of Gynecology and Obstetrics*, 278, 377-382.
25. Surti, U., Hill, L. M., Dunn, J., Prosen, T., & Hoffner, L. (2005). Twin pregnancy with a chimeric androgenetic and biparental placenta in one twin displaying placental mesenchymal dysplasia phenotype. *Prenatal Diagnosis: Published in Affiliation With the International Society for Prenatal Diagnosis*, 25(11), 1048-1056.
26. Inbar-Feigenberg, M., Choufani, S., Cytrynbaum, C., Chen, Y. A., Steele, L., Shuman, C., ... & Weksberg, R. (2013). Mosaicism for genome-wide paternal uniparental disomy with features of multiple imprinting disorders: Diagnostic and management issues. *American Journal of Medical Genetics Part A*, 161(1), 13-20.
27. Sebire, N. J. (2010). Histopathological diagnosis of hydatidiform mole: contemporary features and clinical implications. *Fetal and pediatric pathology*, 29(1), 1-16.
28. Dolapcioglu, K., Gungoren, A., Hakverdi, S., Hakverdi, A. U., & Egilmez, E. (2009). Twin pregnancy with a complete hydatidiform mole and co-existent live fetus: two case reports and review of the literature. *Archives of gynecology and obstetrics*, 279, 431-436.
29. Sebire, N. J., Lindsay, I., Fisher, R. A., & Seckl, M. J. (2005). Intraplacental choriocarcinoma: experience from a tertiary referral center and relationship with infantile choriocarcinoma. *Fetal and Pediatric Pathology*, 24(1), 21-29.
30. Andreasen, L., Christiansen, O. B., Niemann, I., Bolund, L., & Sunde, L. (2013). NLRP7 or KHDC3L genes and the etiology of molar pregnancies and recurrent miscarriage. *Molecular human reproduction*, 19(11), 773-781.
31. Buza, N., & Hui, P. (2014, May). Immunohistochemistry and other ancillary techniques in the diagnosis of gestational trophoblastic diseases. In *Seminars in diagnostic pathology* (Vol. 31, No. 3, pp. 223-232). WB Saunders.
32. Sunde, L., Niemann, I., Hansen, E. S., Hindkjaer, J., Degn, B., Jensen, U. B., & Bolund, L. (2011). Mosaics and moles. *European journal of human genetics*, 19(10), 1026-1031.
33. Fisher, R. A., Tommasi, A., Short, D., Kaur, B., Seckl, M. J., & Sebire, N. J. (2014). Clinical utility of selective molecular genotyping for diagnosis of partial hydatidiform mole; a retrospective study from a regional trophoblastic disease unit. *Journal of clinical pathology*, 67(11), 980-984.
34. Scholz, N. B., Bolund, L., Nyegaard, M., Faaborg, L., Jørgensen, M. W., Lund, H., ... & Sunde, L. (2015). Triploidy—observations in 154 diandric cases. *PLoS One*, 10(11), e0142545.
35. Giurgea, I., Sanlaville, D., Fournet, J. C., Sempoux, C., Bellanne-Chantelot, C., Touati, G., ... & de Lonlay, P. (2006). Congenital hyperinsulinism and mosaic abnormalities of the ploidy. *Journal of medical genetics*, 43(3), 248-254.
36. Aranake-Chrisinger, J., Huettner, P. C., Hagemann, A. R., & Pfeifer, J. D. (2016). Use of short tandem repeat analysis in unusual presentations of trophoblastic tumors and their mimics. *Human pathology*, 52, 92-100.
37. H'mida, D., Gribaa, M., Yacoubi, T., Chaieb, A., Adala, L., Elghezal, H., & Saad, A. (2008). Placental mesenchymal dysplasia with Beckwith-Wiedemann syndrome fetus in the context of biparental and androgenic cell lines. *Placenta*, 29(5), 454-460.
38. Hui, P. (2012). Molecular diagnosis of gestational trophoblastic disease. *Gestational Trophoblastic Disease: Diagnostic and Molecular Genetic Pathology*, 161-178.
39. Romanelli, V., Nevado, J., Fraga, M., Trujillo, A. M., Mori, M. Á., Fernández, L., ... & Lapunzina, P. (2011). Constitutional mosaic genome-wide uniparental disomy due to diploidisation: an unusual cancer-predisposing mechanism. *Journal of medical genetics*, 48(3), 212-216.
40. Lin, M., Chen, J., Liao, B., He, Z., Lin, S., & Luo, Y. (2021). When a vesicular placenta meets a live fetus: case report of twin pregnancy with a partial hydatidiform mole. *BMC Pregnancy and Childbirth*, 21, 1-9.
41. Winberg, J., Gustavsson, P., Lagerstedt-Robinson, K., Blennow, E., Lundin, J., Iwarsson, E., ... & Nordgren, A. (2010). Chimerism resulting from parthenogenetic activation and dispermic fertilization. *American journal of medical genetics Part A*, 152(9), 2277-2286.
42. Destouni, A., & Vermeesch, J. R. (2017). How can zygotes segregate entire parental genomes into distinct blastomeres? The zygote metaphase revisited. *BioEssays*, 39(4), 1600226.
43. Faye-Petersen, O. M., & Kapur, R. P. (2013). Placental mesenchymal dysplasia. *Surgical Pathology Clinics*, 6(1), 127-151.
44. Buza, N., & Hui, P. (2014). Egg donor pregnancy: a potential pitfall in DNA genotyping diagnosis of hydatidiform moles. *International Journal of Gynecological Pathology*, 33(5), 507-510.
45. West, J. D., & Everett, C. A. (2022). Preimplantation chromosomal mosaics, chimaeras and confined placental mosaicism. *Reproduction and Fertility*, 3(2), R66-R90.
46. Berger-Zaslav, A. L., Mehta, L., Jacob, J., Mercado, T., Gadi, I., Tepperberg, J. H., & Palmer, L. S. (2009). Ovotesticular disorder of sexual development (true hermaphroditism). *Urology*, 73(2), 293-296.
47. Surti, U., Hoffner, L., Kolthoff, M., Dunn, J., Hunt, J., Sniezek, L., & Macpherson, T. (2006). Persistent gestational trophoblastic disease after an androgenetic/biparental fetal chimera: a case report and review. *International journal of gynecological pathology*, 25(4), 366-372.

48. Linn, R. L., Minturn, L., Yee, L. M., Maniar, K., Zhang, Y., Fritsch, M. K., ... & Ernst, L. M. (2015). Placental mesenchymal dysplasia without fetal development in a twin gestation: a case report and review of the spectrum of androgenetic biparental mosaicism. *Pediatric and Developmental Pathology*, 18(2), 146-154.
49. Papoutsis, D., Mesogitis, S., Antonakou, A., Goumalatsos, N., Daskalakis, G., Papantoniou, N., ... & Antsaklis, A. (2011). Partial molar pregnancy with a chromosomically and phenotypically normal embryo: presentation of an extremely rare case and review of literature. *The Journal of Maternal-Fetal & Neonatal Medicine*, 24(10), 1289-1293.
50. Schuetzle, M. N., Uphoff, T. S., Hatten, B. A., & Dawson, D. B. (2007). Utility of microsatellite analysis in evaluation of pregnancies with placental mesenchymal dysplasia. *Prenatal Diagnosis: Published in Affiliation With the International Society for Prenatal Diagnosis*, 27(13), 1238-1244.
51. Charles, A., & Khong, T. Y. (2022). Abortion and chromosomal anomalies. *Benirschke's Pathology of the Human Placenta*, 227-257.
52. Andreasen, L., Bolund, L., Niemann, I., Hansen, E. S., & Sunde, L. (2012). Mosaic moles and non-familial biparental moles are not caused by mutations in NLRP7, NLRP2 or C6orf221. *Molecular human reproduction*, 18(12), 593-598.
53. Benirschke, K., Burton, G. J., Baergen, R. N., Benirschke, K., Burton, G. J., & Baergen, R. N. (2012). Molar pregnancies. *Pathology of the human placenta*, 687-722.
54. 刘丛容, & 惠培. (2011). 葡萄胎的分子诊断. *中华病理学杂志*, 40(1), 6-10.
55. Rathod, S., Samal, S. K., & Ghose, S. (2014). Twin pregnancy with hydatidiform mole and coexisting fetus: A Case report and review of literature. *Int J Health Sci Res*, 4(7), 275-279.
56. Sebire, N. J. (2006). Prenatal diagnosis and management of twin pregnancies complicated by a co-existing molar pregnancy. *Prenatal diagnosis*, 26(4), 373.
57. Chen, C. P., Su, Y. N., Lin, M. H., Wang, T. Y., Chern, S. R., Kuo, Y. L., ... & Wang, W. (2014). Detection of altered methylation status at 11p15. 5 and 7q32 in placental mesenchymal dysplasia. *Taiwanese Journal of Obstetrics and Gynecology*, 53(1), 68-73.
58. Ávila-Vergara, M. A., Cardona-Osuna, M. E., Guzmán-Gutiérrez, L. E., Espínola-Magaña, K. M., Caballero-Rodríguez, C. B., Castro-Stringher, D., & Vadillo-Ortega, F. (2017). Mola hidatiforme coexistente con feto vivo después de las 20 semanas de gestación: reporte de dos casos. *Ginecología y obstetricia de México*, 85(12), 853-861.
59. Hsu, C. C., Lee, I. W., Su, M. T., Lin, Y. C., Hsieh, C., Chen, P. Y., ... & Kuo, P. L. (2008). Triple genetic identities for the complete hydatidiform mole, placenta and co-existing fetus after transfer of a single in vitro fertilized oocyte: case report and possible mechanisms. *Human reproduction*, 23(12), 2686-2691.
60. Minelli, A., Guala, A., Groppo, A., Restagno, G., Lala, R., Einaudi, S., ... & Danesino, C. (2011). Mechanism of origin in two cases of chimerism. *Open Journal of Pediatrics*, 1(04), 79.
61. Sebire, N. J., Lindsay, I., & Fisher, R. A. (2007). Recent advances in gestational trophoblastic neoplasia. *Current Diagnostic Pathology*, 13(3), 210-221.
62. Sebire, N. J., & Seckl, M. J. (2009). Gestational trophoblastic disease. *Management of unintended and abnormal pregnancy: Comprehensive abortion care*, 293-301.
63. Sethi, N., Tan, A. G., Kamarudin, M., & Sulaiman, S. (2021). Successful delivery of a twin pregnancy with complete hydatidiform mole and coexistent live fetus: a case report and review of literature. *Clinical and Experimental Obstetrics & Gynecology*, 48(5), 1232-1247.
64. Draper, N. L., & Crooks, K. (2018). Fertilization and Early Embryonic Errors. *Chimerism: A Clinical Guide*, 3-17.
65. Wu, T. C., Shen, S. H., Chang, S. P., Chang, C. Y., & Guo, W. Y. (2005). Magnetic resonance experience of a twin pregnancy with a normal fetus and hydatidiform mole: a case report. *Journal of computer assisted tomography*, 29(3), 415-417.
66. Sebire, N. J., & Fisher, R. A. (2005). Partly molar pregnancies that are not partial moles: additional possibilities and implications. *Pediatric and Developmental Pathology*, 8, 732-733.
67. Khong, Y., Cheung, A. N., & Zheng, W. (2019). *Diagnostic endometrial pathology* 2E. CRC Press.
68. Golubovsky, M. (2006). Mosaic/chimeras and twinning in the current reproductive genetics perspective. *Human Reproduction*, 21(9), 2458-2460.
69. Zheng, L., Cai, F., Fan, F., He, J., Yan, H., Bai, C., ... & Biskup, E. (2019). Case Report Complete hydatidiform mole coexisting live fetus in a twin pregnancy. *Int J Clin Exp Med*, 12(5), 6238-6243.
70. Yela, D. A., Pinheiro, A., Pinto, J. P. L., & Andrade, L. (2011). Gestação gemelar de mola hidatiforme completa com feto vivo. *Jornal Brasileiro de Patologia e Medicina Laboratorial*, 47, 165-170.
71. De Marcillac, F., Akladios, C. Y., Fritz, G., Nisand, I., & Langer, B. (2015). Les grossesses gémellaires molaires associant une môle complète à un fœtus sain à partir de 4 cas et d'une revue de la littérature. *Journal de Gynécologie Obstétrique et Biologie de la Reproduction*, 44(9), 840-847.
72. Ariel, I., Goldman-Wohl, D., Yagel, S., Gazit, E., & Loewenthal, R. (2017). Triple paternal contribution to a normal/complete molar chimeric singleton placenta. *Human Reproduction*, 32(5), 993-998.
73. Sebire, N. J., & Jauniaux, E. (2012). Gestational trophoblastic diseases: The role of ultrasound imaging. *Ultrasound Clinics*, 7(1), 33-45.
74. Buza, N., & Hui, P. (2014). Ancillary techniques to refine diagnosis of GTD. *Current Obstetrics and Gynecology Reports*, 3, 65-75.
75. Yela, D. A., Pinheiro, A., Pinto, J. P. L., & Andrade, L. (2011). Twin pregnancy with complete hydatidiform mole and living fetus. *Jornal Brasileiro de Patologia e Medicina Laboratorial*, 47, 165-170.
76. Buza, N., & Hui, P. (2017). Ancillary studies for precision diagnosis of hydatidiform moles. *Diagnostic Histopathology*, 23(7), 292-302.
77. Buza, N., & Hui, P. (2016). Putative precursor lesions of gestational trophoblastic neoplasia. *Precancerous Lesions of the Gynecologic Tract: Diagnostic and Molecular Genetic Pathology*, 85-102.

78. Ambe, A. K., Oviedo-Cruz, H., Reyes-Mendoza, M. Á., Mestizo-Reyes, V., Sánchez-González, C. M., Martínez-Cruz, N., ... & Carrillo-Garibaldi, O. J. Contenido Content.
79. Tabandeh, A., & Besharat, M. (2013). Twin pregnancy of a complete hydatidiform mole and a co-existent fetus: A very rare case report. *Iranian Red Crescent Medical Journal*, 15(8), 757.
80. De Ponte, A., Serrano, R., & Aponte, A. José Colon.
81. KANAGALAKSHMI, K. (2019). Partial Molar Pregnancy With a Live Fetus. *University Journal of Surgery and Surgical Specialities*, 5(11).
82. De Paepe, M. E. Dichorionic and Higher Order Multiple Gestations.
83. Miskovic, B., Stipoljev, F., Drmic, I., Andonotopo, W., & Kupesic, S. (2006). Complete hydatidiform mole and coexisting healthy twin: A rare case of a benign form. *The Journal of Maternal-Fetal & Neonatal Medicine*, 19(12), 823-828.
84. Ávila-Vergara, M. A., Cardona-Osuna, M. E., Guzmán-Gutiérrez, L. E., Espínola-Magaña, K. M., Caballero-Rodríguez, C. B., Di Castro-Stringher, P., & Vadillo-Ortega, F. (2018). Hydatidiform mole coexisting with a live fetus greater than 20 weeks of gestation: Two cases report. *Ginecología y Obstetricia de México*, 85(12), 853-861.
85. MA, Á. V., ME, C. O., LE, G. G., KM, E. M., & CB, C. R. (2017). Mola hidatiforme coexistente con feto vivo después de las 20 semanas de gestación: reporte dos casos. *Ginecologia y Obstetricia de Mexico*, 85(12).
86. De Ponte, A., Serrano, R., & Aponte, A. Embarazo gemelar: mola hidatiforme y feto vivo. A propósito de un caso.
87. Baxi, L. V., Mansukhani, M., Thaker, H. M., & Parravicini, E. Complete Hydatidiform Mole and Live Born Fetus in a Singleton Pregnancy with Confined Placental Mosaicism and Fetomaternal Hemorrhage.
88. Михайлин, Е. С., Иванова, Л. А., Лисянская, А. С., Савицкий, А. Г., Минина, А. Г., & Гедерим, М. Н. (2014). Клинический случай ведения беременности при подозрении на трофобластическую болезнь в третьем триместре. *Журнал акушерства и женских болезней*, 63(3), 66-70.
89. Mikhaylin, Y. S., Ivanova, L. A., Lisyanskaya, A. S., Savitskiy, A. G., Minina, A. G., & Gederim, M. N. (2014). A clinical case of pregnancy with suspected trophoblastic disease in 3 trimester. *Journal of obstetrics and women's diseases*, 63(3), 66-70.
90. Tahaoğlu, A. E., Balkas, D., Toğrul, C., Satıcı, M., Balsak, B., & Güngör, T. (2014). Komplet Mol ve Canlı Fetusun Birlikte Bulunduğu İkiz Gebelik: Olgu Sunumu. *Türk Jinekolojik Onkoloji Dergisi*, 17(3).
91. Fahd, M. I. Les Maladies Trophoblastiques Gestationnelles.
92. Gestationnelles, M. T., & Charge, D. E. P. E. (2010). Recommandations De Bonne Pratique.
93. Nanayakkara, K. K., & Rodrigo, U. G. (2010). Twin pregnancy with a complete hydatidiform mole and a surviving co-existent twin. *Sri Lanka Journal of Obstetrics and Gynaecology*, 31(2).
94. Moles, H. Molar Pregnancies.
95. Raga, F., Bonilla, F., Sanz-Cortés, M., & Bonilla-Musoles, F. (2008). Three-dimensional inversion mode rendering in molar pregnancy. *Ultrasound in Obstetrics and Gynecology: The Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology*, 31(3), 362-363.
96. Fisher, R. A., & Sebire, N. J. (2006). Gestational trophoblastic disease. *Biology and pathology of trophoblast*. Cambridge University Press, Cambridge, 74-110.
97. Alejandra, H. O., Juliana, B. D. I., Liliana, M. D., & Miguel, R. C. F. (2019). Conservative Management, Follow-up and Perinatal Outcomes After Gestational Trophoblastic Disease with Coexistent Normal Fetus: Case Report. *Journal of Gynecology and Obstetrics*, 7(2), 36-40.

- Assimakopoulos D., Kolettas E., **Zagorianakou N.**, Evangelou A., Skevas A. & Agnantis N. J. (2000). Prognostic significance of p53 in the cancer of the larynx. *Anticancer research*, 20(5B), 3555-3564.

1. Valko, M. M. H. C. M., Morris, H., & Cronin, M. T. D. (2005). Metals, toxicity and oxidative stress. *Current medicinal chemistry*, 12(10), 1161-1208.
2. Evangelou, A. M. (2002). Vanadium in cancer treatment. *Critical reviews in oncology/hematology*, 42(3), 249-265.
3. Barnes, L. (Ed.). (2005). *Pathology and genetics of head and neck tumours* (Vol. 9). IARC.
4. Re, M., Magliulo, G., Gioacchini, F. M., Bajraktari, A., Bertini, A., Çeka, A., ... & Olivieri, F. (2017). Expression levels and clinical significance of miR-21-5p, miR-let-7a, and miR-34c-5p in laryngeal squamous cell carcinoma. *BioMed Research International*, 2017.
5. Vlachtsis, K., Nikolaou, A., Markou, K., Fountzilias, G., & Daniilidis, I. (2005). Clinical and molecular prognostic factors in operable laryngeal cancer. *European Archives of Oto-Rhino-Laryngology and Head & Neck*, 262, 890-898.
6. Hitt, R., Ciruelos, E., Amador, M. L., Benito, A., Sanchez, J. J., Ballestin, C., & Cortes-Funes, H. (2005). Prognostic value of the epidermal growth factor receptor (EGFR) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy. *European journal of cancer*, 41(3), 453-460.
7. Mielcarek-Kuchta, D., Olofsson, J., & Golusinski, W. (2003). p53, Ki67 and cyclin D1 as prognosticators of lymph node metastases in laryngeal carcinoma. *European archives of oto-rhino-laryngology*, 260, 549-554.
8. Geomela, P. A., Kontos, C. K., Yiotakis, I., & Scorilas, A. (2013). Quantitative expression analysis of the apoptosis-related gene, BCL2L12, in head and neck squamous cell carcinoma. *Journal of oral pathology & medicine*, 42(2), 154-161.
9. García-Rodríguez, M. D. C., Hernández-Cortés, L. M., & Altamirano-Lozano, M. A. (2016). In vivo effects of vanadium pentoxide and antioxidants (ascorbic acid and alpha-tocopherol) on apoptotic, cytotoxic, and genotoxic damage in peripheral blood of mice. *Oxidative Medicine and Cellular Longevity*, 2016.

10. Hussein, M. R. (2005). Alterations of p53 and Bcl-2 protein expression in the laryngeal intraepithelial neoplasia. *Cancer biology & therapy*, 4(2), 221-225.
11. Ronchetti, D., Neglia, C. B., Cesana, B. M., Carboni, N., Neri, A., Pruneri, G., & Pignataro, L. (2004). Association between p53 gene mutations and tobacco and alcohol exposure in laryngeal squamous cell carcinoma. *Archives of Otolaryngology-Head & Neck Surgery*, 130(3), 303-306.
12. Günther, T. M. F., Kwiecinski, M. R., Baron, C. C., Felipe, K. B., Farias, M. S., da Silva, F. O., ... & Pedrosa, R. C. (2013). Sodium orthovanadate associated with pharmacological doses of ascorbate causes an increased generation of ROS in tumor cells that inhibits proliferation and triggers apoptosis. *Biochemical and Biophysical Research Communications*, 430(3), 883-888.
13. Salerno, G., Di Vizio, D., Staibano, S., Mottola, G., Quaremba, G., Mascolo, M., ... & Insabato, L. (2006). Prognostic value of p27 Kip1 expression in Basaloid Squamous Cell Carcinoma of the larynx. *BMC cancer*, 6, 1-10.
14. Asensio, C., Zapata, A. N. A., García-Ahijado, J., Gil, B., Salvadores, P., & Schneider, J. (2007). Fas expression is associated with a better prognosis in laryngeal squamous cell carcinoma. *Anticancer research*, 27(6B), 4083-4086.
15. Rashad, U. M., Hussein, M. R., & Algizawy, S. M. (2011). Alterations of p53 and Bcl-2 protein expression in the recurrent laryngeal and pharyngeal squamous cell carcinoma. *American journal of otolaryngology*, 32(3), 210-214.
16. Oğuztüzün, S., Sezgin, Y., Yazıcı, S., Firat, P., Özhevvalı, M., & Özen, H. (2011, September). Expression of glutathione-S-transferases isoenzymes and p53 in exfoliated human bladder cancer cells. In *Urologic Oncology: Seminars and Original Investigations* (Vol. 29, No. 5, pp. 538-544). Elsevier.
17. Sedat, A., Serpil, O., Nurdan, G., Aylin, G., Arif, Ş., Muzeyyen, O., ... & Nimet, K. (2010). Immunohistochemical Localization of Glutathione S-Transferase Isoenzymes (GSTA, GSTP, GSTM4, and GSTT1) and Tumour Marker p53 in Matched Tissue from Normal Larynx and Laryngeal Carcinoma: Correlations with Prognostic Factors. *Journal of Otolaryngology-Head & Neck Surgery*, 39(5).
18. Medina-Banegas, A., Osete-Albaladejo, J. M., Capitán-Guarnizo, A., López-Meseguer, E., & Pastor-Quirante, F. (2003). Double tumor of the larynx: a case report. *European archives of oto-rhino-laryngology*, 260, 341-343.
19. Yildirim, S., Cermik, H., İştımangil, T., Baloglu, H., Gungor, A., & Pekkaşalı, Z. (2002). Significance of p53 and bcl-2 immunoexpression in the prognosis of laryngeal squamous cell carcinoma. *Journal of international medical research*, 30(6), 597-600.
20. Kai, K., Masuda, M., Ide, T., Takase, Y., Miyoshi, A., Kitahara, K., ... & Tokunaga, O. (2013). Mitotic count reflects prognosis of gallbladder cancer particularly among patients with T3 tumor. *Molecular and Clinical Oncology*, 1(4), 633-638.
21. Nejati, V., & Delirazh, N. (2012). Vanadium Schiff base compound mediated apoptosis and cytotoxicity effects in K562 cell line. *Annals of Military and Health Sciences Research*, 10(3).
22. Fraqueza, G. (2013). Interação de oxometalatos de vanádio, nióbio, tungstênio e molibdênio com a Ca²⁺-ATPase de retículo sarcoplasmático: um alvo de ação de fármaco.
23. Žw ŵzūzU, U. U., Štšł, U., & ŠčřŸŤU, Z. Ž. žw ŽčŽžY žŤŦw lžž.
24. Χατζημπούγιας, Δ. (2013). *Ανοσοϊστοχημική και μοριακή μελέτη των δεικτών pten, topoisomerase iia και her3 στο καρκίνωμα του λάρυγγα, με τη μέθοδο των ιστικών μικροσυστοιχιών* (Doctoral dissertation, Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης (ΑΠΘ). Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής. Τομέας Ανατομικής και Παθολογικής Ανατομικής. Εργαστήριο Γενικής Παθολογίας και Παθολογικής Ανατομικής).
25. Whigham, A. S., & Yarbrough, W. G. (2010). Prediction of Nodal Metastases from Genomic Analyses of the Primary Tumor. *Oral Cancer Metastasis*, 75-103.
26. del Carmen García-Rodríguez, M., Hernández-Cortés, L. M., & Altamirano-Lozano, M. A. (2016). Research Article In Vivo Effects of Vanadium Pentoxide and Antioxidants (Ascorbic Acid and Alpha-Tocopherol) on Apoptotic, Cytotoxic, and Genotoxic Damage in Peripheral Blood of Mice.
27. K562. فخرایي مریم، نجاتی وحید، & دلیرژ نوروز. بررسی اثرات سائتوتوکسیسیٹی و القا آپوپتوز ترکیب شیف باز و انادیوم پر ردہ سلولی.
28. Pedrosa, R. C. (2012). Sodium orthovanadate associated with pharmacological doses of ascorbate causes an increased generation of ROS in tumor cells that inhibits proliferation.